JOINT FAO/WHO FOOD STANDARDS PROGRAMME

CODEX ALIMENTARIUS COMMISSION

Forty-third Session

FAO Headquarters, Rome, Italy

6 - 11 July 2020

REPORT OF THE FORTY-FIRST SESSION OF THE
CODEX COMMITTEE ON NUTRITION AND FOODS FOR SPECIAL DIETARY USES

DÜSSELDORF, Germany

24 – 29 November 2019
# TABLE OF CONTENTS

Summary and Status of Work................................................................................................................... page iii

List of Abbreviations .................................................................................................................................. page v

Report of the Forty-first Session of the Codex Committee on Nutrition and Foods for Special Dietary Uses ................................................................................................................................. page 1

**Paragraphs**

Introduction ........................................................................................................................................................ 1

Opening of the Session ..................................................................................................................................... 2 - 4

Adoption of the Agenda (Agenda item 1) ....................................................................................................... 5 - 6

Matters referred to the Committee by the Codex Alimentarius Commission
and/or Other Subsidiary Bodies (Agenda item 2) .......................................................................................... 7 - 13

Matters of interest arising from FAO and WHO (Agenda item 3)................................................................. 14 - 17

Review of the Standard for Follow-up Formula (Agenda item 4)
Draft scope, description and labelling for follow-up formula for older infants (Agenda item 4a).............. 18 - 28

Essential composition for follow-up formula for older infants and [name of product] for young children
(Agenda item 4b) ...................................................................................................................................... 29 - 49

Proposed draft scope, product definition and labelling for [name of product] for young children
(Agenda item 4c) ..................................................................................................................................... 50 - 85

Proposed draft follow-up formula for older infants and [name of product] for young children:
remaining sections (Agenda item 4d)....................................................................................................... 86 - 87

Proposed draft Guideline for Ready-to-Use Therapeutic Foods (Agenda item 5) ................................. 88 - 122

Trans fatty acids (Agenda item 6)

Proposed draft claim for "free of" trans fatty acids (Agenda item 6a) and
Discussion paper on risk management possibilities for the reduction of TFAs (Agenda item 6b) ...... 123 - 131

Proposed draft definition for biofortification (Agenda item 7) ............................................................... 132 - 138

Discussion paper on NRVs-R for Older Infants and Young Children (Agenda item 8) ........................ 139 - 151

Food Additives (Agenda item 9)

Mechanism / Framework for Considering Technological Justification of
Food Additives (Agenda item 9a) ........................................................................................................ 152 - 167

Alignment of Food Additive Provisions in CCNFSDU Standards with the GSFA (Agenda item 9b).... 168 - 173

Prioritization Mechanism to Better Manage the Work of CCNFSDU (Agenda item 10) ....................... 174 - 176

Discussion Paper on Harmonized Probiotic Guidelines for Use in Foods and
Dietary Supplements (Agenda item 11) .................................................................................................... 177 - 185

Discussion Paper on General Guidelines to Establish Nutrient Profiles (Agenda Item 12) ................. 186 - 192

Other business and future work (Agenda item 13)

Methods of Analysis ............................................................................................................................. 193 - 199

New work proposal on establishing harmonized guidelines for the qualification of
nutrition and health claimed food.................................................................................................................... 200

Date and place of next session (Agenda item 14) ......................................................................................... 201

**Appendices**

Appendix I - List of Participants ....................................................................................................................... 23

Appendix II – Review of the Standard for follow-up Formula:
Section A: Draft follow-up formula for older infants (scope, description and labelling).................................................... 43

Appendix III – Review of the Standard for follow-up Formula: Draft essential composition and quality factors:
Sections A and B ............................................................................................................................................. 46

Appendix IV – Review of the Standard for follow-up Formula: Section B: Drink/Product for young children with added nutrients or Drink for young children (scope, description and labelling) ..................................................................................................................... 55

Appendix V – Review of the Standard for follow-up Formula: remaining sections for Sections A and B ......58

Appendix VI – Proposed draft Guidelines for ready to use therapeutic foods (RUTF) .................................63

Appendix VII – Updated project document for new work on nutrient reference values: NRVs-R for persons aged 6 – 36 months of age ...................................................................................................................... 71

Appendix VIII (Part A) – CCNFSDU framework for appraising the technological need for food additives .....74

Appendix VIII (Part B) – New food additive provisions in CXS 72 - 1981 ......................................................78

Appendix IX – Draft guideline for the preliminary assessment and identification of work priorities for CCNFSDU .......................................................... 79
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>CCEXEC79 CAC43</td>
<td>Adoption</td>
<td>Review of the <em>Standard for Follow-up Formula</em>: Section B: Proposed draft scope, definition and labelling</td>
<td>CXS 156-1987</td>
<td>5</td>
<td>85</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Proposed draft Guideline for ready-to-use therapeutic foods</td>
<td>-</td>
<td>5</td>
<td>122</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Provisions for xanthum gum (INS 415) and pectins (INS 440)</td>
<td>CXS 72 – 1981</td>
<td>-</td>
<td>166</td>
</tr>
<tr>
<td></td>
<td>Discontinuation</td>
<td>Condition for a claim for “free of” TFAs</td>
<td>CXG 2 – 1985</td>
<td>-</td>
<td>131</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Definition for biofortification</td>
<td>-</td>
<td>-</td>
<td>138</td>
</tr>
<tr>
<td>CCEXEC79</td>
<td>Information</td>
<td>Revised timeline for work on: (i) Review of the <em>Standard for Follow-up Formula</em>; and (ii) NRVs-R for persons aged 6 – 36 months</td>
<td>CXG 2 – 1985</td>
<td>-</td>
<td>85, 150</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prioritization mechanism</td>
<td>-</td>
<td>-</td>
<td>176</td>
</tr>
<tr>
<td>CCNFSDU42</td>
<td>Hold</td>
<td>Review of the <em>Standard for Follow-up Formula</em>: Section A: scope, description and labelling; and Essential composition requirements for Section A and Section B</td>
<td>CXS 156-1987</td>
<td>7</td>
<td>28 and 49</td>
</tr>
<tr>
<td></td>
<td>Discussion</td>
<td>Review of the <em>Standard for Follow-up Formula</em>: remaining sections</td>
<td>-</td>
<td>4</td>
<td>86</td>
</tr>
<tr>
<td>CCFL46</td>
<td>Information / Endorsement</td>
<td>Review of the <em>Standard for Follow-up Formula</em>: (i) Sections 9.2.2, 9.4.1 and 9.6.5, – labelling provisions for Section A; and (ii) labelling provisions for Section B</td>
<td>CXS 156-1987</td>
<td>7</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Labelling provisions for the Proposed draft Guidelines for Ready to Use Therapeutic Foods (RUTF)</td>
<td>-</td>
<td>5</td>
<td>122</td>
</tr>
<tr>
<td>CCFL46 and CCFO27</td>
<td>Information</td>
<td>Work on condition for claim for “free of” TFA; Risk management options for TFAs / PHOs</td>
<td>-</td>
<td>-</td>
<td>131</td>
</tr>
<tr>
<td>CCFL46</td>
<td>Information / advice</td>
<td>Advice on the extent the work concerning nutrient profiles in CCNFSDU can support the work of CCFL on FOPNL</td>
<td>-</td>
<td>-</td>
<td>192</td>
</tr>
<tr>
<td>CCMAS41</td>
<td>Development / Advice / endorsement</td>
<td>Performance criteria for Type III methods for determination of nine minerals in CXS72</td>
<td>CXS 234 - 1999</td>
<td>-</td>
<td>9</td>
</tr>
<tr>
<td>-------------------</td>
<td>---------</td>
<td>------------</td>
<td>------</td>
<td>------</td>
<td>-------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Methods to measure sweetness in Drink/Product for young children with added nutrients / Drink for young children</td>
<td>CXS 156 – 1987</td>
<td>-</td>
<td>49</td>
</tr>
<tr>
<td>CCFA52</td>
<td>Information / Action</td>
<td>Proposed draft Guideline for RUTF</td>
<td>-</td>
<td>5</td>
<td>122</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Xanthan gum and pectins in CXS 72 and in Food category 13.1.3 of the GSFA</td>
<td>-</td>
<td>-</td>
<td>166</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Alignment of food additive provisions in CCNFSDU standards</td>
<td>-</td>
<td>-</td>
<td>172</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Food additive provisions in CXS 181 and CXS 203</td>
<td>-</td>
<td>-</td>
<td>173</td>
</tr>
<tr>
<td>EWG (New Zealand, France, Indonesia) CCNFSDU42</td>
<td>Drafting</td>
<td>Review of the Standard for Follow up Formula: Definition of Drink/Product for young children with added nutrients / Drink for young children; and Nitrogen to protein conversion factors</td>
<td>CXS 156-1987</td>
<td>6</td>
<td>85</td>
</tr>
<tr>
<td>EWG (Ireland, Costa Rica and United States of America) CCNFSDU42</td>
<td>Drafting</td>
<td>General Principles for the establishment of NRVs-R for persons aged 6 – 36 months</td>
<td>CXG 2 - 1985</td>
<td>2/3</td>
<td>150</td>
</tr>
<tr>
<td>EWG (European Union and Russian Federation) CCNFSDU42</td>
<td>Discussion</td>
<td>Technological justification for several food additives</td>
<td>-</td>
<td>-</td>
<td>167</td>
</tr>
<tr>
<td>PWG (Germany) CCNFSDU42</td>
<td>Redrafting / reviewing</td>
<td>Prioritization mechanism / emerging issues or new work proposals</td>
<td>-</td>
<td>-</td>
<td>176</td>
</tr>
<tr>
<td>EWG (Costa Rica, Paraguay, European Union and United States of America CCNFSDU42</td>
<td>Discussion</td>
<td>General guidelines on nutrient profiles</td>
<td>-</td>
<td>-</td>
<td>192</td>
</tr>
<tr>
<td>Argentina and Malaysia / EWG on prioritization CCNFSDU42</td>
<td>Discussion</td>
<td>Harmonized probiotic guidelines for use in foods and dietary supplements</td>
<td>-</td>
<td>-</td>
<td>185</td>
</tr>
</tbody>
</table>
# LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Full Form</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAC</td>
<td>Codex Alimentarius Commission</td>
</tr>
<tr>
<td>CCEXEC</td>
<td>Executive Committee of the Codex Alimentarius Commission</td>
</tr>
<tr>
<td>CCFA</td>
<td>Codex Committee on Food Additives</td>
</tr>
<tr>
<td>CCFL</td>
<td>Codex Committee on Food Labelling</td>
</tr>
<tr>
<td>CCFO</td>
<td>Codex Committee on Fats and Oils</td>
</tr>
<tr>
<td>CCMAS</td>
<td>Codex Committee on Methods of Analysis and Sampling</td>
</tr>
<tr>
<td>CCNFSDU</td>
<td>Codex Committee on Nutrition and Foods for Special Dietary Uses</td>
</tr>
<tr>
<td>CCCPL</td>
<td>Codex Committee on Cereals, Pulses and Legumes</td>
</tr>
<tr>
<td>CRD</td>
<td>Conference Room Document</td>
</tr>
<tr>
<td>DE</td>
<td>Dextrose equivalent</td>
</tr>
<tr>
<td>EU</td>
<td>European Union</td>
</tr>
<tr>
<td>EWG</td>
<td>Electronic Working Group</td>
</tr>
<tr>
<td>FAO</td>
<td>Food and Agriculture Organization of the United Nations</td>
</tr>
<tr>
<td>FOPNL</td>
<td>Front of pack nutrition labelling</td>
</tr>
<tr>
<td>FSMP</td>
<td>Foods for Special Medical Purposes</td>
</tr>
<tr>
<td>GSFA</td>
<td>General Standard for Food Additives</td>
</tr>
<tr>
<td>ICC</td>
<td>International Association for Cereal Science and Technology</td>
</tr>
<tr>
<td>JECFA</td>
<td>Joint FAO/WHO Expert Committee on Food Additives</td>
</tr>
<tr>
<td>JEMNU</td>
<td>Joint FAO/WHO Expert Meetings on Nutrition</td>
</tr>
<tr>
<td>NUGAG</td>
<td>WHO Nutrition Guidance Expert Advisory Group</td>
</tr>
<tr>
<td>NRV</td>
<td>Nutrient reference value</td>
</tr>
<tr>
<td>NRV-R</td>
<td>Nutrient reference values-requirements</td>
</tr>
<tr>
<td>PWG</td>
<td>Physical Working Group</td>
</tr>
<tr>
<td>RUTF</td>
<td>Ready-to-use therapeutic foods</td>
</tr>
<tr>
<td>SAM</td>
<td>Severe acute malnutrition</td>
</tr>
<tr>
<td>TFA</td>
<td>Trans fatty acid</td>
</tr>
<tr>
<td>UL</td>
<td>Tolerable upper intake level</td>
</tr>
<tr>
<td>UNICEF</td>
<td>The United Nations Children Fund</td>
</tr>
<tr>
<td>WHA</td>
<td>World Health Assembly</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
INTRODUCTION
1. The forty-first Session of the Codex Committee on Nutrition and Foods for Special Dietary Uses (CCNFSDU) was held in Düsseldorf, Germany, from 24 to 29 November 2019 at the kind invitation of the Federal Government of Germany. Dr Anja Brönstrup and Ms Hilke Thordsen-Böhm, both from the Federal Ministry of Food and Agriculture of Germany, served as Chair and vice-Chair of the Session respectively. The Committee was attended by 73 member countries, one member organisation and 41 observer organisations. A list of participants is given in Appendix I.

OPENING OF THE SESSION
2. Ms. Julia Klöckner, Federal Minister of Food and Agriculture, Germany, welcomed delegates via a video message. Dr Lorenz Franken, Director General for Consumer Health Protection, Food and Nutrition and Product Safety in the Federal Ministry of Food and Agriculture, Germany, gave the opening address. He noted how participation in Codex work played a key role in harmonizing food safety and quality and in the fight against malnutrition and the protection of consumers worldwide.
3. The Vice-Chairperson of the Codex Alimentarius Commission (CAC), Prof Purwiyatno Hariyadi (Indonesia), on behalf of the Chairperson and Vice-Chairpersons of the Commission, and Mr Tom Heilandt, Codex Secretary also addressed the meeting.

Division of competence
4. The Committee noted the division of competence between the European Union and its Member States, according to paragraph 5, Rule II of the Rules of Procedure of the Codex Alimentarius Commission as presented in CRD1.

ADOPTION OF THE AGENDA (Agenda Item 1)
5. The Committee adopted the Provisional Agenda with the following additions under Agenda Item 13 – other business and future work:
   i. Proposal for new work on Establishing Harmonized Guidelines for the Qualification of Nutrition and Health Claimed Food (proposed by Republic of Korea);
   ii. Proposal for the introduction of ICC Standard No. 185 (AOAC Method 2017.16) to replace AOAC Method 2009.01 for the analysis of dietary fibre (proposed by the International Association for Cereal Science and Technology (ICC)); and
6. Additionally, the Committee agreed to:
   i. establish an in-session working group on methods of analysis, chaired by the United States, working in English only, to consider:
      • the proposal from ICC regarding the introduction of ICC Standard No. 185 (AOAC Method 2017.16) to replace AOAC Method 2009.01 (see CRD6), and
      • the proposal from the United States regarding analytical methods for provisions in the Standard for Infant Formula and Formulas for Special Medical Purposes Intended for Infants (CXS 72-1981), namely: thiamine, riboflavin, niacin, Vitamin B6; choline, carnitine; fructans; beta carotene, lycopene; biotin (CRD7).
   ii. establish an in-session working group on Ready-to-use Therapeutic Foods (RUTF), chaired by South Africa and co-chaired by Senegal, working in both English and French, with the following terms of reference:
      • to consider the recommendations of the EWG in document (CX/NFSDU 19/41/6) (food additives and protein quality assessment section);
      • to consider the values and text of Annex “Nutrition Composition for RUTF”; and
      • if time permits, to consider recommendations 5, 6 and 15 – 20 listed in Appendix to CX/NFSDU 19/41/6.

1 CRD1 (Annotated Agenda – Division of competence between the EU and its Member States)
2 CX/NFSDU 19/41/1; CRD6 (ICC); CRD7 (United States of America); CRD20 (Republic of Korea)
7. The Committee noted that some matters were for information only, and that several matters would be considered under other relevant Agenda Items and took the following decisions:

**Methods of Analysis**

8. The Committee agreed that the in-session WG established under Agenda Item 1 would also consider the matters referred by CCMAS as follows:

- Whether the methods for Vitamin K in follow-up formula currently in CXS 234-1999 (AOAC 999.15 / EN 14148) should be replaced by the method endorsed as Type II method for infant formula (AOAC 2015.09 / ISO 21446);
- Whether AOAC 2011.14 / ISO 15151 | IDF 229 as Type III method for calcium, copper, iron, magnesium, manganese, phosphorous, potassium, sodium and zinc in infant formula can be included in CXS 234-1999; and
- Whether the currently used microbiological methods for nicotinamide, niacin, pantothenic acid, pyridoxine, cobalamin and Vitamin D (see Appendix II of CX/NFSDU 17/39/2 Rev) should be retained or not.

**Numerical Method Performance Criteria**

9. The Committee agreed to request CCMAS to develop performance criteria for Type III methods for determination of the nine minerals (calcium, copper, iron, magnesium, manganese, phosphorous, potassium, sodium and zinc) in the *Standard for Infant Formula and Formulas for Special Medical Purposes Intended for Infants* (CXS72-1981), noting that this approach would provide flexibility to members to choose methods for general use; and to inform CCMAS that Type II methods should continue to be listed in CXS 234-1999 as specific methods were preferred for dispute settlement purposes.

**Methods of analysis for gluten free**

10. The Committee noted that it was premature to consider the proposed methods as presented in CX/NFSDU 19/41/2, Appendix I, Part C as research is still ongoing to determine the most appropriate method for determination of gluten.

11. The Committee agreed to wait for the completion of ring trial tests and to consider this matter at a future date when more information became available.

**Editorial amendment to section 5.2 of the Standard for Foods for Special Dietary Use for Persons Intolerant to Gluten (CXS 118 – 1979)**

12. The Committee agreed to align section 5.2 with the wording from the Procedural Manual “For checking the compliance with this standard, the methods of analysis and sampling contained in the Recommended Methods of Analysis and Sampling (CXS 234 – 1999) relevant to the provisions in this standard, shall be used.” The Committee noted that the method for determination of gluten, the enzyme-linked immunoassay (ELISA) R5 Mendez Method is listed in CXS 234-1999 and any changes to the method related to the determination of gluten remained the responsibility of CCNFSDU.

**Conclusion**

13. The Committee agreed to submit this editorial amendment to CXS118-1979 to CAC43 for adoption.

**MATTERS OF INTEREST ARISING FROM FAO AND WHO (Agenda Item 3)**

14. The Representative of FAO called the attention of the Committee to the following issues to be considered under relevant Agenda items: 1) The results of the Joint FAO/WHO Expert Meetings on Nutrition (JEMNU), to provide scientific advice for the establishment of nitrogen to protein conversion factors for soy-based and milk-based ingredients used in infant formula and follow-up formula, noting that the main outcomes of the report, along with the systematic review that had been presented during a side event (held on 23 November 2019); and 2) The Report of the FAO Expert Working Group on Protein Quality Assessment in Follow-up Formula for Young Children and Ready to Use Therapeutic Foods that was published in 2018.

---

3  CX/NFSDU 19/41/2
4  CX/NFSDU 19/41/3
15. The Representative of WHO highlighted some of the activities noted in the document CX/NFSDU 19/41/3 which may be of relevance to the on-going work of the Committee, including updating of nutrient requirements for infants and young children aged 0 – 36 months, various on-going guideline development and WHO’s scaled-up action on eliminating industrially-produced trans-fatty acids (TFA). With reference to the updating of nutrient requirements for infants and young children aged 0 – 36 months, she informed the Committee that the scoping reviews of the first 3 priority nutrients (i.e. calcium, vitamin D and zinc) had been completed and the first expert panel meeting was planned in January 2020 to finalize the scope and PICO questions for the systematic reviews which needed to be undertaken to guide the updates.

16. Regarding the on-going guideline development, the Representative highlighted the guideline development on efficacy, safety and effectiveness of RUTF with reduced milk-protein content, complementary feeding of infants and children, the work of the WHO Nutrition Guidance Expert Advisory Group (NUGAG) Subgroup on Diet and Health which will also review the issues related to the use of low-sodium salt substitutes and the NUGAG Subgroup on Policy Actions which will review the evidence reviews conducted on nutrition labelling policies, marketing policies and fiscal/pricing policies. The Representative also highlighted the WHO’s accelerated efforts in eliminating industrially-produced TFA by 2023 which include monitoring of legislative and regulatory actions in countries.

17. The Committee thanked FAO and WHO for the information and noted that certain parts of the information provided would be considered under relevant Agenda Items.

**REVIEW OF THE STANDARD FOR FOLLOW-UP FORMULA (CODEX STAN 156-1987): DRAFT SCOPE, DESCRIPTION AND LABELLING FOR FOLLOW-UP FORMULA FOR OLDER INFANTS (Agenda Item 4a)**

18. The Committee recalled that the draft scope, description and labelling for follow-up formula for older infants had been adopted at Step 5 by CAC42 and circulated for comments at Step 6. The Committee further noted that CCFL45 had endorsed the labelling provisions with amendments, discussed the text on cross-promotion (the last part of 9.6.4) and noted that it required further consideration in the Committee.

19. The Chair noted that there had been extensive discussion and agreement on the scope, description and labelling sections of the Standard allowing to advance these provisions in the Step process. She further noted that some editorial corrections were necessary to the section on labelling in line with decisions taken at earlier sessions and that the only point remaining for discussion was the part on the prohibition of cross-promotion in 9.6.4.

20. In addition to the editorial corrections e.g. removal of square brackets or corrections for purposes of clarity; and reference to “food additives” rather than “additives” in 9.2.2, the Committee also took the following decisions:

- Replaced the reference to 4.7.1 of the General Standard for the Labelling of Prepackaged Foods (CXS 1 – 1985) (GSLPF) with 4.7 of that standard to ensure that ‘storage instructions’ in section 4.7.2 of the GSLPF are captured; and
- Referred to “follow-up formula for older infants” instead of “products” in 9.6.4 as provisions for follow-up formula for older infants needed to be regulated within the standard itself and should not address other products not covered by the Standard.

**Discussion**

21. The Committee discussed how to address the prohibition of “cross-promotion” in the standard by either retaining the text in the last part of 9.6.4 or finding an alternative text.

22. Those members and observers in support of retaining the text including the term “cross-promotion” expressed the view that cross-promotion was problematic and had a negative effect on the health of infants and young children as it misleads caregivers and discourages breastfeeding; and therefore needed to be prohibited; that there was a definition of ‘cross-promotion’ from WHA 63.14; WHA 69.7 Add.1 and other WHO documents that could help to clarify its meaning and that a definition could be included in the text, for example as a footnote. These delegations also expressed their preference for referring to “labelling” rather than “label”.

---

5 REP19/NFSDU, Appendix II; CX/NFSDU 19/4/1/4 (comments of Argentina, Australia, Brazil, Burkina Faso, Cambodia, Canada, Costa Rica, European Union, Ghana, Indonesia, Iran, Iraq, Kuwait, Mali, New Zealand, Nepal, Norway, Peru, Senegal, Somalia, Sri Lanka, Switzerland, United States of America, Vietnam, HKI, ISDI, UNICEF); CX/NFSDU 19/4/1/4 Add.1 (Ecuador, Indonesia, Kenya, Mali, Senegal, HKI, IBFAN, WPHNA); CRD3 (NZ) CRD21 (ROK); CRD25 (Thailand); CRD27 (Nepal); CRD32 (Nigeria); CRD33 (Dominican Republic); CRD35 (India); CRD41 (Malaysia); CRD42 (Mexico); CRD45 (Laos); CRD48 (Uruguay)
23. Other members and an observer expressed the view that the use of the term “cross-promotion” should be avoided as it was not defined in Codex; and that its use could lead to confusion due to the different interpretations of the term. These delegations proposed to either delete this part of 9.6.4 or to more succinctly capture the concept of cross-promotion in the text rather than referring to the term itself and having to define it. Varying views were expressed on whether to refer to “label” or “labelling”.

24. A delegation also expressed the view that restricting cross promotion could be beyond the mandate of the Committee and Codex.

25. The Committee acknowledged that the intent of 9.6.4. was to avoid consumer confusion through the clear differentiation in labelling between the different products, whereas the intent of not permitting cross-promotion was to prevent reference to [name of product] for young children and formula for infants 0 – 6 months on follow-up formula for older infants.

26. To reconcile the positions on how to reflect this concept, the Committee considered a proposal to delete the last part of 9.6.4 and to include a new section 9.6.5 to address the issue of cross-promotion. After considerable discussion, the Committee agreed to the following text: “The labelling of follow-up formula for older infants shall not refer to infant formula, [name of product] for young children, or formula for special medical purposes intended for infants, including numbers, text, statements, or images of these products”.

27. The Committee noted a proposal to replace “refer” by “resemble”. However, this statement as stated in paragraph 26 was supported in the spirit of compromise and to recognise the will of the Committee to progress this work.

Conclusion

28. The Committee agreed:
   i. to hold the scope, description and labelling provisions at Step 7 (Appendix II);
   ii. to send the labelling provisions in 9.6.5 to CCFL46 for endorsement; and
   iii. to inform CCFL of the editorial and other corrections to sections 9.2.2 (see agenda item 4c, para 67), 9.4.1 and 9.6.4.

REVIEW OF THE STANDARD FOR FOLLOW-UP FORMULA (CXS 156-1987): ESSENTIAL COMPOSITION REQUIREMENTS FOR FOLLOW-UP FORMULA FOR OLDER INFANTS AND [PRODUCT] FOR YOUNG CHILDREN (Agenda Item 4b)

29. The Committee recalled that CCNFSDU40 had agreed on the essential composition requirements for follow up formula for older infants and [name of product] for young children which was held at Step 7, but that two open points remained to be resolved, namely, footnote 4 to the provision for carbohydrates, and section 3.2.1 for [name of product] for young children, and that the EWG on follow-up formula had developed two recommendations on these topics.

Carbohydrates: footnote 4 (Recommendation 1 – option 1 in CX/NFSDU 19/14/5)

30. New Zealand as chair of the EWG recalled that CCNFSDU40 had reached agreement on parts of footnote 4 for [name of product] for young children, including the limit for mono- and disaccharides and that sucrose and/or fructose should not be added to the product. How to limit sweetness in products not based on milk protein remained an issue. The EWG had discussed relevant text that had been left in square brackets making reference to a specific DE limit, which was meant to ensure that carbohydrate sources in products not based on milk protein are not sweeter than lactose which is the preferred carbohydrate in products based on milk protein. Two further proposals, not making reference to sweetness and DE limits were also considered by the 2019 EWG and were included in CX/NFSDU 19/41/5.

31. The EWG Chair explained that there was no consensus in the EWG on the different options and the Committee should take into account the already agreed restrictions and prohibitions in footnote 4 and decide on the best option to limit the sweetness of [name of product] for young children not based on milk protein.

32. The EWG Chair further explained that there appeared to be agreement on the intent of the footnote text which was to limit the sweet taste of products and recalled the original text proposed at CCNFSDU39:

“For products based on non-milk protein, carbohydrate sources (like starch) that have no contribution to sweet taste should be preferred.” (Herein referred to as Option 2)

---

6  REP19/NFSDU, Appendix II; CX/NFSDU 19/41/5; CRD9 (comments of Kenya, Mali, Senegal, HKI; CRD21 (ROK); CRD27 (Nepal); CRD32 (Nigeria); CRD42 (Mexico); CRD45 (Laos)

7  The footnote number reflects the footnote number in CX/NFSDU 19/41/5 which has been corrected to footnote 5 in Appendix III to this report.
33. At CCNFSDU39 this statement was not agreed to because of concern around the ability to measure “sweet taste” and hence a statement on DE was introduced.

34. The EWG Chair therefore proposed to reconsider this statement as it addressed the original intent which had been supported by the Committee. She also provided a further option which could address the concerns raised at CCNFSDU39:

“For products based on non-milk protein, carbohydrate sources that are no sweeter than lactose should be used.” (Herein referred to as Option 3)

Discussion

35. There was general agreement with the principle to restrict sugars and to limit sweetness of these products, however, there were varying views on the different options, with delegations divided between supporting Option 2 or 3.

36. Delegations in favour of Option 2 expressed the view that this was the best option to protect children from the negative effects of overly sweet foods, which, because of addition of sugars or other carbohydrates could lead to an increased risk of obesity and dental caries, and because sweet-tasting products could lead to the development of a preference for sweeter foods in later life.

37. A proposal was made to change the phrase “should be preferred” to “should be used” in Option 2.

38. Other delegations expressed the view that neither provision was necessary because footnote 4 already contained a provision limiting mono- and disaccharides to no more than 2.5 g/100kcal ensuring that the product was no sweeter than breastmilk and cow’s milk. These delegations stated however, that they could support Option 3, and agreed with a proposal to amend the statement to refer to ‘not substantially sweeter' for purposes of flexibility.

39. One delegation clarified that they preferred Option 3 because Option 2 would result in non-milk protein (soy-based) products to be substantially less sweet than milk protein-based product which was not the intention and it might be appropriate for these products to be at least as sweet but not more sweet, than the product containing lactose.

40. An Observer drew the attention of the Committee to ‘reduced’ or ‘low-lactose’ products for young children which needed to be considered when establishing provisions for carbohydrates.

41. The Committee then considered merging the two options and to develop a compromise text.

42. The Committee also considered a proposal to ask CCMAS to look into the availability of methods to measure sweetness noting that standards development organizations (SDOs) were discussing ways to measure sweetness.

43. An Observer noted that there was merit in asking CCMAS to review methods, even if they were sensory methods on the understanding that relative sweetness of lactose is, in their view, based on the 2016 Study: Functionality of sugars in foods and health. Comprehensive Reviews in Food Science and Food Safety 15:433-470.

44. In this context, the Secretariat clarified that generally questions on methods did not prevent the progress of a Standard nor its adoption.

Conclusion (Recommendation 1)

45. The Committee agreed the following compromise text:

“For products based on non-milk protein, carbohydrate sources that have no contribution to sweet taste should be preferred and in no case be sweeter than lactose.”

Section 3.2.1 (Recommendation 2)

46. A delegation pointed out that in addition to known ingredients that enhance or impart a sweet taste that are not included in the category of carbohydrates, there was currently considerable momentum to develop such non-sugar ingredients to strengthen policies for reducing sugars intake. Ingredients that impart or enhance a sweet taste might not necessarily in all cases be classified as food additives and it was expected that the number of ingredients would increase in future. While such ingredients might be used to reduce sugar intakes in adults in line with national public health policies, for the age group of infants and young children, their use might negatively influence the development of taste preferences. In order to future-proof the standard, the provision should ensure that the use of such ingredients were covered by the standard. This delegation, together with other delegations supported changing “substances” to “ingredients” to make it clear that it was about optional ingredients.

47. The Committee further noted that the text (see para 48) might be wrongly placed as the section in question
was about optional ingredients being added for nutritional purposes and not about enhancing sweet taste and therefore agreed to move the text to a new section 3.2.4.

Conclusion (Recommendation 2)

48. The Committee agreed to Recommendation 2 as amended:

“Ingredients shall not be added with the purpose of imparting or enhancing a sweet taste of [name of product] for young children”, and its placement in a new section 3.2.4.

Conclusion

49. The Committee agreed:

i. That work on outstanding points on the essential composition for [name of product] for young children had been concluded, and to hold the essential composition requirements at Step 7 (Appendix III); and

ii. to ask CCMAS whether there were internationally validated methods to measure sweetness of carbohydrate sources for these products.

REVIEW OF THE STANDARD FOR FOLLOW-UP FORMULA (CODEX STAN 156-1987): PROPOSED DRAFT PRODUCT DEFINITION AND LABELLING FOR [PRODUCT] FOR YOUNG CHILDREN (Agenda Item 4c)\(^8\)

50. The Chairperson recalled the decision of the CCNFSDU40 to defer discussion on Section B of the standard, namely: product definition and labelling of [product] for young children, the structure of the standard and preamble, to the current session (CCNFSDU41).

51. New Zealand, chair of the 2018 EWG, recalled that the consideration of the definition of [name of product] for young children by the EWG had been a challenging issue and members had been polarised in their views, in particular on the inclusion of the text ‘as a breast-milk substitute’ in the definition.

52. The EWG had also been divided on the proposed deletion of the text in the last two sentences; [in order to contribute to the nutritional needs of young children] [when nutrient intakes may not be adequate to meet nutritional requirements]. It had been commented by some members that the definition should appropriately capture the role and purpose of this product.

53. Given the near equal split in views on the inclusion or exclusion of the text ‘as a breast-milk substitute’ in the definition and given that the 2017 EWG supported excluding this text, the recommendation to the current session was to follow the 2017 EWG and exclude it.

Discussion

2.1 Product Definition

2.1.1

54. The chair of the EWG recalled the principles that had guided the proposed mandatory (core) composition of this product, notably that the product was manufactured to contribute key nutrients from milk while acknowledging that breast milk, formulas for infants and milk were all suitable for this age group and any levels specified in the standard would need to accommodate these foods.

55. The proposed draft definition as shown below was discussed.

[Name of product] for young children means a product specially [formulated and] manufactured for use [as a breast-milk substitute], as a liquid part of the [progressively] [diversified] diet of young children [in order to contribute to the nutritional needs of young children] [when nutrient intakes may not be adequate to meet nutritional requirements].

56. Delegations reiterated their arguments, previously presented in REP19/NFSDU (paras 53, 54), for and against stating in the product definition that the product was a breast-milk substitute.

57. The main arguments for stating in the product definition that [name of product] for young children is a breast-milk substitute included:

\(^8\) REP19/NFSDU, Appendix IV; CX/NFSDU 19/41/5 Add.1; Comments of Australia, Brazil, Burkina Faso, Canada, Colombia, Costa Rica, Guatemala, Iran, Indonesia, Malaysia, Mali, Nepal, Peru, Philippines, Senegal, Sri Lanka, United States of America, Vietnam, CCTA, ISDI, EU Specialty Food Ingredients, HKI, CRD10 (Indonesia, Mali, Philippines, Senegal, HKI, ISDI, WPHNA); CRD25 (Thailand); CRD27 (Nepal); CRD31 (IBFAN); CRD42 (Mexico); CRD45 (Laos); CRD50 (Proposed text for section 9.6 Additional Labelling Requirements).
• the matter of function has to be considered and not only that of composition;
• the products are frequently marketed as breast milk substitutes and classified as breastmilk substitutes in national regulations, mainly in low and middle-income countries;
• any product that is the liquid part of the diversified diet displaces breast milk, especially when the product is a milk type product;
• WHO Guidance on Ending the Inappropriate Promotion of Foods for Infants and Young Children classifies these products as breast-milk substitutes.9

58. The central arguments for not defining the [name of product] for young children as a breast-milk substitute included:
• the product does not cover all nutritional requirements of a child and can therefore not be defined as a breast-milk substitute;
• it is misleading to describe the product as designed to replace breast milk and could be harmful to the health of infants and young children if it were perceived by consumers as such;
• defining such products as breast-milk substitutes will give them status as alternatives to breast milk;
• the product is used as an alternative to cow’s milk rather than breast milk and was developed to contribute to the needs of young children when they couldn’t get enough micronutrients in their diets.

59. Further discussion followed together with suggested amendments to the text. One proposal was to revise the text to read:

**[Name of product] for young children** means a product manufactured for use as a liquid part of the diversified diet of young children that functions as a substitute for either breast milk or other milks but is not nutritionally adequate to meet the requirements of young children.

60. This definition; particularly the phrase ‘functions as a substitute …’ and ‘… but is not nutritionally adequate …’ received considerable support, but did not allow the Committee to reach consensus. However, in a spirit of compromise and in order to reach consensus, the Committee reached agreement on a revised definition that followed the guidance of the EWG that Codex remain silent on the issue of whether the product was or was not to be described as a breast-milk substitute but with the addition of a footnote to state the fact that these products are regulated as breastmilk substitutes in some countries.

**[Name of product] for young children** means a product manufactured for use as a liquid part of the diversified diet of young children [which may contribute to the nutritional needs of young children].

**Footnote:** In some countries these products are regulated as breast-milk substitutes.

61. The Codex Secretary clarified that while it was preferable to come to clear definitions without having to use footnotes, such footnotes had been used in Codex on occasion to find consensus and resolve issues of different usage of products in different jurisdictions as was the case here with [name of product] for young children.

62. The United States of America expressed its reservation with respect to the footnote to the product definition (section 2.1.1), noting that the use of footnotes, when it is difficult to reach consensus, has proven to be problematic in other committees, and given that a footnote does not reflect a conclusion by Codex but simply states that some countries regulate these products in a certain way at this time. In the US view, the Committee had made many significant revisions to the existing standard; Codex Standards should be forward looking and global in nature.

2.1.2

63. The Committee agreed to maintain a text identical to that for follow-up formula for older infants that was already at Step 7.

**[Name of product] for young children** [Follow-up formula] is so processed by physical means only and so packaged as to prevent spoilage and contamination under all normal conditions of handling, storage and distribution in the country where the product is sold.

---

9 Definition as presented in A69/7 Add.1 to the 69th WHA.
2.2 Other Definitions
2.2.1
The Committee agreed to the text as presented in 2.2.1.

9 Labelling
9.1 The name of the product
64. The Committee agreed to maintain the text corresponding to that for the Section A: follow-up formula for older infants.

9.2 List of ingredients
9.2.1
65. The Committee agreed to maintain the identical text to that for follow-up formula for older infants.

A complete list of ingredients [including optional ingredients] shall be declared on the label in descending order of proportion except that in the case of added vitamins and minerals, these ingredients may be arranged as separate groups for vitamins and minerals. Within these groups the vitamins and minerals need not be listed in descending order of proportion.

9.2.2
66. The Committee agreed to revise the text as it is mandatory to declare functional classes and therefore replace ‘may’ with ‘shall’. It was noted that this wording was a deviation from the General Standard for the Labelling of Prepackaged Foods (CXS 1-1985), section 4.2.3.3, but that the Procedural Manual provided for such deviations.

67. A consequential amendment, substituting ‘may’ for ‘shall’, was therefore also made to the Section A: follow-up formula for older infants (see Appendix II, section 9.2.2)

The specific name shall be declared for ingredients of animal or plant origin and for food additives. In addition, appropriate functional classes for food additives shall be included on the label. The food additive INS number may also be optionally declared.

9.3 Declaration of Nutritive Value
68. The Committee agreed to maintain the text as proposed by CCFL which was similar to the text in the draft standard for follow-up formula for older infants except for paragraph c) regarding serving size. It was acknowledged that explicit mention of serving size was a repetition of indications in the Guidelines on Nutrition Labelling (CXG 2-1985), section 3.4.5, but considered helpful to include in the text as it could prove to be beneficial when dealing with claims.

69. In addition, the declaration of nutrients in a) and b) per [serving size and/or per] 100 kilocalories (kcal) (or per 100 kilojoules) (kJ) and/or per serving size, provided that the serving size is quantified on the label, is permitted.

9.4 Date Marking and Storage Instructions
70. For sections 9.5.1 through 9.5.5 the Committee agreed to use the same text as amended and agreed for Section A: follow-up formula for older infants.

9.5 Information for use
71. The Committee considered the proposed text:

The label of [name of product] for young children shall include a statement that the product shall not be introduced before 12 months of age and should be part of a [diversified] [balanced] diet.

10 Section II: Elaboration of Codex texts
72. The Committee amended the text to clarify the appropriate term for the intended minimum age and to introduce the information that the product 'is not to be used as a sole source of nutrition'.

73. The amended text reads:

The label of [name of product] for young children shall include a statement that the product shall not be introduced to infants 12 months of age or less and is not to be used as a sole source of nutrition.

9.6 Additional Labelling Requirements

74. The Chairperson of the EWG recalled the work that had led up to the drafting of section 9.6 and that the EWG had decided to present a succinct version of the text to the Committee as shown below:

[9.6.1 The label of [name of product] for young children shall have no image, text or representation [including pictures of feeding bottles] that could undermine or discourage breastfeeding or which idealises the use of [name of product] for young children. The terms 'humanized', 'maternalized' or other similar terms must not be used on the label.]

[9.6.2 Products shall be labelled in such a way as to avoid any risk of confusion between infant formula, follow-up formula for older infants, [name of product] for young children, and formula for special medical purposes[ and to enable consumers to make a clear distinction between them, in particular as to the text, images and colours used].

75. The Committee noted that it would not be appropriate to draft the text for this section of the standard drawing on the wording in the Section A: follow-up formula for older infants.

76. The Committee therefore elaborated a revised text which was presented in CRD50.

77. In the discussions on this revised text and subsequent proposed amendments (e.g. adding the text 'Breast milk is the best food for your young child and you should continue to breastfeed'), one member organisation suggested, consistent with decisions taken for section 2.1.1, that a footnote could be employed to serve those countries where the [product] for young children was considered to be a breast-milk substitute.

78. With respect to Section 9.6.5, a Member clarified their understanding that the intention of this provision is that the product labelling cannot include numbers that refer to the other listed products, statements or text that describe or refer to the other listed products, or pictures or pack-shots of the other listed products.

79. The Committee agreed on the text for section 9.6 as presented in CRD50 with an amendment under 9.6.2: the statement 'Breastfeeding is recommended up to two years and beyond' and without footnotes.

80. One Observer expressed their preference for the wording 'resembles' in place of 'refers to' in section 9.6.5.

Name of [product] for young children

81. The Committee considered two names for the product:

'Drink for young children with added nutrients' and 'Drink for young children'.

82. Discussion centred on the need for a name that was neutral and specific without being too generic, as indicated in section 4.1 of the General Standard for the Labelling of Prepackaged Foods which also provides the option to have more than one name for a product.

83. While, some members expressed concern with the first option, as it could be construed as a nutrition claim, it was suggested that two names could be retained in a spirit of compromise. Some Members also proposed to use the term "product", because it may also be available in powder form.

84. The Committee agreed that the names of the product would be 'Drink/Product for young children with added nutrients' and 'Drink for young children', with countries able to choose between these options.

Conclusion

85. The Committee agreed to:

i. forward the proposed draft scope, definition and labelling section to Step 5 for adoption by CAC43 (Appendix IV);

ii. to inform CCEXEC79 that the deadline for completion of work on the Review of the Standard for Follow-up Formula would be adoption by CAC in 2022;

iii. send the labelling provisions to CCFL for endorsement; and
iv. re-establish the EWG chaired by New Zealand and co-chaired by France and Indonesia and working in English to:

a. Finalise the definition of ‘Drink/Product for young children with added nutrients’ and ‘Drink for young children’, by reviewing the outstanding text [which may contribute to the nutritional needs of young children];

b. Consider the linkages and impact between the definition and name for ‘Drink/Product for young children with added nutrients’ and ‘Drink for young children’; and

c. Consider the report and options provided by JEMNU in the Nitrogen to protein conversion factors for soy-based and milk-based ingredient used in infants and follow-up formula, and to what extent it needs to be considered for the revision of the draft standard/s for follow up formula for older infants and ‘Drink/Product for young children with added nutrients’ and ‘Drink for young children’.

REVIEW OF THE STANDARD FOR FOLLOW-UP FORMULA (CODEX STAN 156-1987): PROPOSED DRAFT FOLLOW UP FORMULA FOR OLDER INFANTS AND [PRODUCT] FOR YOUNG CHILDREN (Agenda Item 4d)\textsuperscript{11}

86. Due to time constraints, the Committee agreed to defer discussion on this item to CCNFSDU42 (Appendix V).
87. The Chairperson also informed the Committee that as previously agreed, the structure of the standard and the proposed preamble\textsuperscript{12} would be considered after completion of the other sections of the standard.

PROPOSED DRAFT GUIDELINE FOR READY-TO-USE THERAPEUTIC FOODS (Agenda Item 5a and 5b)\textsuperscript{13}

88. The Chairperson recalled the decisions reached by the Committee at its previous sessions on the various aspects of the guideline. In terms of approach, CCNFSDU agreed that the proposed guideline would cover RUTF as foods for special medical purposes (FSMP) and that the preamble or the introduction (Section 1) should set the scene. CCNFSDU had considered and agreed the following sections (held at Step 4) - Purpose of the guideline (Section 2); Scope (Section 3); the age range of 6-59 months (Section 4 Description); Suitable raw materials and ingredients (Section 5); and Energy (Section 6.1).
89. South Africa, as Chair of the EWG and in-session WG, speaking also on behalf of the co-Chairs Senegal and Uganda, introduced the item and highlighted the recommendations of the in-session WG as contained in CRD49.
90. The Committee agreed to discuss the remaining sections based on recommendations contained in CRD49 and document CX/NFSDU 19/41/6; addressed each recommendation, made appropriate editorial changes and clarified various sections.

\textbf{Section 5.1.4 Cereals and [Tubers]}

91. The Committee confirmed that in some countries or regions “Tubers” were used as raw materials in preparation of RUTF, and that tubers were classified under “tubers, roots and derived products” as per the FAO definition and classification of commodities. Consequently, the heading of the section together with its descriptive text were amended to replace [tubers] with “Roots, Tubers and derived products” and based on these changes the square brackets were deleted.

92. An Observer proposed to insert after “milled cereals” the words “gluten-free by nature”, because 5.6 % of children in Africa were suffering from Coeliac disease and therefore gluten containing foods might cause life-threatening situations for SAM children. South Africa as chair of the eWG informed the Committee that RUTF was manufactured from diverse raw materials and ingredients depending on the country or region and that it would not be practical to require that all raw materials should be gluten-free. The Committee therefore agreed to not accept the proposal.

\textsuperscript{11} CX/NFSDU 19/41/5, CX/NFSDFU 19/41/5 Add.1 (comments of Australia, Brazil, Burkina Faso, Canada, Colombia, Costa Rica, Guatemala, Iran, Indonesia, Malaysia, Mali, Nepal, Peru, Philippines, Senegal, Sri Lanka, United States of America, Vietnam, CCTA, ISDI, EU Special Food Ingredients, HKI); CX/NFSDU 19/41/5 Add. 2 (Chile, Costa Rica, Ecuador, Kenya, Mali, Senegal, HKI, WPHNA) CRD28 (EU); CRD32 (Nigeria)

\textsuperscript{12} REP19/NFSDU Appendix IV

\textsuperscript{13} CX/NFSDU 19/41/6; REP19/NFSDU, Appendix V; CL 2018/64-NFSDU; CX/NFSDU 19/41/6 Add.1 (comments of Argentina, Brazil, Colombia, Ecuador, India, Jamaica, Japan, Malawi, Norway, Sri Lanka, EU Speciality Food Ingredients, HKI, ICAAS, IBFAN, IACFO, IDF, ISDI, MF, UNICEF); CX/NFSDU 19/41/6 Add.2 (Kenya, Senegal); CRD11 (EU, Senegal); CRD19 (AOECS); CRD23 (ISDI); CRD24 (Japan); CRD25 (Thailand); CRD31 (IBFAN); CRD32 (Nigeria); CRD34 (EU)
**Section. 5.2.1 Carbohydrates**

93. The Committee reaffirmed that the use or addition of free sugars in the manufacture of RUTF should be limited and that this should not exceed 20% of total energy. It was also agreed that use of fructose and glucose should not be allowed, and a sentence limiting use of these two ingredients was inserted into the text. The text was endorsed and square brackets were removed from the section.

94. The Representative of WHO stated that WHO has been indicating that free sugars’ content being 20% of total energy was too high and was not in line with the WHO’s guideline on sugars intake, but understood that at present that would be the lowest which could be achieved in order to maintain the integrity of the product. However, further efforts were being made by the suppliers of RUTF to explore the possibilities of lowering the contents of free sugars and therefore the Representative requested UNICEF to provide updates on this effort.

95. The observer from UNICEF explained that they were currently aiming to limit the addition of free sugars to 20% of the energy, which is considered reasonable. However due to the need to ensure a stable supply base, and avoid disruption in the supply chain for RUTF due to changes in specifications, reduction in percentage of added sugar would take a bit of time.

**Section 5.2.2. Food additives**

96. The Committee endorsed the recommendation, agreed to the text on food additives as well as the revised Table A – (Additives in RUTF formulation); and made the following further changes:

- Expressed the maximum use levels for Ascorbyl palmitate (INS 304) and Tocopherol concentrate mixed (307b) as mg/kg RUTF instead of mg/100ml basis; and agreed on a maximum use level of 10 mg/kg;

- Deleted the expression “singly or in combination” on the maximum use levels for Ascorbyl palmitate (INS 304) and tocopherol concentrate mixed (INS 307b).

97. A Member Organisation welcomed the limitation of additives used in RUTF and that this was appropriately ensured through the inclusion of a table that provided a closed list of additives. They noted that in principle, only additives falling under the food category 13.1.3 of the GSFA (Formulae for special medical purposes for infants) for which an appropriate technological justification has been provided should be permitted in RUTF. The use of Ascorbic acid (INS 300) and Silicon dioxide, amorphous (INS 551) though not included in food category 13.1.3, their inclusion in the Table A was however acceptable and that these two additives would comply with all the criteria of use in RUTF.

98. Concerning the placement of the additives, whether in the GSFA or in the guidelines for RUTF, the Codex Secretariat clarified that the Procedural Manual provided for deviations from the procedural requirements of referencing of GSFA, however such deviations have to be fully justified by the Committee.

99. The Committee agreed to include the table of additives in the guidelines noting that this would be the most pragmatic way; and that this would avoid unnecessary delays in the finalization of the guidelines.

**Section 6. Nutritional composition and quality factors**

100. The Committee inserted an introductory statement to ensure linkage between the provisions outlined in the section and those in the Annex.

6.2 Proteins

101. The Committee agreed to the proposal from the in-session WG to the revised text on proteins and endorsed it.

102. On the proposal by a delegation to replace “milk proteins” with “whey proteins” (as these were preferable to “casein” due to their better digestibility properties), the Chairperson noted that it would not be appropriate to refer to a specific type of protein.

**Section 6.5. Water Activity**

103. The Committee transferred the provision on water activity from the Annex to the main body of the standard as a new section 6.5. It was further agreed that only the maximum value of 0.6, should be set.

**Section 7. Contaminants**

104. The Committee considered the section and deleted the extra reference to contaminants arising from pesticide residues (other contaminants); and further agreed with the explanation of the Codex Secretariat to delete proposed maximum values for aflatoxin of 10 ppb as the value would require to be scientifically justified.
Section 8. Processing technologies

105. The Committee endorsed the recommendation on the proposed text for processing technology noting that the section was relevant to the processing and handling of low moisture foods like RUTF.

Section 9: GMP and Good Hygiene Practices

106. The Committee agreed to make reference to other relevant Codex texts noting that this will ensure future proofing of the Standard. Concerning the proposal to include a reference to the Code of Hygienic Practice for Powdered Formulae for Infants and Young Children (CXC 66 -2008), it was clarified that CXC 66 -2008 was applicable to powdered formulas and did not apply to RUTF.

Section 10. Methods of Analysis and Sampling

107. Taking into account the explanation by the Codex Secretariat that CXS 234-1999 was currently under review and that this standard would become the single reference source for methods analysis, the Committee amended the text and made reference to CXS 234-1999 only.

Section 11: Packaging

108. The Committee endorsed the recommendation related to packaging.

Section 12. Labelling

109. The Committee endorsed the labelling provisions as proposed by the In-session working group and agreed that:
   i. The name of the food should make reference to the fact that the target group is SAM children;
   ii. The provisions of section 4.4 and 4.5 in the Standard for the Labelling and Claims for Foods for Special Medical Purposes (CXS 180 -1991) applied to the additional mandatory labelling requirements for RUTF.

Annex

110. The Committee considered the provisions in the Annex – Table of Composition for RUTF and made the following general decisions:
   a) Agreed that the Minimum and Maximum requirements would be expressed per 100 kcal only for both micro- and macronutrients;
   b) Confirmed the minimum and maximum values for energy;
   c) Endorsed recommendations for the proposed minimum and maximum values for: proteins; lipids; vitamins D, E and K, B1; B2; C; B6; B12; Folic acid; Niacin; Pantothenic acid; Biotin; Sodium; Potassium; Calcium; Phosphorus; Iron, Zinc, Copper, Selenium and Iodine.

111. A concern was expressed by one delegation that the nutritional requirements were based on weight of a child and that proposed values for mineral nutrients could exceed the tolerable upper intake level (UL). The Chairperson clarified that RUTF was a short-term intervention for children with SAM, and that the UL values were more applicable to a target population of healthy people and long-term intake of nutrients.

 Essential Fatty acids

112. The Committee considered a proposal to decrease the maximum level of n-6 fatty acids to 780 mg/100kcal and to increase the minimum level of n-3 fatty acids to 110 mg/kcal to avoid negative effects that may arise from depletion of n-3 fatty acids in children with SAM and which may negatively affect their mental development. The Committee noted that more time was needed to examine the implication of the proposed values and agreed to put the values in square brackets for further consideration. The corresponding values in section 6.3 were placed in square brackets accordingly.

 Vitamin A

113. The Committee agreed to the proposal to adjust the maximum value for Vitamin A to a higher value of 308 µg RE/100kcal as this level would take into account raw material variability and degradation of the nutrient through the supply chain i.e. during transportation and storage of premix, RUTF processing and harsh conditions during transport and storage of finished products (i.e. shelf life of 24 months).

 Vitamin D

114. The Committee confirmed that the identified forms of Vitamins D i.e. cholecalciferol (D3) and ergocalciferol (D2) were consistent with the Advisory lists of nutrient compounds for use in foods for special dietary uses intended for infants and young children (CAC/GL 10-1979). It was further observed that both these forms of the Vitamin may be used. Consequentially the square brackets were deleted.
Vitamin E

115. The Committee noted that both the natural or synthetic forms of the nutrient are used in RUTF, and that the conversion factors in the footnotes were important in ensuring that the correct dosage was added to RUTF during manufacture.

Calcium and Magnesium

116. One Observer expressed concern over the high ratio of calcium to magnesium as well as over the generally low minimum and maximum levels being set for magnesium, stating that extensive science supporting higher levels exists and had been previously submitted to the Committee. It was proposed that the levels for magnesium be doubled to be closer to the proposed values for calcium, which was supported by a member and another observer. The Committee agreed to place the proposed values for magnesium in square brackets for further consideration at the next session.

Water Activity

117. The Committee transferred the provision to the main body of the guideline, as the provision was related to the general quality factors (see Section 6.5. Water Activity).

Preamble

118. The Committee considered the preamble recalling the previous decision that this section would be discussed after considering all other sections, and that the section would in general take into account: the appropriate use of RUTF; integration of RUTF into sustainable local family-food-based solutions and how the guidelines on RUTF would be used.

119. The Committee agreed to simplify the text of the preamble to include aspects on basic composition of the product; target age group; and that RUTF was one of the options of dietary management of children with uncomplicated SAM, and the source information that was included in a footnote and to retain the preamble in square brackets for further consideration.

120. One delegation made a proposal, regarding the footnote on the Preamble, to remove the reference to the Joint Statement on Community-Based Management of Severe Acute Malnutrition and also the 1981 International code of marketing of breast-milk substitutes and subsequent relevant WHA resolutions on infant and young child feeding as these products did not fall under the Code.

In response, the Representative of WHO indicated that the proposed draft guidelines for RUTF were based on the 2007 Joint Statement and therefore, it would be important to keep this reference and also the reference to the Code, as well as related WHA resolutions on infant and young child feeding. These would be very relevant and important and should be included in the footnote.

Conclusion

122. The Committee agreed to:

i. Forward the Guidelines for Ready-to-Use Therapeutic Foods to Step 5 for adoption by CAC43 (Appendix VI); and

ii. Send the labelling provisions to CCFL for endorsement; and

iii. Send the food additive provisions to CCFA for endorsement (Appendix VI Table A).

TRANS-FATTY ACIDS

PROPOSED DRAFT CLAIM FOR “FREE OF” TRANSFATTY ACIDS (Agenda Item 6a)

DISCUSSION PAPER ON RISK MANAGEMENT POSSIBILITIES FOR THE REDUCTION OF TFAs (Agenda Item 6b)

123. Canada introduced the item, recalled the history of discussions in CCNFDU on the condition for a claim for “free of” trans fatty acids (TFA) and outlined the approach taken in developing the discussion paper. She proposed that the committee first consider the Codex risk management roles associated with: options C (prohibiting partially hydrogenated oils (PHO)); E (mandatory declaration of TFA on food labels); and G (mandatory distinct declaration of PHO and fully hydrogenated oils in ingredient lists), as these would require amendments to existing standards developed by CCFL and Codex Committee on Fats and Oils (CCFO), which could be completed in a timely manner.

124. The Committee agreed to consider the recommendations as outlined in CX/NSDU 19/41/7 Rev.
Discussion

125. One Member Organization pointed out that following an in-depth impact assessment in 2018, it was concluded that a legal limit for the presence of industrially manufactured TFA in food performed best and a 2% maximum limit in this regard had been established subsequently. It was further suggested that both option B (adopting regulations that limit TFA levels in processed food) and option C (prohibiting partially hydrogenated oils) could mitigate the TFA intake level. Option E (i.e. adopting regulations related to the mandatory declaration of TFA on labels of prepackaged processed foods) was neither cost-effective nor efficient since foods in bakeries and street food which might contain high TFA contents would not normally be labelled. As potential role for Codex to support member countries, most risk management options (4 out of 7) referred to CCMAS to provide advice on reference methods for TFA analysis. Options B and C referred to CCFO and to amend commodity standards to include trans-fat limits and possibly a PHO ban.

126. One Member pointed out that they could not support option E (i.e. amending the Guidelines on Nutrition Labelling (CXG 2-1985)) as this matter had already been considered by CCFL, and that the declaration of trans-fatty acids in nutrition labelling had already been included in footnote 6 of the Guidelines on Nutrition Labelling (CXG 2-1985).

127. The Committee noted the support for option A, option B and/or option C expressed by other Members.

128. The Representative of WHO expressed WHO’s appreciation to the comprehensive analysis done by Canada on risk management possibilities within the Codex mechanism. As also reiterated in Agenda item 3, the elimination of industrially produced TFA by 2023 was WHO’s target and scaled-up actions had been undertaken by WHO and its partners since last year. In this context, WHO was encouraging countries to implement mandatory TFA limitation (described as risk management option B) and PHO ban (described as risk management option C) which WHO considered as the best practice regulatory actions for eliminating industrially produced TFA. Therefore, WHO supported proposed actions by CCFO as suggested by Canada in the document CX/NFSDU 19/41/7-Rev.

129. The Representative further stated that WHO would also support the risk management option E which is to request CCFL/CCNFSDU to make TFA a mandatory nutrient to be declared in nutrient declaration. Unfortunately, TFA was not included in the mandatory nutrients to be declared when total sugars, saturated fatty acids and sodium became the mandatory nutrients to be declared as various countries indicated the lack of TFA data was one of the obstacles in making TFA declaration as mandatory. Therefore, the resolution was to note in a footnote in the Guidelines on Nutrition Labelling (CXG2 – 1985) as an option for countries where the intake level of TFA is a public health concern to implement the declaration of TFA. She pointed out that presently many more countries had TFA data. For example, within the last year, approximately 20 countries had conducted TFA assessments in their food supplies as part of accelerated efforts in eliminating industrially produced TFA by 2023. So the situation was different today and TFA data were available in many more countries.

130. With regards to the comments to seek advice from CCMAS on suitable reference methods of analysis regarding TFA, it was explained that the request was relevant to possible work on labelling which was not under the mandate of CCNSFDU.

Conclusion

131. The Committee agreed:
   i. To discontinue work on the claim for “free” of TFAs and to inform CCEXEC79 and CAC43 accordingly;
   ii. To inform:
      • CCFL of the Committee’s decision to discontinue the work on the condition for a claim for “free” of TFAs and to consider possible actions in CCFL;
      • CCFO of the Committee’s discussions, and to consider work in CCFO on possible ways to reduce TFAs or eliminate PHOs.
   iii. That any member could make proposals to other Codex committees for new work to address the issue of TFAs and could take necessary actions at the national level taking into account the work of WHO.
PROPOSED DRAFT DEFINITION FOR BIOFORTIFICATION (Agenda Item 7)  

132. The Committee recalled the decision of CCNFSDU40 and the view of CCFL45 and highlighted the recommendation of CCEXEC77 i.e. to clarify how a definition would be useful in the context of Codex work and to consider discontinuation of this work if no use was identified (see agenda item 2).

133. Zimbabwe, as the previous Chair of the EWG, speaking also on behalf of the previous co-Chair South Africa, introduced the history of the discussions, explained that extensive work had been undertaken and that the purpose of biofortification was to solve the problem incurred by micronutrient deficiency. He reiterated the importance of the definition in particular for developing countries and proposed possible approaches for the use of a definition e.g. in WHO documents (noting that WHO was possibly working on a definition for biofortification), or in Codex commodity committees such as the Codex Committee on Cereals, Pulses and Legumes (CCCPL).

134. An Observer drew the Committee’s attention to questions relating to: (i) whether biofortification fell within “fortification” as contained in the General Principles for the Addition of Essential Nutrients to Foods (CXG 9-1987); (ii) to consider definitions of the three methods i.e. “agronomic fortification”, “fortification using conventional breeding techniques” and “fortification using the techniques of modern biotechnology” were acceptable; (iii) whether “addition” in the context of the nutrition texts of commodity standards should be defined and whether biofortification could be considered as an “addition”; and (iv) whether this matter could be referred to CCCPL for its consideration on the possibility to add a section in their standards regarding the nutrient profiles.

135. She also informed that a potential location for biofortification in Codex texts could be an amendment to the Codex Principles for the Addition of Essential Nutrients (CXG 9-1987) to include the addition of essential nutrients to foods by indirect methods, including biofortification.

136. The Committee noted: (i) that when this item was first considered by CCNFSDU34 (2012), there were no explanations on different types of biofortification; as well as whether they should be included in the General Principles for the Addition of Essential Nutrients to Foods (CXG 9-1987); and (ii) the view of an Observer, that while biofortification of foods could be beneficial, a much larger problem existed from the significant decline in nutritional content of existing farm produce due to poor agricultural practices in both developed and developing countries; and that this should be addressed.

137. In response to a question about the recent work of WHO on biofortification, the Representative of WHO noted that if the question was referring to the 2016 WHO/FAO technical consultation held in New York and the publication of a series of background papers which were prepared for the consultation, as previously informed to the Committee, it was not a guideline development meeting and therefore did not develop any recommendations. The Representative further noted that there was a description of biofortification of staple foods in the WHO e-Library of Evidence for Nutrition Actions (eLENA). It originated from the fortification work done in 2006 and was updated with the information from the 2016 WHO/FAO technical consultation. At present WHO was not planning to undertake any further work on biofortification.

Conclusion

138. The Committee agreed to discontinue the work and to inform CCEXEC79 and CAC43 accordingly. The Committee noted that any member could, in future, present a proposal for work in this field to any other Codex Committee taking into account the work and conclusion of CCNFSDU.

DISCUSSION PAPER ON NRVs-R FOR OLDER INFANTS AND YOUNG CHILDREN (Agenda Item 8)  

139. Ireland, chair of the EWG, introduced the item, and highlighted the work of the EWG and its key recommendations.

140. She explained that seven recommendations were being put forward for consideration by the Committee, and that there was clear support for recommendations 1, 3, 5 and 6 in the EWG, but that recommendations 2, 4 and 7 had generated mixed feedback and required more detailed discussion by the Committee.

15 REP19/NFSDU, Appendix VI; CRD5 (IFPRI); CRD13 (EU); CRD21 (Republic of Korea); CRD35 (India); CRD36 (Russian Federation); CRD45 (Lao People’s Democratic Republic)

16 CX/NFSDU 19/41/8; CRD14 (Indonesia, Senegal); CRD21 (ROK); CRD25 (Thailand); CRD28 (EU)
Discussion

Recommendation 1 (age ranges)

141. The Committee noted that the proposed age ranges for harmonisation of definitions for older infants would remove the concept of “infants” in four Codex texts, which would be replaced with a new concept of older infants that was only used so far in the Guidelines on formulated complementary foods for older infants and young children (CXG 8 – 1991) and in the draft version of the revised Standard for follow-up formula (see Agenda item 4). The preference was therefore to maintain the established concepts and not to create new terminology. It was noted that in all other relevant Codex texts, infants were considered to be persons of not more than 12 months of age.

142. The Chair of the eWG explained that when considering recommendations from FAO/WHO and other Recognized Authoritative Scientific Bodies (RASBs), different age ranges were used, and it was necessary to clearly define the age ranges for which the work on NRVs was intended.

Conclusion

143. The Committee therefore agreed that NRVs would be developed for persons from 6 months to not more than 12 months and persons from more than 12 months to 36 months (from 1 day after the 1st birthday to day of the 3rd birthday).

Recommendations 2 and 4

144. A Member Organisation expressed the view that establishment of NRVs-R in the Guidelines on Nutrition Labelling might introduce uncertainties for nutrition labelling of certain foods that could be considered as foods for special dietary use and that locating the NRVs-R in these guidelines could lead to the creation of a new product category at the Codex level. The NRVs-R should be established for the age groups agreed under recommendation 1 for voluntary micronutrient declaration under the conditions to be determined within the frame of each of the texts for the 4 standards: i) processed cereal-based foods for infants and young children; ii) canned baby foods; iii) formulated complementary foods for older infants and young children, and iv) follow-up formula for older infants; and located in these standards and guidelines. This was supported by some Members.

145. Other Members expressed support to locate the NRVs-R in the Guidelines on Nutrition Labelling as the other NRV-Rs were already located in these guidelines; and that NRVs-R should apply to general foods for young children. These members explained that in their countries there were already products targeted at young children that were not foods for special dietary use and that these foods would benefit from NRVs for the purpose of labelling to guide appropriate choices by consumers.

Conclusion

146. The Committee agreed that the general principles for the establishment of NRVs-R for the identified age groups would be established in the Guidelines on Nutrition Labelling and that once the NRVs-R were established consideration should be given to how they were presented in the Guidelines on Nutrition Labelling in order to clarify to which foods these would apply to.

Recommendation 5 and 6

147. The Committee agreed to add potassium to the list for which NRVs-R would be established.

148. The Committee noted the diverse views expressed, and agreed to include protein in the list of nutrients to be considered for deriving NRVs-R, but giving it low priority.

Project Document

149. The Committee considered the revised project document, noted the changes made and agreed to the revised timeline.

Conclusion

150. The Committee agreed:

   iv. to continue its work on NRVs-R for persons aged 6 to 36 months following the work programme as spelt out in the revised project document (Appendix VII);

   v. to inform CCEXEC79 of the revised timeline for completion of work;

   vi. to establish an EWG, chaired by Ireland, and co-chaired by Costa Rica and the United States of America, working in English and Spanish, to develop general principles to guide the establishment of NRVs-R for persons aged 6 to 36 months that describe:
a. the most appropriate approach to derive NRVs -R, based on an analysis of Dietary Intake Reference Values (DIRVs) from FAO/WHO and the 6 RASBs; and

b. the purpose(s) of these NRVs -R for labelling and, if appropriate, for composition for Guidelines on Formulated Complementary Foods for Older Infants and Young Children;

The EWG should take into account discussions at CCNFSDU41.

151. The Committee also noted there would be a need for scientific advice which would focus on how the requirements for each of the 24 nutrients were derived by FAO/WHO and 6 RASBs and evaluate and rank these nutrient requirements based on quality of evidence to help inform the work of the Committee.

MECHANISM/FRAMEWORK FOR CONSIDERING THE TECHNOLOGICAL JUSTIFICATION OF FOOD ADDITIVES (Agenda Item 9a)\(^\text{17}\)

152. The European Union, chair of the PWG that met immediately prior to the session, speaking also on behalf of the co-Chair, the Russian Federation, introduced the item, explained the discussions in the PWG, presented the decisions of the PWG and highlighted that the PWG had reached consensus on all the tasks assigned with the exception of the technological justification of gellan gum (INS 418) which had to be decided on by the plenary.

153. The Committee considered the PWG recommendations (as contained in CRD2), took decisions and made comments as follows:

**Recommendation 1: Q3.1 of the framework**

154. The Committee endorsed the recommendation regarding Q3.1 as follows:

> "Q3.1: Does the proposed food additive perform the same/similar technological purpose as other additives that have already been authorized for use in the same product category? If not, what is the justification for the need for an additive with a new functional class and/or technological purpose? If yes, what advantage(s) does the proposed additive provide over currently permitted options?"

**Recommendations 2 and 3: Appraisal of the technological need for xanthan gum (INS 415) and pectins (INS 440)**

155. The Committee endorsed the recommendations that:

- the use of xanthan gum (INS 415) as a thickener in formulas for special medical purposes intended for infants at the maximum level (ML) of 0.1g/100mL, limited to powdered hydrolysed protein and/or amino acid-based formula, is technologically justified; and
- the use of pectins (INS 440) as a thickener in formulas for special medical purposes intended for infants at the ML of 0.2g/100mL, limited to liquid infant formula containing hydrolysed protein is technologically justified.

**Recommendation 4: Appraisal of the technological need for gellan gum**

156. The Committee noted that: (i) the additive for appraisal was low-acyl clarified gellan gum; (ii) additional information in response to the questions raised at the PWG meeting had been provided by the applicant (CRD44); and (iii) the eighty-seventh meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA) had completed the safety evaluation for the substance and concluded there were no safety concerns under the intended conditions of use, and the specifications were assigned as “tentative”.

157. The Committee was reminded to focus its discussions on the technological justification rather than safety aspects which were outside the scope of CCNFSDU.

158. Delegations expressed divergent views on whether sufficient information had been provided on the technological justification for use of the additive in CXS72-1981.

159. Some delegations proposed to defer the consideration of this matter to the next session as more time would be required in order to analyse the additional information provided; others were of the view that the information provided by the applicant was sufficient to justify the technological need as there was an advantage by enabling a lower use level of the additives in formulas for special medical purposes for infants.

\(^\text{17}\) REP19/NFSDU, Appendix VIII; CX/NFSDU 18/40/11; CRD2 (Report of the PWG on the Mechanism/framework for considering the technological justification of food additives); CRD8 (EU); CRD36 (Russian Federation); CRD44 (ISDI)
160. In response to a question relating to the inconsistency of information provided, the applicant confirmed that the substance was used in hydrolysed protein and/or amino acid-based formula in liquid form rather than powdered form (CRD18).

161. The Committee agreed to request the applicant to provide more information on the substance in particular its advantages over currently permitted food additives (i.e. Q3 of the framework).

Others

Inclusion of xanthan gum (INS 415) and pectins (INS440) in CXS 72-1981

162. Following the conclusion on the technological need for xanthan gum (INS 415) and pectins (INS 440), the Committee considered the recommendations referred by the forty-ninth Session of the Codex Committee on Food Additives (CCFA) pertinent to the inclusion of the two food additives in the Standard for Infant Formula and Formulas for Special Medical Purposes Intended for Infants (CXS 72-1981).

163. In light of the fact that the table of food additives in CXS 72-1981 was located in Section A (i.e. infant formula), although these food additives should exclusively be permitted for use in section B (i.e. formulas for special medical purposes intended for infants), the Committee agreed to continue with the current practice i.e. listing these two food additives in Section A of CXS 72-1981, noting that this issue would be corrected through the alignment work.

Appraisal of the technological need for the relevant food additives in CRD15rev of CCFA49

164. One Member Organization, noting that there were additives in CXS 72-1981 for which no appropriate safety assessment for infants (below 12 weeks of age) had been undertaken by JECFA, proposed to initiate a review of technological justifications of additives in CRD15rev of CCFA49 by using the new framework, and to start with the food additives with an ADI specified. The Member Organization further proposed the process to implement this exercise i.e. to set a deadline to collect information, to review the information and to provide recommendations for consideration by the Committee.

165. An Observer supported the proposal and expressed the need to receive sufficient time in order to allow them to consult with their members and generate the required information.

Conclusion

166. The Committee agreed to:

- publish the document titled “CCNFSDU framework for appraising the technological need” as an information document on the Codex website (Appendix VIII Part A);
- forward to CAC43 for adoption the provisions for xanthan gum (INS 415) and pectins (INS 440) as thickeners in the Standard for Infant Formula and Formulas for Special Medical Purposes Intended for Infants, (CXS 72-1981) (Appendix VIII Part B); and
- inform CCFA of the aforementioned decisions and request CCFA to include xanthan gum (INS 415) and pectins (INS 440) in food category 13.1.3 “Formulae for special medical purposes for infants” of the General Standard for Food Additives (CXS 192-1995).

167. The Committee further agreed to establish an EWG, chaired by the European Union and co-chaired by the Russian Federation, working in English with the following terms of reference:

- to collect information from the applicants on the following additives: low acyl clarified gellan gum, ascorbyl palmitate (INS 304), mixed tocopherol concentrates (INS307b) and phosphates (INS 339(i), 339 (ii) and 339(iii) and INS 340(i), 340(ii), and 340(iii)) with the framework for considering technological justifications for use in CXS 72-1981; and
- to review the information provided by the applicants and provide recommendation to the Committee on the technological justification of each additive.
ALIGNMENT OF FOOD ADDITIVE PROVISIONS IN CCNFSDU STANDARDS WITH THE GSFA (Agenda Item 9b)\(^{18}\)

168. Germany introduced the document and explained how the principles for alignment in the guidance document developed by CCFA had been applied for its elaboration.

169. The Chairperson noted that the document would form the basis for further discussion by CCFA. She explained that before forwarding the document to CCFA, the Committee should consider the minimum requirements for alignment (i.e. correct name of each food additive, INS numbers, functional class, and food category).

170. Delegations expressed their appreciation to Germany for the extensive work performed to prepare the document and supported its submission to CCFA for continuation of the alignment work.

171. The Committee agreed that “phosphoric acid (INS 338)”, which had been inadvertently omitted, would be included in Part C of the document (i.e. the Standard for Processed Cereal-Based Foods for Infants and Young Children (CXS 74-1981)).

Conclusion

172. The Committee agreed to forward the document with the correction as indicated in para 171 for consideration by CCFA.

173. With regard to the questions from CCFA\(^{51}\) relating to the appropriate food additive provisions and MLs for the Standard for Formula Foods for Use in Weight Control Diets (CXS 181-1991) and the Standard for Formula Foods for Use in very Low Energy Diets for Weight Reduction (CXS 203-1995) (see agenda item 2), the Committee agreed to inform CCFA that the food additive provisions of the GSFA, in particular those for the food category 13.4 and those of Table 3, are applicable to foods conforming to the two standards.

PRIORITIZATION MECHANISM TO BETTER MANAGE THE WORK OF CCNFSDU (Agenda Item 10)\(^{19}\)

174. Germany as host Secretariat introduced the item and recalled that CCEXC\(^{75}\) requested CCNFSDU to consider a prioritization mechanism to better manage its work. CCNFSDU\(^{40}\) agreed to request the host Secretariat to prepare a discussion paper addressing the concerns of CCEXC. The discussion paper put forward a number of proposals for CCNFSDU to better manage its work: a uniform approach on submission of work proposals; additional prioritisation criteria besides what is set out in the Procedural Manual; use of a circular letter to collect new work proposals; and establishing an ad-hoc working group to review submitted work proposals.

Discussion

175. The Committee welcomed the discussion paper along with the various proposals and approach put forward on work management and noted the following comments made by delegations:

a. A prioritisation mechanism would support in the selection of its work; and allow for establishing long-term planning and work management of the Committee.

b. The criteria for the establishment of work priorities of the Codex Procedural Manual provide a robust starting point for establishing a mechanism for CCNFSDU; and this should be the starting point when setting additional requirements.

c. The prioritisation mechanism should include: i) collection of new topics and the preparation of a summary document; ii) a meeting to review and prioritise the proposals. Beside submitting new work or identifying new topics, the process should also consider how members should take forward or progress such topics.

d. The prioritisation process/framework should be simple and not very burdensome. Some aspects of the proposed mechanism e.g. decision tree would need clarification and review.

e. A framework for identification of emerging issues (topics) should also be considered or included as part of CCNFSDU work management;

f. A pilot phase should be encouraged and undertaken to try out the mechanism.

g. In-session working group to review the proposals and prioritise the proposals would be more sustainable and preferable than holding a physical working group as it would also ensure a higher level of participation.

\(^{18}\) CX/NFSDU 19/41/9; CRD25 (Thailand); CRD35 (India); CRD40 (ISDI)

\(^{19}\) CX/NFSDU 19/41/10; CRD15 (CRN, IADSA); CRD21 (ROK); CRD22 (Canada); CRD25 (Thailand); CRD32 (Nigeria)
h. The availability or the need to request scientific advice may not have a direct link with the prioritisation as some work with highest priority may require extensive scientific advice yet the resources may not be available.

Conclusion

176. The Committee agreed to:

i. The prioritisation mechanism (Appendix IX) and to start it on a pilot basis to assess its usefulness. The framework for prioritisation, after review by the PWG and finalisation by the Committee, would be published as an information document on the Codex website for internal use by the Committee.

ii. Inform CCEXEC that it would be piloting a prioritisation process in line with its request.

iii. Request the Secretariat to issue a Circular Letter (CL) requesting emerging issues and proposals for new work; and

iv. Hold a physical working group, chaired by Germany, working in English, French and Spanish, meeting immediately prior to the next session with the following terms of reference:

a. Adjust the draft framework as necessary of the prioritization mechanism outlined in the draft guideline for the preliminary assessment and identification of work priorities for CCNFSDU with regard to simplification of the criteria and the process.

b. Conduct a case-by-case review of the proposals submitted by the members in response to the CL requesting members and observers to provide information on emerging issues or proposals for new work.

DISCUSSION PAPER ON HARMONIZED PROBIOTIC GUIDELINES FOR USE IN FOODS AND DIETARY SUPPLEMENTS (Agenda Item 11)20

177. Argentina introduced the item and highlighted that the proposed new work aimed at developing an appropriate international framework or harmonised guidelines for probiotics for the use in foods and dietary supplements that would facilitate trade as well as ensure safety to protect the health of consumers. Probiotics were produced and traded globally as live cultures for use as ingredients in foods or dietary supplements. The proposed new work was expected to support national legislative frameworks; and provide a general understanding through setting a definition, minimum characterization requirements, safety criteria, quality and labelling criteria.

Discussion

178. Delegations in support of CCNFSDU initiating new work on the topic, highlighting the need for such a guideline, noted that the guidelines could be established taking into account existing FAO and WHO definitions and guidelines; and that such guidelines should provide high level guidance and principles; should focus on the use of probiotics as ingredients; and should address the need for regulatory harmonisation.

179. Delegations opposed to initiating new work, noted that many of the provisions suggested in the draft discussion paper were already addressed by other Codex standards and guidelines. For example, Codex has adopted principles and horizontal guidelines on labelling, claims, contaminants, safety and hygiene covering all foods, including supplements. Therefore, undertaking the work could risk creating significant duplication, by repeating in a vertical guideline what has already been agreed.

180. These delegations were of the view that FAO and WHO have already undertaken work in this area including establishing a definition for probiotics, and the definition was already widely used as a basis for regulating probiotics and there was no need to use Codex resources to address these issues again.

181. An Observer noted that it had conducted a survey among its members and that it had not identified any trade barriers for the trade of probiotics as food supplements.

182. While responding to the concern whether dietary supplements were covered under the scope of CCNFSDU, the Codex Secretariat clarified that Codex previously elaborated “Guidelines for Vitamin and Mineral Food Supplements (CXG 55-2005) and that they apply only in those jurisdictions where such products as defined in the guideline were regulated as foods (Section 2.1 of the Guidelines).

183. Some delegations confirmed that in their countries dietary supplements including probiotics were regulated under food.

---

20 CX/NFSDU 19/41/11; CRD16 (Indonesia, CRN, IADSA, IPA, YLFA); CRD21 (ROK); CRD25 (Thailand); CRD32 (Nigeria); CRD35 (India); CRD36 (Russian Federation); CRD 39 (Malaysia)
184. The Committee noted that the paper along with the proposed project document needed further clarification especially with regard to the scope and identification of the gaps that needed to be addressed.

**Conclusion**

185. The Committee agreed that the proposal could be submitted in accordance with the prioritization mechanism (see Agenda item 10) for consideration by the WG on prioritization. The Committee noted the offer of Argentina and Malaysia to prepare a revised proposal.

**DISCUSSION PAPER ON GENERAL GUIDELINES TO ESTABLISH NUTRIENT PROFILES (Agenda Item 12)**

186. The Chairperson introduced the agenda item recalling that CCFL44 had informed CCNFSDU about new work on front of pack nutrition labelling (FOPNL) and had asked CCNFSDU to consider how it could contribute.

187. Costa Rica presented the item noting that current Codex texts did not contain any information on the establishment of nutrient profiles which were used on the FOPNL. As regards nutrient profiles for use for front of pack labelling, Costa Rica underlined the need to provide harmonised guidance for nutrient profiles based on scientific evidence and suggested a course of action for the Committee in establishing an EWG to analyze the discussion paper and to define a scope for the development of guidelines to establish nutrient profiles for FOPNL.

**Discussion**

188. The Committee noted that it would be useful to have guidance in order to establish nutrient profiles for the use in FOPNL and that this guidance would be complementary to the work in CCFL on front of pack nutrition labelling.

189. Regarding the work carried out so far and presented in CX/NFSDU 19/41/12, delegations made the following observations:

- the scope of the work needs to be clearly defined also to ensure that it does align well with the CCFL work;
- the link between nutrient profile models and front of pack labelling needs to be clarified;
- it is important to recognize the significance of nutrient profiling, and much work available is based on a large body of science;
- the work could result in guidelines which would also be useful for health claims and an important tool for general health guidelines;
- general guidelines for establishing science-based nutrient profiles together with the progression of work on the front of pack nutrition labelling guidelines at CCFL will provide a common set of guidelines for countries and other stakeholders to use when developing the profiles to support their labelling systems.

190. The Codex Secretariat advised that due to the proximity of the upcoming sessions of both CCFL and CCNFSDU in 2020 (October and November, respectively), there would a need for close coordination with the chairpersons of the EWGs on FOPNL.

191. The Representative of WHO noted that, if the Committee through the EWG intended to work on the principles for developing general guidelines for establishing nutrient profiles, then, it needed to take into consideration the work of CCFL as the nutrient profile is a tool for supporting the development of front of pack labelling, and the nutrient profile should not pre-empt the guidance on the types of front of pack labelling.

**Conclusion**

192. The Committee agreed:

a. to establish an EWG, chaired by Costa Rica and co-chaired by Paraguay, the EU and the United States of America, working in Spanish and English with the following terms of reference:

i. Analyse document CX/NFSDU 19/41/12 ; and

ii. Develop a discussion paper and project document which defines the scope for developing general guidelines for the establishment of nutrient profiles for use in front of pack nutrition labelling.

---

21 CX/NFSDU 19/41/12; CRD17 (Senegal and ISDI); CRD25 (Thailand); CRD32 (Nigeria); CRD33 (Dominican Republic); CRD34 (European Union); CRD36 (Russian Federation); CRD42 (Mexico); CRD46 (Nicaragua)
b. to inform CCFL of the ongoing discussion in CCNFSDU and to ask CCFL to what extent the work concerning nutrient profiles in CCNFSDU can support the work of CCFL on FOPNL and to what extent it is taken into account:

**OTHER BUSINESS AND FUTURE WORK (Agenda Item 13)**

**Methods of analysis**

193. The United States of America introduced the report of the in-session working group (CRD52) and highlighted the recommendations of the WG.

194. The Committee considered the recommendations and took the following decisions:

**Dietary fibre: Applicable to the Guidelines for Use of Nutrition and Health Claims (CXG 23-1997): Table of Conditions for Claims**

195. The Committee noted a concern expressed by a Member Organization that the method was intrinsically linked to the condition for a claim in the Guidelines for Use of Nutrition and Health Claims and should be considered more closely, and in case concerns were raised at CCMAS it should be referred back to CCNFSDU.

196. The Committee agreed to submit to CCMAS the method for dietary fibre, ICC Standard No. 185 / AOAC 2017.16 / as Type I method to replace AOAC 2009.01 / AACC Intl 32-45.01.

**Methods of analysis for provisions in the Standard for Infant Formula and Formulas for Special Medical Purposes Intended for Infants (CXS 72-1981)**

197. The Committee agreed to:

- submit the methods to CCMAS for review, endorsement as Type II and inclusion in CXS 234-1999:
  i. AOAC 2015.14 / ISO DIS 21470 for thiamine, riboflavin, niacin, vitamin B6;
  ii. AOAC 2015.10 / ISO DIS 21468 for choline and carnitine;
  iii. AOAC 2016.13 / ISO 23443 for beta-carotene and lycopene;
  iv. AOAC 2016 17 / ISO DIS 22579 | IDF 241 for fructans;
  v. AOAC 2016.02 / ISO DIS 23305 for biotin.
- request CCMAS to re-type the existing Type II methods for aforementioned nutrients as Type III in CXS 234-1999; and
- inform CCMAS that it could include AOAC 2011.14 / ISO 15151 | IDF 229 for calcium, copper, iron, magnesium, manganese, phosphorous, potassium, sodium and zinc as Type III in CXS 234-1999.

**Microbiological methods**

198. The Committee agreed to inform CCMAS that the microbiological methods for nicotinamide, niacin, pantothenic acid, pyridoxine, cobalamin, and Vitamin D were still in use and to retain these methods.

**Methods of analysis for provisions in the Standard for Follow-Up Formula (CXS 156 -1987)**

199. The Committee agreed to inform CCMAS to replace AOAC 999.15 / EN 14148 for vitamin K with AOAC 2015.09 / ISO 21446 as Type II.

**New work proposal on establishing harmonized guidelines for the qualification of nutrition and health claimed food**

200. The Committee noted the proposal of Republic of Korea for new work on establishing harmonized guidelines for qualification of nutrition and health claimed food and agreed that the proposal should be resubmitted in accordance with the prioritization mechanism (see agenda item 10) for consideration by CCNFSDU42.

**DATE AND PLACE OF THE NEXT SESSION (Agenda Item 14)**

201. The Committee was informed that the 42nd session was scheduled to be held from 23 to 27 November 2020, the final arrangements being subject to confirmation by the host government in consultation with the Codex Secretariat.

---

**Notes:**

22 CRD6 (ICC); CRD7 (USA); CRD20 (ROK); CRD30 (ISDI)
APPENDIX I

LIST OF PARTICIPANTS
LISTE DES PARTICIPANTS
LISTA DE PARTICIPANTES

CHAIRPERSON – PRÉSIDENT – PRESIDENTE
Dr Anja Brönstrup
Federal Ministry of Food and Agriculture
Bonn

VICE-CHAIRPERSON – VICE-PRÉSIDENT – VICEPRESIDENTE
Mrs Hilke Thordsen
Federal Ministry of Food and Agriculture
Berlin

ASSISTANT TO THE CHAIRPERSON - ASSISTANT AU PRÉSIDENT - ASISTENTE AL PRESIDENTE
Dr Manuela Rist
Max-Rubner-Institut
Karlsruhe

MEMBER COUNTRIES - PAYS MEMBRES - PAÍSES MIEMBROS

ALGERIA - ALGÉRIE - ARGELIA
Eng Henda Souilamas
Directrice de la qualité et de la consommation
Alger

ARGENTINA - ARGENTINE
Ms Andrea Moser
Jefa del Servicio de Alimentos Especiales
Ministerio de Salud y Desarrollo Social
Buenos Aires

Ms Soledad Echarri
Asistente técnica
Ministerio de Salud y Desarrollo Social
Buenos Aires

Ms María Belén García
Regulatory Science Manager
Asociación de Empresas de Nutrición Infantil (ANI)
Munro, Provincia de Buenos Aires

Eng María Alejandra Larre
Asesora del Punto Focal del Codex Alimentarius de Argentina

ARGENTINA - ARGENTINE

Ms Emilce Analía Castellani
Presidente del Departamento Técnico
Centro de la Industria Lechera
Buenos Aires

Ms María Belén García
Regulatory Science Manager
Asociación de Empresas de Nutrición Infantil (ANI)
Munro, Provincia de Buenos Aires

Eng María Alejandra Larre
Asesora del Punto Focal del Codex Alimentarius de Argentina

AUSTRALIA - AUSTRALIE
Ms Jenny Hazelton
Manager, Labelling and Information Standards
Food Standards Australia New Zealand (FSANZ)
Kingston ACT

Ms Christel Leemhius
Director, Food & Nutrition Policy
Australian Government Department of Health
Canberra

Mr Justin Peace
Technical, Research and Development Manager
Nuchev Food
Melbourne
AUSTRIA - AUTRICHE
Mrs Lisa-Maria Urban
Deputy Head of Division
Federal Ministry of Labour, Social Affairs, Health and Consumer Protection - Austria
Vienna

Ms Judith Benedics
Executive Officer
Federal Ministry of Labour, Social Affairs, Health and Consumer Protection - Austria
Vienna

BANGladesh
Mr Md. Nozir Ahmmod Miah
Assistant Director
Bangladesh Standards and Testing Institution
Dhaka

BELGIUM - BELGIQUE - BÉLGICA
Ms Isabelle Laquière
Regulatory Expert
FPS public health.
Brussels

BOTSWANA
Ms Onalenna Ntshebe
Chief Health Officer
Ministry of Health and Wellness
Gaborone

Mrs Vanity Motsapele Mafule
Assistant Director
Ministry of Local Government and Rural Development
Gaborone

Ms Lephutshe Ada Senwelo
Senior Scientific Officer – Food Safety
Ministry of Health and Wellness
Gaborone

Mr Solly Setso
Deputy Ambassador - Germany
Botswana Embassy - Germany

Mrs Gladness Oabile Tlhomelang
Chief Dietitian
Ministry of Health and Wellness
Gaborone

BRAZIL - BRÉSIL - BRASIL
Mrs Ana Claudia Marquim Firmo De Araujo
Specialist on Regulation and Health Surveillance
Brazilian Health Surveillance Agency - ANVISA
Brasília-DF

Ms Isabelle Laquière
Regulatory Expert
FPS public health.
Brussels

Mr Alexandre Novachi
Director of Scientific and Regulatory Affairs
ABIA – Brazilian Association of Food Industries
São Paulo

Ms Isabelle Laquière
Regulatory Expert
FPS public health.
Brussels

Ms Fabiana Seung Ji De Queiroz
Director of Regulatory Affairs and Pharmacovigilance
Confederação Nacional da Indústria - CNI
São Paulo

Mr Helio Vannucchi
Senior Professor
University of São Paulo
Riberão Preto

BURKINA FASO
Mr Cyrille Sansan Régis Kambire
Cadre Supérieur/Service du Contrôle Phytosanitaire et de la Qualité des Aliments
Ministère de l’Agriculture
ouagadougou

Mr Abdoulaye Gueye
Responsable de la sécurité sanitaire des aliments
Ministère de la Santé Publique
ouagadougou

CAMBODIA - CAMBODGE - CAMBOYA
Mr Theng Dim
Deputy Director General
Ministry of Commerce
Phnom Penh

Mr Kroeun Hou
Deputy Director
Helen Keller International Cambodia Office
Phnom Penh
<table>
<thead>
<tr>
<th>Country</th>
<th>Name</th>
<th>Position</th>
<th>Organization/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAMEROON</td>
<td>Mrs Cecile Patricia Ngo Sak</td>
<td>Sous directeur de l'Alimentation et de la Nutrition</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mr Louis Walter Mamia Ndongo</td>
<td>Chargé d'Étude Assistant</td>
<td>Ministère des Mines de l'Industrie et du Développement Technologique</td>
</tr>
<tr>
<td>CANADA</td>
<td>Ms Maya Villeneuve</td>
<td>Associate Director</td>
<td>Bureau of Nutritional Sciences Health Canada Ottawa</td>
</tr>
<tr>
<td></td>
<td>Ms Patricia Hoy</td>
<td>Senior Trade Policy Analyst</td>
<td>Agriculture and Agri-Food Canada Ottawa</td>
</tr>
<tr>
<td></td>
<td>Mrs Chantal Martineau</td>
<td>Manager, Regulatory Projects</td>
<td>Health Canada Ottawa</td>
</tr>
<tr>
<td></td>
<td>Mrs Annie Morvan</td>
<td>National Manager</td>
<td>Canadian Food Inspection Agency Ottawa</td>
</tr>
<tr>
<td>CHILE</td>
<td>Mrs María Paz Grandon</td>
<td>Jefe de División</td>
<td>Ministerio de Salud Santiago</td>
</tr>
<tr>
<td></td>
<td>Mr Cristian Cofre</td>
<td>Asesor Técnico</td>
<td>Ministerio de Salud Santiago</td>
</tr>
<tr>
<td>CHINA</td>
<td>Ms Ailun Chao</td>
<td>Scientific Regulatory Affair Manager</td>
<td>China Nutrition and Health Food Association Regulatory Standards Committee</td>
</tr>
<tr>
<td></td>
<td>Mrs Fang Gao</td>
<td>Deputy Division Director</td>
<td>Center for Agro-Food Quality &amp; Safety, Ministry of Agriculture and Rural Affairs, P.R.China</td>
</tr>
<tr>
<td></td>
<td>Prof Junhua Han</td>
<td>Professor</td>
<td>Chinese Nutrition Society</td>
</tr>
<tr>
<td></td>
<td>Ms Nuo Jin</td>
<td>Research Assistant</td>
<td>Institute of Food Science and Technology CAAS</td>
</tr>
<tr>
<td></td>
<td>Mrs Xiaowei Li</td>
<td>Regulatory Affairs Manager</td>
<td>China Nutrition and Health Food Association Regulatory Standards Committee</td>
</tr>
<tr>
<td></td>
<td>Mrs Heli Liu</td>
<td>Regulatory Affairs Director of Greater China</td>
<td>China Nutrition and Health Food Association Regulatory Standards Committee</td>
</tr>
<tr>
<td></td>
<td>Mr Aidong Liu</td>
<td>Researcher</td>
<td>China National Center for Food Safety Risk Assessment</td>
</tr>
<tr>
<td></td>
<td>Mrs Hong Wu</td>
<td>Director of Regulatory Affairs</td>
<td>China Nutrition and Health Food Association Regulatory Standards Committee</td>
</tr>
<tr>
<td></td>
<td>Mrs Hoi Lam Alam Ng</td>
<td>Scientific Officer</td>
<td>Food and Environmental Hygiene Department, Hong Kong</td>
</tr>
<tr>
<td></td>
<td>Ms Mengting Wang</td>
<td>Assistant of Regulations Department</td>
<td>China Nutrition and Health Food Association</td>
</tr>
<tr>
<td>COSTA RICA</td>
<td>Ms Amanda Cruz</td>
<td>Asesor Codex</td>
<td></td>
</tr>
<tr>
<td>COLOMBIA</td>
<td>Prof Alba Rocio Jimenez Tovar</td>
<td>Profesional Especializada</td>
<td>Instituto Nacional de Vigilancia de Medicamentos y Alimentos – INVIMA</td>
</tr>
<tr>
<td></td>
<td>Mr Haiqi Yu</td>
<td>Regulatory Affairs Manager</td>
<td>China Nutrition and Health Food Association Ingredients Specialized Committee</td>
</tr>
<tr>
<td></td>
<td>Ms Amanda Cruz</td>
<td>Asesor Codex</td>
<td></td>
</tr>
</tbody>
</table>
Ministerio de economía Industria y Comercio
San Jose

Mrs Laura Judith Otalora Cortes
Cámara Costarricense de la Industria
Alimentario - CACIA
San Jose

CROATIA - CROATIE - CROACIA

Ms Marija Pašalić
Head of Service
Ministry of Health
Zagreb

CUBA

Mrs Yarisa Domínguez Ayllón
Jefa Departamento de Nutrición Comunitaria
Instituto de Higiene Epidemiología y
Microbiología INHEM
La Habana

DENMARK - DANEMARK - DINAMARCA

Mrs Dagny Løvoll Warming
Scientific Officer
Danish Veterinary and Food Administration
Glostrup

Mrs Charlotte Ruby
Senior Advisor
Sedan

ECUADOR - ÉQUATEUR

Ms Angélica Dayana Tutasí Lozada
Coordinadora de Nutrición, Seguridad y
Soberanía Alimentaria
Ministerio de Salud Pública
Quito

EGYPT - ÉGYPTE - EGIPTO

Dr Haidy Mohyeldin Hamdy Abdelkarim
Regulatory Affairs External Engagement
Manager-North Africa & Levant
PepsiCo International Egypt
Cairo

Dr Adel Saadeldin Ismail Abdin
Research and Development Director
Hero Middle East & Africa
New Cairo

Dr Laila Ahmed Kamal Alsayed
Quality Consultant
Riri Baby Food Co.
Cairo

Dr Rasha Salaheldin Kamel Galal
Head of the Department
Egyptian National Food Safety Authority
Cairo

Dr Nermeen Ibrahim Eldesokey Khalifa
Scientific & Regulatory Affairs Senior Manager
Coca-Cola Atlantic Industries
Cairo

Prof Mervat Ahmed Fouad Nasr
Consultant of Special Food and Pharmacognosy
National Nutrition Institute (NNI)
Giza

Dr Shaymaa Mohamed Gamaleldein Khalel
Regulatory and Scientific Affairs Senior
Manager North East Africa
Nestle-Egypt
New Cairo

Eng Yasser Mansour Khalil Shazly
Regulatory & Scientific Manager
Nestle Waters
Cairo

ESTONIA - ESTONIE

Mrs Evelin Kivima
Chief Specialist
Ministry of Rural Affairs
Tallinn

EUROPEAN UNION - UNION EUROPÉENNE -
UNIÓN EUROPEA

Mr Sebastian Goux
Deputy Head of Unit
European Commission
Brussels

Ms Stephanie Bodenbach
Administrator
European Commission
Brussels

Ms Fruzsina Nyemecz
Administrator
European Commission
Brussels

Mr Jiri Sochor
Head of Sector
European Commission
Brussels

Ms Anna Szajkowska
Administrator
European Commission
Brussels

FINLAND - FINLANDE - FINLANDIA

Ms Anna Lemström
Senior Officer, Food Policy
Ministry of Agriculture and Forestry

Dr Minna Huttunen
Senior Officer, Food Policy
Ministry of Agriculture and Forestry

Mr Alexander Rogge
Political Administrator
Council of the European Union - Directorate-General LIFE

FRANCE - FRANCIA

Ms Alice Stengel
Ministère de l'économie, de l'industrie et du numérique
Paris

Mrs Louise Dangy
Point de contact national
SGAE
Paris

GAMBIA - GAMBIE

Dr Amat Bah
Deputy Executive Director
National

GERMANY - ALLEMANGE - ALEMANIA

Mr Nikolas Roh
Federal Ministry for Food and Agriculture
Berlin

Mr Hermann Josef Brei
Deputy Head of Unit
Federal Ministry of Food and Agriculture
Bonn

Dr Anke Weißenborn
Scientist
Federal Institute for Risk Assessment
Berlin

Mrs Tatjana Drewitz
Federal Office of Consumer Protection and Food Safety
Berlin

Ms Claudia Callies-kläpfel
Manager Global Regulatory & External Affairs
Human Nutrition
BASF SE
Lampertheim

Ms Maria Dubitsky
Managing Director
Maria Dubitsky Consulting GmbH
München

Dr Gert Krabichler
Representing P&G Health Germany GmbH
Darmstadt
Food-Pharma OTC Consult
Grenzach

Dr Sarah Methner
Regulatory and Scientific Affairs
Federation of German Dietetic Foods Industry
Bonn

Ms Angelika Mrohs
Managing Director
Food Federation Germany
Berlin

Mr Norbert Pahne
Managing Director
Diätverband e.V.
Bonn

Ms Antje Preußker
Manager Scientific and Regulatory Affairs
Food Federation Germany
Berlin

Dr Joerg Rieke
Executive Director
Association of the German Dairy Industry
Berlin

Ms Sabine Sulzer
Regulatory and Scientific Affairs
Nestlé Deutschland AG
Frankfurt am Main

Mrs Petra Wendorf-Ams
Nutricia Research Early Nutrition Team
Milupa Nutricia GmbH
GHANA
Ms Maria Aba Lovelace-Johnson
Chief Regulatory Officer
Food and Drugs Authority
Accra

Mrs Gloria Aba Aryee
Principal Regulatory Officer
Food and Drugs Authority
Accra

HUNGARY - HONGRIE - HUNGRÍA
Dr Márta Horacsek
Head of Department
National Institute of Pharmacy and Nutrition
Budapest

INDIA - INDE
Dr Suchita Ninawe
Scientist-G
Ministry of Science and Technology
New Delhi

Mr Ganesh Vishweshwar Bhat
Technical Officer
Food Safety and Standards Authority of India
New Delhi

Mrs Shalini Gupta
Assistant Technical Adviser
Ministry of Women and Child Development
New Delhi

Mr Lalan Prasad Sharma
Deputy Secretary
Ministry of consumer Affairs, Food and public Distribution
New Delhi

INDONESIA - INDONÉSIE
Dr Sutanti Siti Namtini
Director of Processed Food Standardization
National Agency of Drug and Food Control
Jakarta

Mr Rifqi Ansari
Head of Section on Industrial Resources
Ministry of Industry of Indonesia
Jakarta

Prof Purwiyatno Hariyadi
Vice Chairperson of the Codex Alimentarius Commission

Bogor Agricultural University (IPB)
Bogor

Mrs Nani Hidayani
Indonesia Position
Asosiasi Perusahaan Produk berNutrisi untuk Ibu dan Anak (APPNIA)
Jakarta Selatan

Mr Agus Jarwanto
Head of Subdirectorate
Ministry of Industry of Indonesia
Jakarta

Mrs Fenta Yanuwati Sandiko
Asosiasi Perusahaan Produk berNutrisi untuk Ibu dan Anak (APPNIA)
Jakarta Selatan

Dr Prima Sehanputri
Committee
The Indonesian Food and Beverages Association
Jakarta Selatan

Mrs Roch Ratri Wandansari
Vice Chairman
The Indonesian Food and Beverages Association
Jakarta Selatan

IRAN (ISLAMIC REPUBLIC OF) - IRAN (RÉPUBLIQUE ISLAMIQUE D') - IRÁN (REPÚBLICA ISLÁMICA DEL)
Mr Hany Tahvilzade
Expert
Private Sector
Teheran

IRELAND - IRLANDE - IRLANDA
Dr Mary Flynn
Chief Specialist Public Health Nutrition
Food Safety Authority of Ireland
Dublin

Ms Oonagh Lyons
Technical Executive
Food Safety Authority of Ireland
Dublin

ITALY - ITALIE - ITALIA
Mr Ciro Impagnatiello
Codex Contact Point
Ministry of Agricultural Food and Forestry
Policies
Rome

JAPAN - JAPON - JAPÓN

Ms Kaoru Uno
Deputy Director
Consumer Affairs Agency
Tokyo

Dr Tsuyoshi Chiba
Chief of Department
National Institute of Health and Nutrition,
National Institutes of Biomedical Innovation,
Health and Nutrition
Tokyo

Ms Akane Hayashi
Technical Officer
Ministry of Health, Labour and Welfare
Tokyo

Ms Hiroko Hosaka
Assistant manager
Consumer Affairs Agency
Tokyo

Ms Mitsuko Imai
Deputy Director
Ministry of Health, Labour and Welfare
Tokyo

Dr Hidemi Takimoto
Chief of department
National Institute of Health and Nutrition,
National Institutes of Biomedical Innovation,
Health and Nutrition
Tokyo

KENYA

Mr Mutua Peter
Ag, Assistant Manager - Food Standards
Kenya Bureau of Standards
NAIROBI

Ms Beatrice Nyamwamu
Manager
Regulations and Compliance
Nairobi

Mr James Ojambo Olumbe
Member National Codex - Executive Committee
Nestle Kenya Limited
Nairobi

JORDAN - JORDANIE - JORDANIA

Mrs Reema Zoubi
Standardization Officer
Jordan Standard and Metrology Organization
Amman

KAZAKHSTAN - KAZAJSTÁN

Dr Nailya Karsybekova
Regional Coordinator CCEURO
Ministry of Health of RoK
Astana

Ms Zhanar Tolysbayeva
Expert on hygiene of nutrition
Ministry of Healthcare the Republic of

LITHUANIA - LITUANIE - LITUANIA

Mrs Ieva Gudanaviciene
Chief expert of Health Promotion Division
Ministry of Health of Lithuania
Vilnius

MALAYSIA - MALAISIE - MALASIA

Ms Ruhana Abdul Latif
Principal Assistant Director
Ministry of Health Malaysia
Putrajaya

Mr Ali Muzammil Abdullah
Regulatory Affairs and Policy Director
Mead Johnson Nutrition (Malaysia) Sdn Bhd
Kuala Lumpur

Mr Hiroshi Hamada
Director
Yakult (Malaysia) Sdn Bhd
Shah Alam, Selangor

Ms Mazlyn Mena Mustapha
Senior Manager
Yakult (Malaysia) Sdn Bhd
Shah Alam, Selangor

Dr Kanga Rani Selvaduray
Head of Nutrition Unit
Malaysian Palm Oil Board
Kajang, Selangor

Ms Fatimah Sulong
Senior Principal Assistant Director
Ministry of Health Malaysia
Putrajaya

Dr E Siong Tee
President
Nutrition Society of Malaysia
Petaling Jaya

MOROCCO - MAROC - MARRUECOS

Dr Nezha Mouane
Presidente
Moroccan Society of Pediatric Gastroenterology and Nutrition
RABAT

Prof Youssef Aboussaleh
Professor and Researcher / General Secretary
of the Moroccan Nutrition Society
Ibn Tofail University / Moroccan Nutrition Society
Kenitra

Mr Hicham Badour
Chef d'Unité
Département Pharmacie
Rabat

Dr Salima Bennani
Pharmacist inspector
Medicines and Pharmacy Directorate
Rabat

Mrs Nawal Bentahila
Presidente
Association Marocaine de Nutrition Infantile
Casablanca

Mr Tannaoui Mohamed
Chef de la Section Agricole
Laboratoire Officiel d'Analyses et de Recherches Chimiques
Casablanca

Eng Karom Mohamed El Mahdi
Ingénieur en Industrie Agro-alimentaire
ONSSA
Rabat

NEPAL - NÉPAL

Dr Matina Joshi Vaidya
Director General
Department of Food Technology and Quality
Control, Ministry of Agriculture and Livestock Development
Kathmandu

Dr Atul Upadhyay
Project Director
Helen Keller International
Kathmandu

NETHERLANDS - PAYS-BAS - PAÍSES BAJOS

Ms Erika Smale
Senior Policy Advisor
Ministry of Health, Welfare and Sports
The Hague
NEW ZEALAND - NOUVELLE-ZÉLANDE - NUEVA ZELANDIA

Ms Jenny Reid
Manager, Market Access
Ministry for Primary Industries
Wellington

Ms Jane Broughton
Regulatory Manager
Fonterra CO-OP LTD.
Palmerston North

Mrs Charlotte Channer
Specialist Adviser Nutrition
Ministry for Primary Industries
Wellington

Ms Dianne Lowry
Regulatory and Technical Liaison Manager
Dairy Goat Co-operative (NZ) Ltd
Hamilton

NIGER - NÍGER

Mr Salou Dioffo Alahouynouma
Point de contact codex Niger (Spécialiste en Nutrition et santé des Populations Direction de la Nutrition/Ministère de la Santé Publique Niamey

Mr Madame Tahirou Rahila Rabiou
Conseillère à l’ambassade du Niger à Rome en Italie Ambassade du Niger en Italie

NIGERIA - NIGÉRIA

Mrs Eva Obiageli Edwards
Deputy Director
National Agency for Food and Drug Administration and Control
Lagos

NORWAY - NORVÈGE - NORUEGA

Mrs Svanhild Vaskinn
Senior Adviser
Norwegian Food Safety Authority
Brumunddal

Mrs Gry Hay
Senior Adviser, Dr.Philos
Norwegian Directorate of Health
Oslo

PANAMA - PANAMÁ

Eng Joseph Gallardo
Ingeniero de Alimentos / Punto de Contacto Codex
Ministerio de Comercio e Industrias Panama

PARAGUAY

Mr Alberto Francisco Bareiro Arce
Coordinador de Asuntos Regulatorios Instituto Nacional de Alimentación y Nutrición del Ministerio de Salud Pública y Bienestar Social
Asunción

PERU - PÉROU - PERÚ

Mrs Mirtha Rosario Trujillo Almandoz
Presidente del Comité Nacional del Codex DIGESA/MINSA Lima

Mr Robinson Cruz Gallo
Miembro del Comité Nacional del Codex de Nutrición y Remines-Perú Instituto IIDENUT
Lima

Eng Ernesto José Dávila Taboada
Aseor Tecnico ADEX (ASOCIACION DE EXPORTADORES)
Lima

PHILIPPINES - FILIPINAS

Ms Helena Alcaraz
Food and Drug Regulation Officer V Food and Drug Administration
Muntinlupa City

Ms Strawberry Alberto
Nutrition Officer ii Nutrition Policy and Planning Division
Taguig

Ms Michelle Mendador
Official Representative Infant Nutrition Association of the Philippines
Makati City

POLAND - POLOGNE - POLONIA

Dr Katarzyna Stos
Deputy Director
National Food and Nutrition Institute  
Warsaw

Mrs Anna Janasik  
Main Expert  
Agricultural and Food Quality Inspection  
Warsaw

REPUBLIC OF KOREA - RÉPUBLIQUE DE CORÉE - REPÚBLICA DE COREA

Dr Chan Soo Lee  
Officer  
Ministry of Food and Drug Safety  
ChungCheongBuk-Do

Ms Young-Ji Jung  
Scientific Officer  
Ministry of Food and Drug Safety  
ChungCheongBuk-Do

Ms Youngsin Kim  
Codex Researcher  
Ministry of Food and Drug Safety  
ChungCheongBuk-Do

Ms Hye Ok Min  
Scientific Officer  
Ministry of Food and Drug Safety  
ChungCheongBuk-Do

RUSSIAN FEDERATION - FÉDÉRATION DE RUSSIE - FEDERACIÓN DE RUSIA

Dr Elena Smirnova  
Scientific Secretary  
Federal Research Centre of Nutrition, Biotechnology and Food Safety  
Moscow

Mrs Yuliya Kalinova  
Regulatory Affairs Expert  
Consumer Market Participants Union  
Moscow

Mr Dmitriy Miklin  
Regulatory Affairs Expert  
Consumer Market Participants Union  
Moscow

Dr Alexey Petrenko  
Expert  
Federal Research Centre of Nutrition, Biotechnology and Food Safety  
Moscow

Mrs Veronika Vysotskaya  
Expert

Consumer Market Participants Union  
Moscow

SAUDI ARABIA - ARABIE SAoudite - ARABIA SAUDITA

Mr Fahad Albadr  
Senior Nutrition Specialist  
Saudi Food and Drug Authority  
Riyadh

Mr Abdulaziz Alangaree  
Senior Nutrition Specialist  
Saudi Food and Drug Authority  
Riyadh

Mrs Tagreed Alfuraih  
Senior Dietitian  
Saudi Food and Drug Authority  
Riyadh

SENÉGAL - SÉNÉGAL

Dr Maty Diagne Camara  
Chef de la division de l'Alimentation et de la Nutrition  
Ministère de la Santé et de l'Action Sociale  
Dakar

Dr Ismaila Thiam  
Chef Departement Alimentation et bien etre  
Universite Gaston Berger  
Saint-Louis

SINGAPORE - SINGAPOUR - SINGAPUR

Ms Peik Ching Seah  
Deputy Director  
Singapore Food Agency

Ms Yi Ling Tan  
Assistant Director  
Singapore Food Agency  
Singapore

SLOVAKIA - SLOVAQUIE - ESLOVAQUIA

Dr Iveta Trusková  
Deputy Director for Professional Activities  
Public Health Authority of the Slovak Republic  
Bratislava

SOUTH AFRICA - AFRIQUE DU SUD - SUDÁFRICA

Mr Gilbert Tshitaudzi  
Deputy Director: Nutrition
Department of Health  
Pretoria

**SOUTH SUDAN - SOUDAN DU SUD - SUDÁN DEL SUR**

Mr John David Lam Atong  
Deputy Chairman  
South Sudan Gum Arabic Federal Union  
Juba

Mr Kuyu Kudwel Dhel  
Consultant  
South Sudan Gum Arabic Federal Union  
Juba

Dr Kuorwel Kuai Kuorwel  
Dean  
Juba University  
Juba

Mrs Liza Nelson Michael Taban  
Director International Relationship  
South Sudan National Bureau of Standards  
Juba

**SPAIN - ESPAGNE - ESPAÑA**

Dr Álvaro Rol Rúa  
Advanced technician  
Spanish Agency for Food Safety and Nutrition  
Madrid

**SUDAN - SOUDAN - SUDÁN**

Mrs Thoria Akasha Ali Ebeid  
Director of Inspection Department  
Sudanese Standards and Metrology Organisation  
Khartoum

Mrs Maha Abdalla Mohamed Ibrahim  
Manager Research & Planning  
Sudanese Standards and Metrology  
Khartoum

**SWEDEN - SUÈDE - SUECIA**

Ms Cecilia Wanhainen  
Principal Regulatory Officer  
Swedish Food Agency  
Uppsala

**SWITZERLAND - SUISSE - SUIZA**

Mrs Franziska Franchini  
Scientific Advisor  
Federal Food Safety and Veterinary Office

**FSVO**  
Bern

Dr Dirk Cremer  
Regulatory Affairs Manager  
DSM Nutritional Products Europe Ltd., Human Nutrition and Health  
Basel

Dr Karola Krell Zbinden  
Managing Director  
Swiss Association of Nutrition Industries - SANI  
Muri bei Bern

Mr Gert Meijer  
Deputy Head  
Nestec S.A.  
Vevey

**THAILAND - THAÏLANDE - TAILANDIA**

Dr Umaporn Suthuvoravut  
Associate professor  
Faculty of Medicine Ramathibodi Hospital, Mahidol University  
Bangkok

Ms Mayuree Ditmetharoj  
Food and Drug Technical Officer, Professional level  
Ministry of Public Health  
Nonthaburi

Dr Pichet Itkor  
Vice Chairman  
The Federation of Thai Industries  
Bangkok

Ms Nathaya Juengjamroenkij  
member  
The Federation of Thai Industries  
Bangkok

Ms Sanida Khoonpanich  
Standards Officer, Professional Level  
Ministry of Agriculture and Cooperatives  
Bangkok

Ms Kanlaya Thiangtrong  
member  
The Federation of Thai Industries  
Bangkok

**TURKEY - TURQUIE - TURQUÍA**

Dr Mehmet Beykaya  
Advisor
The Ministry of Agriculture and Forestry
Ankara

Mr Dursun Kodaz
Engineer
The Ministry of Agriculture and Forestry
Ankara

Ms M. Emel Molla
Engineer
Ministry of Agriculture and Forestry
Ankara

Mr Samet Serttas
Head of Association
Association on Food Supplements and Nutrition
Ankara

UNITED KINGDOM - ROYAUME-UNI - REINO UNIDO

Mrs Debby Webb
London

Ms Mary McNamara
Department of Health and Social Care
London

Mr Mike O'Neill
Head of Codex Policy and Strategy
Food Standards Agency
London

Mr Steve Wearne
Director of Global Affairs
London

UNITED REPUBLIC OF TANZANIA - RÉPUBLIQUE-UNIE DE TANZANIE - REPÚBLICA UNIDA DE TANZANÍA

Ms Stephanie Silas Kaaya
Standards Officer
Tanzania Bureau of Standards
Dar-Es-Salaam

Mr Hussein Hassan Tattue Tarimo
STEERING COUNCIL MEMBER
WABA
Dar es salaam

UNITED STATES OF AMERICA - ÉTATS-UNIS D'AMÉRIQUE - ESTADOSUNIDOS DE AMÉRICA

Dr Douglas Balentine
Director

U.S. Food and Drug Administration
College Park, MD

Ms Jeniece Alvey
Nutrition Advisor
USAID
Washington DC

Dr Julie Callahan
Deputy Assistant U.S. Trade Representative, Agricultural Affairs
Office of the United States Trade Representative
Washington, D.C.

Dr Kellie Casavale
Senior Nutrition Advisor
CFSAN/FDA
College Park, MD

Dr Carolyn Chung
Nutritionist
U.S. Food and Drug Administration
College Park, MD

Ms Audrae Erickson
Vice President External and Public Affairs
Mead Johnson Nutrition
Washington, DC

Dr Daniel Folmer
Review Chemist
U.S. Food and Drug Administration
College Park, MD

Mr Nicholas Gardner
Director, Codex and International Regulatory Affairs
U.S. Dairy Export Council
Arlington, VA

Ms Kristen Hendricks
International Issues Analyst
U.S. Department of Agriculture
Washington, DC

Ms Mary Frances Lowe
U.S. Manager for Codex Alimentarius
U.S. Codex Office
Washington, DC

Ms Mardi Mountford
President
Infant Nutrition Council of America
Atlanta, GA

Dr Pamela Pehrsson
Research Leader
ARS-Nutrient Data Laboratory  
Beltsville

Dr Rufino Perez  
USAID/FFP Senior Food Technology Advisor  
Office for Food for Peace  
Wheeling, IL

Dr Laura Sima  
Senior Trade Advisor  
Foreign Agricultural Service  
Washington DC

Mr Richard White  
Consultant  
Corn Refiners Association  
Bradenton, FL

VIET NAM

Mr Thanh Van Hoang  
Official  
Hanoi

Mr Minh Chau Hoang  
Director  
Hanoi

Mrs Thi Ngoc Dung Huynh  
Manager  
VINAMILK  
Ho Chi Minh

Mr Van Le  
Official  
Hanoi

Mrs Nguyet Anh Leu  
Expert  
Hanoi

Mr Thanh Nhan Ngo  
VINAMILK  
Ho Chi Minh

Mrs Thi Minh Ha Nguyen  
Deputy Head  
Vietnam Codex Office  
Hanoi

Mr Van Luan Nguyen  
General of Director  
Hanoi

Mr Hong Uy Nguyen  
Director  
Hanoi

Abbott Laboratories SA  
Hanoi

Mr Huu Dung Nguyen  
Chairman  
Hanoi

Mr Xuan Hoang Nguyen  
Chairman  
Hanoi

Mr Dang Huu Nguyen  
Director  
Hanoi

Mr Thanh Phong Nguyen  
Director  
Ministry of Health  
Hanoi

Mr Quang Thai Nguyen  
Director  
Hanoi

Mrs Quynh Van Nguyen  
Manager of Operation & Research support  
Hanoi

Mrs Thi Ngoc Pham  
Staff  
Die  
Hanoi

Mr Tran Quang Trung  
Chair  
Vietnam Dairy Association  
Hanoi

Mrs Bui Thi Thu Hoai  
RD Manager  
VINAMILK  
Ho Chi Minh

Mr Quoc Bao Truong  
Expert  
Hanoi

Ms Thuy Tien Vu  
Manager  
YAKULT VIETNAM LTD. CO  
Ho Chi Minh City

Mr Masaya Watanabe  
Sale & Marketing Director  
YAKULT VIETNAM LTD. CO  
Ho Chi Minh City
ZIMBABWE
Mr Fredy Chinyavanhu
Deputy Director-Food Control
Ministry of Health and Child Care
Harare

SPECIAL OBSERVERS - OBSERVATEURS SPECIAUX - OBSERVADORES ESPECIALES

PALESTINE
Mr Saleem Jayyousi
Chair, National Codex Committee
Palestine Standards Institution

ORGANIZATIONS - ORGANISATIONS OBSERVATEURS - ORGANIZACIONES OBSERVADORAS

INTER-AMERICAN INSTITUTE FOR COOPERATION ON AGRICULTURE (IICA)
Dr Horrys Friaca
Agricultural Health and Food Safety Specialist
IICA
Washington

AMERICAN OIL CHEMISTS' SOCIETY (AOCS)
Dr Barry Tulk
Lead, Analytical Sciences St. Louis Protein Solutions
DowDuPont Specialty Products (DuPont)
Division
St. Louis, MO

ASSOCIATION INTERNATIONALE POUR LE DEVELOPPEMENT DES GOMMES NATURELLES (AIDGUM)
Mr Olivier Bove
AIDGUM

ASSOCIATION FOR INTERNATIONAL PROMOTION OF GUMS (AIPG)
Mr Francis Thevenet
Scientific Adviser
Association for International Promotion of Gums
Hamburg

ASSOCIATION OF EUROPEAN COELIAC SOCIETIES (AOECS)
Mrs Hertha Deutsch
Codex and Regulatory Affairs
AOECS
Wien

AMERICAN OIL CHEMISTS' SOCIETY (AOCS)
Dr Barry Tulk
Lead, Analytical Sciences St. Louis Protein Solutions
DowDuPont Specialty Products (DuPont)
Division
St. Louis, MO

COUNCIL FOR RESPONSIBLE NUTRITION (CRN)
Dr James Griffiths
Senior Vice President
CRN
Washington

ASSOCIATION OF MANUFACTURERS AND FORMULATORS OF ENZYME PRODUCTS (AMFEP)
Dr Paul Tenning
DuPont Nutrition & Biosciences ApS
Copenhagen K

Ms Maya English
Manager
CRN
Washington

AOAC INTERNATIONAL (AOAC)
Mr Darryl Sullivan
AOAC INTERNATIONAL

Ms Jeannette Griffiths
Nutrition Scientist
CRN
Washington

Dr Palmer Orlandi
Chief Science Officer
AOAC INTERNATIONAL
EUROPEAN NETWORK OF CHILDBIRTH ASSOCIATIONS (ENCA)

Ms Patti Rundall
Global Advocacy spokesperson
Baby Milk Action/IBFAN UK
Cambridge

FEDERATION OF EUROPEAN SPECIALTY FOOD INGREDIENTS INDUSTRIES (EU SPECIALTY FOOD INGREDIENTS )

Mrs Catherine Mignot
Member
EU Specialty Food Ingredients

Ms Caroline Bustandi
Member
EU Specialty Food Ingredients

Mr Petr Mensik
EU Specialty Food Ingredients

Dr Stephane Pasteau
Member
EU Specialty Food Ingredients

Ms Christina Rudolph
Member
EU Specialty Food Ingredients

EUROPEAN VEGETABLE PROTEIN ASSOCIATION (EUVEPRO)

Mr Huub Scheres
Director Regulatory Science & Advocacy
DuPont Nutrition & Biosciences
Leiden

Mr Victor Basuki
Southeast Asia Regulatory & Scientific Affairs
DuPont Nutrition & Biosciences
Jakarta

Mrs Jamilla Abdulle
Regulatory Affairs Manager, Regulatory Affairs & Food Law EMEAI
Archer Daniels Midlands
Amsterdam

Ms Nuria Moreno Odero
Secretary General
EUVEPRO
Brussels

FOODDRINKEUROPE

Mr Dirk Jacobs
Deputy Director General
FoodDrinkEurope
Bruxelles

Ms Wendy Blom
Global Nutrition Manager Positions and Claims
Unilever
Vlaardingen

Ms Catherine Carson
Director Global Nutrition Policy & Government Relations
DSM
Bruxelles

Ms Sara Lamonaca
Manager
FoodDrinkEurope
Bruxelles

Ms Annie Loc'h
Regulatory Affairs Director
Danone
Paris

Ms Aleksandra Wesolowska
Manager
Coca-Cola
Brussels

HELEN KELLER INTERNATIONAL (HKI)

Ms Jane Badham
HKI Consultant
JB Consultancy
Johannesburg

Mrs Ndeye Yaga Sy
ARCH Project Manager Senegal
Helen Keller International
Dakar

Mr Paul Zambrano
Regional Technical Specialist
Alive & Thrive fhi360
Manila

Mrs Elizabeth Zehner
Director - ARCH Project
Helen Keller International
Washington
INTERNATIONAL ASSOCIATION FOR CEREAL SCIENCE AND TECHNOLOGY (IACST)

Dr David Mangan
ICC Technical Expert
ICC-International Association for Cereal Science and Technology

Mrs Michaela Pichler
Secretary General
ICC - International Association for Cereal Science & Technology
Vienna

INTERNATIONAL ALLIANCE OF DIETARY/FOOD SUPPLEMENT ASSOCIATIONS (IADSA)

Mr Simon Pettman
Executive Director
International Alliance of Dietary/Food Supplements Associations (IADSA)
London

Mr Patrick Coppens
London

Ms Leigh Gunkel-Keuler
International Alliance of Dietary/Food Supplements Associations
London

Mrs Cynthia Rousselot
Dir. Regulatory and Technical Affairs
International Alliance of Dietary/Food Supplements Associations (IADSA)
London

Mrs Michelle Stout
London

Dr Mikihiko Yoshida
Member
IADSA

INTERNATIONAL BABY FOOD ACTION NETWORK (IBFAN)

Ms Elisabeth Sterken
Director InFACT Canada
International Baby Food Action Network (IBFAN)

INTERNATIONAL CO-OPERATIVE ALLIANCE (ICA)

Mr Kazuo Onitake
Senior Scientist, Quality Assurance Department

International Co-operative Alliance
Tokyo

INTERNATIONAL COUNCIL ON AMINO ACID SCIENCE (ICAAS)

Dr Miro Smriga
CEO
ICAAS
Brussels

Dr Kaori Ono
ICAAS
Brussels

Mr Keiji Takahashi
ICAAS Japan
Tokyo

INTERNATIONAL COUNCIL OF BEVERAGES ASSOCIATIONS (ICBA)

Ms Joanna Skinner
Manager, Regulatory Labeling & Nutrition
The Coca-Cola Company
Atlanta

Ms Jacqueline Dillon
Manager
PepsiCo
Chicago

Dr Tatsuya Ehara
Technical Advisor
Morinaga Milk Industry Co.,LTD
Zama city

Mr Hidekazu Hosono
General Manager
Suntory Business Expert

INTERNATIONAL CHEWING GUM ASSOCIATION (ICGA) (ICGA)

Mr Christophe Leprêtre
Executive Director Regulatory and Scientific Affairs
International Chewing Gum Association
Brussels

Dr Lynn Yu
Global Scientific and Regulatory Affairs
Mars Wrigley Confectionery
Chicago, IL
INTERNATIONAL COUNCIL OF GROCERY MANUFACTURERS ASSOCIATIONS (ICGMA)

Mrs Loretta Difrancesco
Scientific & Regulatory Affairs Advisor
Food & Consumer Products of Canada

INTERNATIONAL DAIRY FEDERATION (IDF/FIL)

Ms Laurence Rycken
Scientific Standards Program Manager
International Dairy Federation
Brussels

Mr John Allan
Vice President of Regulatory Affairs & International Standards
International Dairy Foods Association
Washington, D.C.

Ms Mélanie Lembert
Regulatory Affairs Officer
ATLA, French Dairy Processors’ Association

Mr Matt Morrison
Government Relations & Strategic Partnerships
Dairy Farmers of Canada

Prof Tiny Van Boekel
professor Emeritus
Wageningen University

Mr Harrie Van Den Bijgaart
Operations Manager Laboratories
Qlip B.V.
Zutphen

INTERNATIONAL FOOD ADDITIVES COUNCIL (IFAC)

Mr Ray Devirgiliis
International Food Additives Council

INSTITUTE OF FOOD TECHNOLOGISTS (IFT)

Dr Rosetta Newsome Gardner
Director, Science, Policy & Scientific and Regulatory Affairs
Institute of Food Technologists
Chicago, IL

INTERNATIONAL FRUIT AND VEGETABLE JUICE ASSOCIATION (IFU)

Mrs Romana Vanova Hrnčířík
Chair of the IFU Legislation Commission

IFU (Int. Fruit and Vegetable Juice Association)
Paris

INTERNATIONAL LACTATION CONSULTANT ASSOCIATION (ILCA)

Ms Maryse Arendt
Advocacy Committee Representative
ILCA
Luxemburg

INTERNATIONAL LIFE SCIENCES INSTITUTE (ILSI)

Ms Flavia Goldfinger
Executive Director
ILSI Brazil
São Paulo

Dr Jasvir Singh
Regulatory, Scientific & Government Affairs Leader – South Asia
DuPont Nutrition & Health, Danisco (India)
Haryana

Dr Peter Van Dael
Head of Nutrition Science and Advocacy
DSM
Kaiseraugst

INTERNATIONAL PROBIOTICS ASSOCIATION (IPA)

Mr George Paraskevakos
Executive Director
International Probiotics Association (IPA)
Los Angeles

Mrs Aliah Abdul Wahab
Regional Regulatory Affairs Director, APAC
CHR. Hansen Singapore Pte Ltd

Mrs Marjon Dey-Wolters
Regulatory Affairs Manager
Yakult Europe

Mrs Rosanna Pecere
Executive Director
IPA EUROPE
Brussels

Mr David Pineda Ereno
International Probiotics Association
INTERNATIONAL SPECIAL DIETARY FOODS INDUSTRIES (ISDI)

Ms Shefa Alhalah
Danone Nutricia Middle East

Ms Sandrine Alloncle
Global Regulatory & Scientific Affairs Senior Manager
Nestle Nutrition

Ms Celine Benini
Scientific and Regulatory Affairs Officer
ISDI-International Special Dietary Foods Industries

Ms Magali Bocquet
Secretary General
L'Alliance 7

Ms Cristine Bradley
Head of IFCN Global Regulatory Policy
Reckitt Benckiser Health

Mr Marian Brestovansky
Regulatory Affairs Officer
ISDI-International Special Dietary Foods Industries

Mrs Jan Carey
CEO
Infant Nutrition Council

Mr Shiraz Choudhary
Corporate Affairs
Nestle Nutrition

Ms Yang Dan
Senior Regulatory Affairs manager
Nutricia Pharmaceutical

Ms Wioleta Dzieszuk-Brzozowska
Head of Global Regulatory Affairs, ELN General Secretary
Danone Nutricia Early Life Nutrition

Ms Louise Gottsche
Group Regulatory and Scientific Affairs Manager
Aspen Pharmacare

Dr Paul Hanlon
Director of Regulatory Affairs
Abbott Nutrition
Columbus, OH

Mr Kaushik Janakiraman
Regulatory Affairs Officer
Reckitt Benckiser Health

Ms Nynke Keestra
Regulatory Affairs Manager Infant Food
FrieslandCampina

Mr Jean Christophe Kremer
Secretary General
ISDI-International Special Dietary Foods Industries

Mr Xavier Lavigne
Director, Regulatory Policy & Intelligence
Abbott Nutrition

Mr Huw Longton
Communications Manager
ISDI-International Special Dietary Foods Industries

Ms Venetta Miranda
President
ISDI-International Special Dietary Foods Industries

Mr Kevin O'Brien
Director Regulatory Affairs
Abbott Nutrition

Ms Nishita Rao
Senior Associate
White Rook Advisory

Ms Sabine Seggelke
Director Global Public Affairs - Specialized Nutrition
Danone

Ms Ding Xi
Government Affairs Assistant
European Union Chamber of Commerce in China

Ms Ziting Zhang
Head of Government Affairs
European Union Chamber of Commerce in China

INTERNATIONAL FOOD POLICY RESEARCH INSTITUTE

Ms Anne Mackenzie
Standards & Regulatory Issues, HarvestPlus
HarvestPlus
Mahone Bay, Nova Scotia
Mrs Marili Nuti  
Director  
Latin America and Caribbean  
IFPRI

INTERNATIONAL READY TO USE FOODS ASSOCIATION (IRUFA)

Mrs Mathilde Bridier

Mr Thomas Couaillet

Mr Mark Manary

MÉDECINS SANS FRONTIÈRES INTERNATIONAL MSF (MSF)

Dr Andre Briend

Mrs Odile Caron  
QA Coordinator Specialised Food  
MSF International

Dr Kirrily De Polnay  
MSF Nutrition WG leader  
MSF International

NATIONAL HEALTH FEDERATION (NHF)

Mr Scott Tips  
President & General Counsel  
National Health Federation  
Monrovia

SPECIALISED NUTRITION EUROPE (SNE)

Ms Aurelie Perrichet  
Specialised Nutrition Europe  
Brussels

Ms Laure De Hauteclouque  
Specialised Nutrition Europe  
Brussels

Mr Julien Dey  
Specialised Nutrition Europe  
Brussels

Ms Sandra Iagallo  
Specialised Nutrition Europe  
Brussels

Ms Sasha Lazidu  
Specialised Nutrition Europe  
Brussels

Ms Evangelia Mavromichali  
Specialised Nutrition Europe  
Brussels

WORLD OBESITY FEDERATION (WOF)

Prof Mary L’Abbé  
Professor, Department of Nutritional Sciences  
Faculty of Medicine, University of Toronto  
Toronto

WORLD PUBLIC HEALTH NUTRITION ASSOCIATION (WPHNA)

Dr Sara Garduno-Diaz  
WPHNA

ASSOCIATION OF YOGHURTS & LIVE FERMENTED MILKYS (YLFA)

Mr Svend Laulund  
Senior Manager - Global External Affairs  
YLFA International  
Hoersholm

UNITED NATIONS CHILDREN’S FUND (UNICEF)

Mrs Alison Fleet  
Technical Specialist  
UNICEF  
Copenhagen

Mr David Clark  
Legal Specialist  
UNICEF

CODEX SECRETARIAT

Ms Verna Carolissen-Mackay  
Food Standards Officer  
Food and Agriculture Organization of the United Nations (FAO)  
Rome

Mr Tom Heilandt  
Secretary, Codex Alimentarius Commission  
Food and Agriculture Organization of the United Nations (FAO)  
Rome

Mr Patrick Sekitoleko  
Foods Standards Officer  
Food and Agriculture Organization of the United Nations (FAO)  
Rome
Ms Lingping Zhang  
Food Standards Officer  
Joint FAO/WHO Food Standards Programme  
Food and Agriculture Organization of the UN  
Rome

Mr David Massey  
Special Advisor  
Food and Agriculture Organization of the United Nations (FAO)  
Rome

**FAO**

Ms Maria Xipsiti  
Nutrition Officer  
FAO

**WHO**

Dr Chizuru Nishida  
Coordinator, Nutrition Policy and Scientific Advice Unit  
World Health Organization (WHO)  
Geneva

Dr Fabio Da Silva Gomes  
Advisor, Nutrition and Physical Activity, Risk Factors and Nutrition Unit  
Pan American Health Organization / WHO  
Regional Office for the Americas  
Washington, DC

Dr Katrin Engelhardt  
Scientist (Health Diet Policies), Nutrition Policy and Scientific Advice Unit  
World Health Organization  
Geneva

Dr Laurence Grummer-Strawn  
Technical Officer  
World Health Organization  
Geneva

Dr Jason Montez  
Scientist (Nutrition, Obesity & Diet-related NCDs)  
World Health Organization  
Geneva

Dr Rain Yamamoto  
Scientist, Nutrition Policy and Scientific Advice Unit  
World Health Organization  
Geneva

**CCNFSDU HOST SECRETARIAT**

Ms Alina Steinert  
Federal Ministry of Food and Agriculture  
Bonn

Mrs Mischgan Säll  
Federal Ministry of Food and Agriculture  
Bonn

Ms Vanessa Beier  
Federal Ministry of Food and Agriculture  
Berlin
APPENDIX II

REVIEW OF THE STANDARD FOR FOLLOW UP FORMULA:
SECTION A: FOLLOW-UP FORMULA FOR OLDER INFANTS
(At Step 7)

1 SCOPE

1.1 This section of the Standard applies to Follow-up Formula for Older Infants, as defined in Section 2.1, in liquid or powdered form.

1.2 This section of the Standard contains compositional, quality, safety, labelling, analytical and sampling requirements for Follow-up Formula for Older Infants.

1.3 Only products that comply with the criteria laid down in the provisions of this section of this Standard shall be presented as Follow-up Formula for Older Infants.

2 DESCRIPTION

2.1 Product Definition

2.1.1 Follow-up formula for older infants means a product, manufactured for use as a breastmilk-substitute, as a liquid part of a diet for older infants when progressively diversified complementary feeding is introduced.

2.1.2 Follow-up formula for older infants is so processed by physical means only and so packaged as to prevent spoilage and contamination under all normal conditions of handling, storage and distribution in the country where the product is sold.

2.2 Other Definitions

2.2.1 The term infant means a person of not more than 12 months of age.

2.2.2 The term older infant means a person from the age of 6 months and not more than 12 months of age.

9 LABELLING

The requirements of the General Standard for the Labelling of Prepackaged Foods (CXS 1-1985), the Guidelines on Nutrition Labelling (CXG 2-1985) and the Guidelines for Use of Nutrition and Health Claims (CXG 23-1997) apply to Follow-up Formula for Older Infants. These requirements include a prohibition on the use of nutrition and health claims for foods for infants except where specifically provided for in relevant Codex Standards or national legislation.

9.1 The Name of the Product

9.1.1 The text of the label and all other information accompanying the product shall be written in the appropriate language(s).

9.1.2 The name of the product shall be Follow-up Formula for Older Infants as defined in Section 2.1, or any appropriate designation indicating the true nature of the product, in accordance with national or regional usage.

9.1.3 The sources of protein in the product shall be clearly shown on the label.

a) If [name of animal] milk is the only source of protein*, the product may be labelled ‘Follow-up Formula for Older Infants Based on [name of animal] milk protein.

b) If [name of plant] is the only source of protein*, the product may be labelled ‘Follow-up Formula for Older Infants Based on [name of plant] protein.

c) If [name of animal] milk and [name of plant] are the sources of protein*, the product may be labelled ‘Follow-up Formula for Older Infants Based on [name of animal] milk protein and [name of plant] protein’ or ‘Follow-up Formula for Older Infants Based on [name of plant] protein and [name of animal] milk protein’.

* For clarity, addition of individual amino acids where needed to improve protein quality does not preclude use of the above labelling options.

9.1.4 A product which contains neither milk nor any milk derivative shall be labelled “contains no milk or milk products” or an equivalent phrase.
9.2 **List of Ingredients**

9.2.1 A complete list of ingredients shall be declared on the label in descending order of proportion except that in the case of added vitamins and minerals, these ingredients may be arranged as separate groups for vitamins and minerals. Within these groups the vitamins and minerals need not be listed in descending order of proportion.

9.2.2 The specific name shall be declared for ingredients of animal or plant origin and for food additives. In addition, appropriate functional classes for food additives shall be included on the label. The food additives INS number may also be optionally declared.

9.3 **Declaration of Nutritive Value**

The declaration of nutrition information for Follow-up Formula for Older Infants shall contain the following information which should be in the following order:

a) the amount of energy, expressed in kilocalories (kcal) and/or kilojoules (kJ), and the number of grams of protein, carbohydrate and fat per 100 g or per 100 ml of the food as sold as well as per 100 ml of the food ready for use, when prepared according to the instructions on the label.

b) the total quantity of each vitamin, and mineral as listed in paragraph 3.1.3 of Section A and any other ingredient as listed in paragraph 3.2 of Section A per 100 g or per 100 ml of the food as sold as well as per 100 ml of the food ready for use, when prepared according to the instructions on the label.

c) In addition, the declaration of nutrients in a) and b) per 100 kilocalories (kcal) (or per 100 kilojoules (kJ)) is permitted.

9.4 **Date Marking and Storage Instructions**

9.4.1 The date marking and storage instructions shall be in accordance with section 4.7 of the General Standard for the Labelling of Prepackaged Foods.

9.4.2 Where practicable, storage instructions shall be in close proximity to the date marking.

9.5 **Information for use**

9.5.1 Ready to use products in liquid form should be used directly. Concentrated liquid products and powdered products, must be prepared with potable water that is safe or has been rendered safe by previous boiling before feeding, according to directions for use. Adequate directions for the appropriate preparation and handling should be in accordance with Good Hygienic Practice.

9.5.2 Adequate directions for the appropriate preparation and use of the product, including its storage and disposal after preparation, i.e. that product remaining after feeding should be discarded, shall appear on the label.

9.5.3 The label shall carry clear graphic instructions illustrating the method of preparation of the product.

9.5.4 The directions should be accompanied by a warning about the health hazards of inappropriate preparation, storage and use.

9.5.5 Adequate directions regarding the storage of the product after the container has been opened, shall appear on the label.

9.5.6 The label of Follow-up Formula for Older Infants shall include a statement that the product shall not be introduced before 6 months of age, is not to be used as a sole source of nutrition and that older infants should receive complementary foods in addition to the product.

9.6 **Additional Labelling Requirements**

9.6.1 Labels should not discourage breastfeeding. Each container label shall have a clear, conspicuous and easily readable message which includes the following points:

a) the words “important notice” or their equivalent;

b) the statement "Breast-milk is the best food for your baby" or a similar statement as to the superiority of breastfeeding or breast-milk;

c) a statement that the product should only be used on advice of a health worker as to the need for its use and the proper method of use.

d) the statement; ‘The use of this product should not lead to cessation of continued breastfeeding’.

9.6.2 The label shall have no pictures of infants, young children and women nor any other picture, text, or representation that might:
9.6.2.1 idealize the use of Follow-up Formula for Older Infants;

9.6.2.2 suggest use for infants under the age of 6 months (including references to milestones and stages);

9.6.2.3 recommend or promote bottle feeding;

9.6.2.4 undermine or discourage breastfeeding; or that makes a comparison to breast-milk, or suggests that the product is similar, equivalent to or superior to breast-milk;

9.6.2.5 convey an endorsement or anything that may be construed as an endorsement by a professional or any other body, unless this has been specifically approved by relevant national or regional regulatory authorities.

9.6.3 The terms "humanized", "maternalized" or other similar terms shall not be used.

9.6.4 Follow-up formula for older infants shall be distinctly labelled in such a way as to avoid any risk of confusion with Infant Formula, Drink/Product for young children with added nutrients or Drink for young children, and Formula for Special Medical Purposes intended for infants, in particular as to the text, images and colours used, to enable consumers to make a clear distinction between them.

9.6.5 The labelling of follow-up formula for older infants shall not refer to infant formula, Drink/Product for young children with added nutrients or Drink for young children, or formula for special medical purposes intended for infants, including numbers, text, statements, or images of these products.
APPENDIX III

REVIEW OF THE STANDARD FOR FOLLOW-UP FORMULA (CXS 156-1987):
DRAFT ESSENTIAL COMPOSITION AND QUALITY FACTORS –
(at Step 7)

SECTION A: FOLLOW-UP FORMULA FOR OLDER INFANTS

3 ESSENTIAL COMPOSITION AND QUALITY FACTORS

3.1 Essential composition

3.1.1 Follow-up formula for older infants is a product based on milk of cows or other animals or a mixture thereof and/or other ingredients which have been proven to be safe and suitable for the feeding of older infants. The nutritional safety and adequacy of follow-up formula for older infants shall be scientifically demonstrated to support growth and development of older infants.

3.1.2 When prepared ready for consumption in accordance with the instructions of the manufacturer, the products shall contain per 100 ml not less than 60 kcal (251 kJ) and not more than 70 kcal (293 kJ) of energy.

3.1.3 Follow-up formula for older infants prepared ready for consumption shall contain per 100 kcal (100 kJ) the following nutrients with the following minimum and maximum or guidance upper levels (GUL) as appropriate.

a) Protein

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>g/100 kcal</td>
<td>1.8 (^2), 3), 4)</td>
<td>3.0</td>
<td>-</td>
</tr>
<tr>
<td>g/100 kJ</td>
<td>0.43 (^5), 6)</td>
<td>0.72</td>
<td>-</td>
</tr>
</tbody>
</table>

\(^2\) For the purpose of this standard the calculation of the protein content of the final product ready for consumption should be based on N x 6.25, unless a scientific justification is provided for the use of a different conversion factor for a particular product. The protein levels set in this standard are based on a nitrogen conversion factor of 6.25. For information the value of 6.38 is used as a specific factor appropriate for conversion of nitrogen to protein in other Codex standards for milk products.

\(^3\) For an equal energy value the formula must contain an available quantity of each essential and semi-essential amino acid at least equal to that contained in the reference protein (breast-milk as defined in Annex I of the Standard for Infant Formula and Formulas for Special Medical Purposes Intended for Infants (CXS 72-1981)); nevertheless for calculation purposes the concentrations of tyrosine and phenylalanine may be added together and the concentrations of methionine and cysteine may be added together.

\(^4\) Isolated amino acids may be added to follow-up formula for older infants only to improve its nutritional value for infants. Essential and semi-essential amino acids may be added to improve protein quality, only in amounts necessary for that purpose. Only L-forms of amino acids shall be used.

\(^5\) The minimum value applies to cows’ and goats’ milk protein. For follow-up formula for older infants based on non-cows’ or non-goats’ milk protein other minimum values may need to be applied. For follow-up formula based on soy protein isolate, a minimum value of 2.25 g/100 kcal (0.54 g/100 kJ) applies.

\(^6\) A lower minimum protein level between 1.6 and 1.8 g/100 kcal (0.38 and 0.43 g/100 kJ) in follow-up formula for older infants based on non-hydrolysed milk protein can be accepted. Such follow-up formula and follow-up formula for older infants based on hydrolysed protein should be evaluated for their safety and suitability and assessed by a competent national and/or regional authority based on clinical evidence.

\(^1\) Guidance upper levels are for nutrients without sufficient information for a science-based risk assessment. These levels are values derived on the basis of meeting nutritional requirements of young children and an established history of apparent safe use. They may be adjusted based on relevant scientific or technological progress. The purpose of the GULs is to provide guidance to manufacturers and they should not be interpreted as goal values. Nutrient contents in follow-up formula for older infants should usually not exceed the GULs unless higher nutrient levels cannot be avoided due to high or variable contents in constituents of follow-up formula for older infants or due to technological reasons. When a product type or form has ordinarly contained lower levels than the GULs, manufacturers should not increase levels of nutrients to approach the GULs.
b) Lipids

Total Fat \(^7\), \(^8\)

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>g/100 kcal</td>
<td>4.4</td>
<td>6.0</td>
<td>-</td>
</tr>
<tr>
<td>g/100 kJ</td>
<td>1.1</td>
<td>1.4</td>
<td>-</td>
</tr>
</tbody>
</table>

\(^7\) Partially hydrogenated oils and fats shall not be used in follow-up formula for older infants.

\(^8\) Lauric acid and myristic acid are constituents of fats, but combined shall not exceed 20% of total fatty acids. The content of trans fatty acids shall not exceed 3% of total fatty acids. Trans fatty acids are endogenous components of milk fat. The acceptance of up to 3% of trans fatty acids is intended to allow for the use of milk fat in follow-up formula for older infants. The erucic acid content shall not exceed 1% of total fatty acids. The total content of phospholipids should not exceed 300 mg/100 kcal (72 mg/100 kJ).

Linoleic acid

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg/100 kcal</td>
<td>300</td>
<td>-</td>
<td>1400</td>
</tr>
<tr>
<td>mg/100 kJ</td>
<td>72</td>
<td>-</td>
<td>335</td>
</tr>
</tbody>
</table>

\(\alpha\)-Linolenic acid

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg/100 kcal</td>
<td>50</td>
<td>N.S.*</td>
<td>-</td>
</tr>
<tr>
<td>mg/100 kJ</td>
<td>12</td>
<td>N.S.</td>
<td>-</td>
</tr>
</tbody>
</table>

*N.S. = not specified

Ratio Linoleic acid/ \(\alpha\)-Linolenic acid

<table>
<thead>
<tr>
<th>Min</th>
<th>Max</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:1</td>
<td>15:1</td>
</tr>
</tbody>
</table>

c) Carbohydrates

Available carbohydrates \(^9\)

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>g/100 kcal</td>
<td>9.0</td>
<td>14.0</td>
<td>-</td>
</tr>
<tr>
<td>g/100 kJ</td>
<td>2.2</td>
<td>3.3</td>
<td>-</td>
</tr>
</tbody>
</table>

\(^9\) Lactose and glucose polymers should be the preferred carbohydrates in follow-up formula for older infants based on milk protein and hydrolysed protein. Only precooked and/or gelatinised starches gluten-free by nature may be added. Sucrose and/or fructose should not be added, unless needed as a carbohydrate source, and provided the sum of these does not exceed 20% of available carbohydrate.

d) Vitamins

Vitamin A

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg RE(^{10})/100 kcal</td>
<td>75</td>
<td>180</td>
<td>-</td>
</tr>
<tr>
<td>µg RE(^{10})/100 kJ</td>
<td>18</td>
<td>43</td>
<td>-</td>
</tr>
</tbody>
</table>

\(^{10}\) expressed as retinol equivalents (RE)

1 µg RE = 3.33 IU Vitamin A = 1 µg all-trans retinol. Retinol contents shall be provided by preformed retinol, while any contents of carotenoids should not be included in the calculation and declaration of vitamin A activity.
**Vitamin D**

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg /100 kcal</td>
<td>1.0</td>
<td>3.0</td>
<td>-</td>
</tr>
<tr>
<td>µg /100 kJ</td>
<td>0.24</td>
<td>0.72</td>
<td>-</td>
</tr>
</tbody>
</table>

11) Calciferol, 1 µg calciferol = 40 IU Vitamin D.

**Vitamin E**

<table>
<thead>
<tr>
<th>Unit (α-TE)</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg /100 kcal</td>
<td>0.5</td>
<td>-</td>
<td>5</td>
</tr>
<tr>
<td>mg α-TE /100 kcal</td>
<td>0.12</td>
<td>-</td>
<td>1.2</td>
</tr>
</tbody>
</table>

12) 1 mg α-TE (alpha-tocopherol equivalents) = 1 mg d-α-tocopherol

13) Vitamin E shall be at least 0.5 mg α-TE per g PUFA, using the following factors of equivalence to adapt the minimal vitamin E content to the number of fatty acid double bonds in the formula: 0.5 mg α-TE/g linoleic acid (18:2 n-6); 0.75 α-TE/g α-linolenic acid (18:3 n-3); 1.0 mg α-TE/g arachidonic acid (20:4 n-6); 1.25 mg α-TE/g eicosapentanoic acid (20:5 n-3); 1.5 mg α-TE/g docosahexaenoic acid (22:6 n-3).

**Vitamin K**

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg /100 kcal</td>
<td>4</td>
<td>-</td>
<td>27</td>
</tr>
<tr>
<td>µg /100 kJ</td>
<td>0.96</td>
<td>-</td>
<td>6</td>
</tr>
</tbody>
</table>

**Thiamin**

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg /100 kcal</td>
<td>60</td>
<td>-</td>
<td>300</td>
</tr>
<tr>
<td>µg /100 kJ</td>
<td>14</td>
<td>-</td>
<td>72</td>
</tr>
</tbody>
</table>

**Riboflavin**

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg /100 kcal</td>
<td>80</td>
<td>-</td>
<td>500</td>
</tr>
<tr>
<td>µg /100 kJ</td>
<td>19</td>
<td>-</td>
<td>120</td>
</tr>
</tbody>
</table>

**Niacin**

14) Niacin refers to preformed niacin

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg /100 kcal</td>
<td>300</td>
<td>-</td>
<td>1500</td>
</tr>
<tr>
<td>µg /100 kJ</td>
<td>72</td>
<td>-</td>
<td>359</td>
</tr>
</tbody>
</table>

**Vitamin B₆**

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg /100 kcal</td>
<td>35</td>
<td>-</td>
<td>175</td>
</tr>
<tr>
<td>µg /100 kJ</td>
<td>8</td>
<td>-</td>
<td>42</td>
</tr>
</tbody>
</table>

**Vitamin B₁₂**

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg /100 kcal</td>
<td>0.1</td>
<td>-</td>
<td>1.5</td>
</tr>
<tr>
<td>µg /100 kJ</td>
<td>0.02</td>
<td>-</td>
<td>0.36</td>
</tr>
</tbody>
</table>

**Pantothenic acid**

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg /100 kcal</td>
<td>400</td>
<td>-</td>
<td>2000</td>
</tr>
<tr>
<td>µg /100 kJ</td>
<td>96</td>
<td>-</td>
<td>478</td>
</tr>
</tbody>
</table>

**Folic acid**

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg /100 kcal</td>
<td>10</td>
<td>-</td>
<td>50</td>
</tr>
<tr>
<td>µg /100 kJ</td>
<td>2.4</td>
<td>-</td>
<td>12</td>
</tr>
</tbody>
</table>

**Vitamin C**

15) *Vitamin C* refers to ascorbic acid.

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg /100 kcal</td>
<td>10</td>
<td>-</td>
<td>70</td>
</tr>
</tbody>
</table>

16) Vit. C shall be at least 10 mg ascorbic acid per g PUFA, using the following factors of equivalence to adapt the minimal vitamin C content to the number of fatty acid double bonds in the formula: 0.8 mg ascorbic acid/g linoleic acid (18:2 n-6); 1.2 mg ascorbic acid/g α-linolenic acid (18:3 n-3); 1.5 mg ascorbic acid/g arachidonic acid (20:4 n-6); 1.8 mg ascorbic acid/g eicosapentanoic acid (20:5 n-3); 2.0 mg ascorbic acid/g docosahexaenoic acid (22:6 n-3).
mg /100 kJ  2.4 - 17)  

15) expressed as L-ascorbic acid
16) This GUL has been set to account for possible high losses over shelf-life in liquid products; for powdered products lower upper levels should be aimed for.

### Biotin

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg /100 kcal</td>
<td>1.5</td>
<td>-</td>
<td>10</td>
</tr>
<tr>
<td>µg /100 kJ</td>
<td>0.36</td>
<td>-</td>
<td>2.4</td>
</tr>
</tbody>
</table>

e) Minerals and Trace Elements

### Iron

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg /100 kcal</td>
<td>1.0</td>
<td>2.0</td>
<td>-</td>
</tr>
<tr>
<td>mg /100 kJ</td>
<td>0.24</td>
<td>0.48</td>
<td>-</td>
</tr>
</tbody>
</table>

17) For follow-up formula for older infants based on soy protein isolate a minimum value of 1.5 mg/100 kcal (0.36/100 kJ) and maximum of 2.5 mg/100 kcal (0.6 mg/100 kJ) applies.

### Calcium

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg /100 kcal</td>
<td>50</td>
<td>-</td>
<td>180</td>
</tr>
<tr>
<td>mg /100 kJ</td>
<td>12</td>
<td>-</td>
<td>43</td>
</tr>
</tbody>
</table>

### Phosphorus

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg /100 kcal</td>
<td>25</td>
<td>-</td>
<td>100</td>
</tr>
<tr>
<td>mg /100 kJ</td>
<td>6</td>
<td>-</td>
<td>24</td>
</tr>
</tbody>
</table>

18) This GUL should accommodate higher needs with follow-up formula for older infants based on soy protein isolate.

### Ratio Calcium/Phosphorus

<table>
<thead>
<tr>
<th>Min</th>
<th>Max</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:1</td>
<td>2:1</td>
</tr>
</tbody>
</table>

### Magnesium

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg /100 kcal</td>
<td>5</td>
<td>-</td>
<td>15</td>
</tr>
<tr>
<td>mg /100 kJ</td>
<td>1.2</td>
<td>-</td>
<td>3.6</td>
</tr>
</tbody>
</table>

### Sodium

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg /100 kcal</td>
<td>20</td>
<td>60</td>
<td>-</td>
</tr>
<tr>
<td>mg /100 kJ</td>
<td>4.8</td>
<td>14</td>
<td>-</td>
</tr>
</tbody>
</table>

### Chloride

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg /100 kcal</td>
<td>50</td>
<td>160</td>
<td>-</td>
</tr>
<tr>
<td>mg /100 kJ</td>
<td>12</td>
<td>38</td>
<td>-</td>
</tr>
</tbody>
</table>

### Potassium

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg /100 kcal</td>
<td>60</td>
<td>180</td>
<td>-</td>
</tr>
<tr>
<td>mg /100 kJ</td>
<td>14</td>
<td>43</td>
<td>-</td>
</tr>
</tbody>
</table>

### Manganese

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg /100 kcal</td>
<td>1.0</td>
<td>-</td>
<td>100</td>
</tr>
<tr>
<td>µg /100 kJ</td>
<td>0.24</td>
<td>-</td>
<td>24</td>
</tr>
</tbody>
</table>
### Iodine

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg /100 kcal</td>
<td>10</td>
<td>-</td>
<td>60</td>
</tr>
<tr>
<td>µg /100 kJ</td>
<td>2.4</td>
<td>-</td>
<td>14</td>
</tr>
</tbody>
</table>

### Selenium

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg /100 kcal</td>
<td>2</td>
<td>-</td>
<td>9</td>
</tr>
<tr>
<td>µg /100 kJ</td>
<td>0.48</td>
<td>-</td>
<td>2.2</td>
</tr>
</tbody>
</table>

### Copper\(^{19}\)

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg /100 kcal</td>
<td>35</td>
<td>-</td>
<td>120</td>
</tr>
<tr>
<td>µg /100 kJ</td>
<td>8</td>
<td>-</td>
<td>29</td>
</tr>
</tbody>
</table>

\(^{19}\) Adjustment may be needed in these levels for follow-up formula for older infants made in regions with a high content of copper in the water supply.

### Zinc\(^{20}\)

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg /100 kcal</td>
<td>0.5</td>
<td>-</td>
<td>1.5</td>
</tr>
<tr>
<td>mg /100 kJ</td>
<td>0.12</td>
<td>-</td>
<td>0.36</td>
</tr>
</tbody>
</table>

\(^{20}\) For follow-up formula for older infants based on soy protein isolate a minimum value of 0.75 mg/100 kcal (0.18 mg/100 kJ) applies.

### Optional Ingredients

3.2.1 In addition to the compositional requirements listed under 3.1.3 Section A, other ingredients or substances may be added to follow-up formula for older infants where the safety and suitability of the optional ingredient for particular nutritional purposes, at the level of use, is evaluated and demonstrated by generally accepted scientific evidence.

3.2.2 When any of these ingredients or substances is added the formula shall contain sufficient amounts to achieve the intended effect, taking into account levels in human milk.

3.2.3 The following substances may be added in conformity with national legislation, in which case their content per 100 kcal (100 kJ) in the follow-up formula for older infants ready for consumption shall not exceed the levels listed below. This is not intended to be an exhaustive list, but provides a guide for competent national and/or regional authorities as to appropriate levels when these substances are added.

### Taurine

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg /100 kcal</td>
<td>-</td>
<td>12</td>
<td>-</td>
</tr>
<tr>
<td>mg /100 kJ</td>
<td>-</td>
<td>2.9</td>
<td>-</td>
</tr>
</tbody>
</table>

### Total nucleotides

Levels may need to be determined by national authorities.

### Docosahexaenoic acid\(^{21}\)

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg /100 kcal</td>
<td>-</td>
<td>-</td>
<td>30</td>
</tr>
<tr>
<td>mg /100 kJ</td>
<td>-</td>
<td>-</td>
<td>7</td>
</tr>
</tbody>
</table>

\(^{21}\) If docosahexaenoic acid (22:6 n-3) is added to follow-up formula for older infants, a minimum level of 20 mg/100 kcal (4.8 mg/100 kJ) should be reached, and arachidonic acid (20:4 n-6) contents should reach at least the same concentration as DHA. The content of eicosapentaenoic acid (20:5 n-3), which can occur in sources of LC-PUFA, should not exceed the content of docosahexaenoic acid. Competent national and/or regional authorities may deviate from the above conditions, as appropriate for the nutritional needs of their population.
### Choline

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg /100 kcal</td>
<td>-</td>
<td>-</td>
<td>50</td>
</tr>
<tr>
<td>mg /100 kJ</td>
<td>-</td>
<td>-</td>
<td>12</td>
</tr>
</tbody>
</table>

### Myo-inositol

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg /100 kcal</td>
<td>-</td>
<td>-</td>
<td>40</td>
</tr>
<tr>
<td>mg /100 kJ</td>
<td>-</td>
<td>-</td>
<td>10</td>
</tr>
</tbody>
</table>

### L-carnitine

Levels may need to be determined by national authorities.

### L (+) lactic acid-producing cultures

Only L (+) lactic acid-producing cultures may be used for the purpose of producing acidified follow-up formula for older infants. The acidified final product should not contain significant amounts of viable L (+) lactic acid-producing cultures, and residual amounts should not represent any health risk.

The safety and suitability of the addition of specific strains of L(+) lactic acid-producing cultures for particular beneficial physiological effects, at the level of use, must be demonstrated by clinical evaluation and generally accepted scientific evidence. When added for this purpose, the final product ready for consumption shall contain sufficient amounts of viable cultures to achieve the intended effect.
SECTION B: DRINK/PRODUCT FOR YOUNG CHILDREN WITH ADDED NUTRIENTS OR DRINK FOR YOUNG CHILDREN

3 ESSENTIAL COMPOSITION AND QUALITY FACTORS

3.1 Essential composition

3.1.1 The product as defined in Section 2.1 is a product based on milk of cows or other animals or a mixture thereof and/or other ingredients which have been proven to be safe and suitable for the feeding of young children. The nutritional safety and adequacy of the product as defined in Section 2.1 shall be scientifically demonstrated to support growth and development of young children.

3.1.2 When prepared ready for consumption in accordance with the instructions of the manufacturer, the products shall contain per 100 ml not less than 60 kcal (251 kJ) and not more than 70 kcal (293 kJ) of energy. National and/or regional authorities can deviate from the minimum energy content in line with national/regional dietary guidelines taking into account the nutritional needs of the local population.

3.1.3 The product as defined in Section 2.1 prepared ready for consumption shall contain per 100 kcal (100 kJ) the following nutrients with the following minimum and maximum or guidance upper levels (GUL), as appropriate. The general principles for establishing these levels are identified in Annex I of this standard.

a) Protein

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>g/100 kcal</td>
<td>1.8</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>g/100 kJ</td>
<td>0.43</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

2) For the purpose of this standard the calculation of the protein content of the final product ready for consumption should be based on N x 6.25, unless a scientific justification is provided for the use of a different conversion factor for a particular product. The protein levels set in this standard are based on a nitrogen conversion factor of 6.25. For information the value of 6.38 is used as a specific factor appropriate for conversion of nitrogen to protein in other Codex standards for milk products.

3) PDCAAS is the preferred method to determine protein quality. However, PER can continue to be used. DIAAS could also be considered should it be recognized by FAO in the future. When determined using PDCAAS methodology, appropriate Digestibility values and the reference amino acid pattern (see Table 5 of the Report of the FAO Expert Working Group: Protein quality assessment in follow-up formula for young children and ready to use therapeutic food), the PDCAAS shall be not less than 90. In formulations with lower scores the quality and/or quantity of protein should be adjusted to achieve the desired value. Detail on how to calculate the PDCAAS is listed in the Report of the FAO Expert Working Group: Protein quality assessment in follow-up formula for young children and ready to use therapeutic food. When determined by PER methodology the protein quality shall not be less than 85% of that of casein.

b) Lipids

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>g/100 kcal</td>
<td>3.5</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>g/100 kJ</td>
<td>0.84</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

4) Partially hydrogenated oils and fats shall not be used in the product as defined in Section 2.1.

1 Guidance upper levels are for nutrients without sufficient information for a science-based risk assessment. These levels are values derived on the basis of meeting nutritional requirements of young children and an established history of apparent safe use. They may be adjusted based on relevant scientific or technological progress. The purpose of the GULs is to provide guidance to manufacturers and they should not be interpreted as goal values. Nutrient contents in the product as defined in Section 2.1 should usually not exceed the GULs unless higher nutrient levels cannot be avoided due to high or variable contents in constituents of the product as defined in Section 2.1 or due to technological reasons. When a product type or form has ordinarily contained lower levels than the GULs, manufacturers should not increase levels of nutrients to approach the GULs.
**α-Linolenic acid**

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg /100 kcal</td>
<td>50</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>mg /100 kJ</td>
<td>12</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**Linoleic acid**

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg /100 kcal</td>
<td>300</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>mg /100 kJ</td>
<td>72</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**c) Carbohydrates**

**available carbohydrates**

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum(^5)</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>g /100 kcal</td>
<td>*</td>
<td>12.5</td>
<td>-</td>
</tr>
<tr>
<td>g /100 kJ</td>
<td></td>
<td>3.0</td>
<td>-</td>
</tr>
</tbody>
</table>

\(^5\) Lactose should be the preferred carbohydrate in the product as defined in Section 2.1 based on milk protein.

For products based on non-milk protein, carbohydrate sources that have no contribution to sweet taste should be preferred and in no case be sweeter than lactose.

Mono- and disaccharides, other than lactose, should not exceed 2.5 g/100 kcal (0.60 g/100 kJ). National and/or regional authorities may limit this level to 1.25 g/100 kcal (0.30 g/100 kJ). Sucrose and/or fructose should not be added.

\(^6\) For the product as defined in Section 2.1 with a protein level below 3.0 g/100 kcal a maximum level of available carbohydrates up to 14 g/100 kcal (3.3 g/100 kJ) may be permitted by competent national and/or regional authorities.

**d) Vitamins**

**Vitamin A**

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg RE(^7) /100 kcal</td>
<td>60</td>
<td>180</td>
<td>-</td>
</tr>
<tr>
<td>µg RE(^7) /100 kJ</td>
<td>14</td>
<td>43</td>
<td>-</td>
</tr>
</tbody>
</table>

\(^7\) expressed as retinol equivalents (RE)

1 µg RE = 3.33 IU Vitamin A = 1 µg all-trans retinol. Retinol contents shall be provided by preformed retinol, while any contents of carotenoids should not be included in the calculation and declaration of Vitamin A activity.

**Vitamin D**

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg(^8) /100 kcal</td>
<td>1.5</td>
<td>4.5</td>
<td>-</td>
</tr>
<tr>
<td>µg(^8) /100 kJ</td>
<td>0.36</td>
<td>1.1</td>
<td>-</td>
</tr>
</tbody>
</table>

\(^8\) Competent national and/or regional authorities may deviate from the conditions as appropriate for the nutritional needs of their population.

**Riboflavin**

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg /100 kcal</td>
<td>80</td>
<td>-</td>
<td>650</td>
</tr>
<tr>
<td>µg /100 kJ</td>
<td>19</td>
<td>-</td>
<td>155</td>
</tr>
</tbody>
</table>

**Vitamin B\(_{12}\)**

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg /100 kcal</td>
<td>0.1</td>
<td>-</td>
<td>2.0</td>
</tr>
<tr>
<td>µg /100 kJ</td>
<td>0.02</td>
<td>-</td>
<td>0.48</td>
</tr>
</tbody>
</table>
**Vitamin C**

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg /100 kcal</td>
<td>10</td>
<td>-</td>
<td>70</td>
</tr>
<tr>
<td>mg /100 kJ</td>
<td>2.4</td>
<td>-</td>
<td>17</td>
</tr>
</tbody>
</table>

*10) expressed as L-ascorbic acid*

e) **Minerals and Trace Elements**

**Iron**

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg /100 kcal</td>
<td>1.0</td>
<td>3.0</td>
<td>-</td>
</tr>
<tr>
<td>mg /100 kJ</td>
<td>0.24</td>
<td>0.72</td>
<td>-</td>
</tr>
</tbody>
</table>

*11) For the product as defined in Section 2.1 based on soy protein isolate a minimum value of 1.5 mg/100 kcal (0.36 mg/100 kJ) applies.*

**Calcium**

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg /100 kcal</td>
<td>90</td>
<td>-</td>
<td>280</td>
</tr>
<tr>
<td>mg /100 kJ</td>
<td>22</td>
<td>-</td>
<td>67</td>
</tr>
</tbody>
</table>

**Zinc**

<table>
<thead>
<tr>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg /100 kcal</td>
<td>0.5</td>
<td>-</td>
<td>1.5</td>
</tr>
<tr>
<td>mg /100 kJ</td>
<td>0.12</td>
<td>-</td>
<td>0.36</td>
</tr>
</tbody>
</table>

**Sodium chloride** should not be added to the product as defined in Section 2.1.

3.1.4 National and/or regional authorities may add mandatory requirements for essential nutrients listed under 3.1.3, Section B. Any additional mandatory nutrients should be chosen from the essential composition of follow-up formula for older infants under 3.1.3 Section A. If additional mandatory nutrients are added, the nutrient levels must be based on the nutrient composition of follow-up formula for older infants (3.1.3 Section A) which is informed by the composition of breast milk, and take into account the inherent levels of nutrients in cows’ milk. All nutrient levels may be amended if the nutritional needs of the local population and scientific justification warrants such deviation.

3.2 Optional Ingredients

3.2.1 In addition to the compositional requirements listed under 3.1.3 Section B, other ingredients or substances may be added to the product as defined in Section 2.1 where the safety and suitability of the optional ingredient for particular nutritional purposes, at the level of use, is evaluated by national and/or regional authorities and demonstrated by generally accepted scientific evidence. Optional ingredients listed in 3.2.3 Section A are also permitted.

3.2.2 When any of these ingredients or substances is added the product as defined in Section 2.1 shall contain sufficient amounts to achieve the intended effect.

3.2.3 Additional nutrients may also be added to the product as defined in Section 2.1 provided these nutrients are chosen from the essential composition of follow-up formula for older infants and levels are as per the minimum, maximum, GULs stipulated for follow-up formula for older infants (3.1.3 Section A) and take into account the inherent levels of nutrients in cows’ milk; or amended by national and/or regional authorities if the nutritional needs of the local population and scientific justification warrants such deviation.

3.2.4 Ingredients shall not be added with the purpose of imparting or enhancing a sweet taste of the product as defined in Section 2.1.
SECTION B
(at Step 5)

SECTION B: DRINK/PRODUCT FOR YOUNG CHILDREN WITH ADDED NUTRIENTS OR DRINK FOR YOUNG CHILDREN

1 SCOPE

1.1 This section of the Standard applies to the product as defined in Section 2.1, in liquid or powdered form.

1.2 This section of the Standard contains compositional, quality, safety, labelling, analytical and sampling requirements for the product as defined in Section 2.1.

1.3 Only products that comply with the criteria laid down in the provisions of this section of this Standard shall be presented as the product defined in Section 2.1.

2 DESCRIPTION

2.1 Product Definition

2.1.1 Drink/product for young children with added nutrients or Drink for young children means a product manufactured for use as a liquid part of the diversified diet of young children [which may contribute to the nutritional needs of young children]1

2.1.2 Drink/product for young children with added nutrients or Drink for young children is so processed by physical means only and so packaged as to prevent spoilage and contamination under all normal conditions of handling, storage and distribution in the country where the product is sold.

2.2 Other Definitions

2.2.1 The term young child means a person from the age of more than 12 months up to the age of three years (36 months).

9. LABELLING

The requirements of the General Standard for the Labelling of Pre-packaged Foods (CXS 1-1985), the Guidelines on Nutrition Labelling (CXG 2-1985) and the Guidelines for Use of Nutrition and Health Claims (CXG 23-1997) apply to the product as defined in Section 2.1. These requirements include a prohibition on the use of nutrition and health claims for foods for infants and young children except where specifically provided for in relevant Codex Standards or national legislation.

9.1 The Name of the Product

9.1.1 The text of the label and all other information accompanying the product shall be written in the appropriate language(s).

9.1.2 The name of the product shall be “Drink/Product for Young Children with Added Nutrients” or “Drink for Young Children” as defined in Section 2.1, or any appropriate designation indicating the true nature of the product, in accordance with national or regional usage.

9.1.3 The sources of protein in the product shall be clearly shown on the label.

a) If [name of animal] milk is the only source of protein*, the product may be labelled “Drink/Product for Young Children with Added Nutrients Based on [name of animal] milk protein” or “Drink for Young Children Based on [name of animal] milk protein”.

b) If [name of plant] is the only source of protein*, the product may be labelled “Drink/Product for Young Children with Added Nutrients Based on [name of plant] protein” or “Drink for Young Children Based on [name of plant] protein”.

---

1 In some countries these products are regulated as breast-milk substitutes.
c) if [name of animal] milk and [name of plant] are the sources of proteins*, the product may be labelled “Drink/Product for Young Children with Added Nutrients Based on [name of animal] milk protein and [name of plant] protein” or “Drink for Young Children Based on [name of animal] milk protein and [name of plant] protein” or “Drink/Product for Young Children with Added Nutrients Based on [name of plant] protein and [name of animal] milk protein” or “Drink for Young Children Based on [name of plant] protein and [name of animal] milk protein”.

* For clarity, addition of individual amino acids where needed to improve protein quality does not preclude use of the above labelling options.

9.1.4 A product which contains neither milk nor any milk derivative shall be labelled "contains no milk or milk products" or an equivalent phrase.

9.2 List of Ingredients

9.2.1 A complete list of ingredients shall be declared on the label in descending order of proportion except that in the case of added vitamins and minerals, these ingredients may be arranged as separate groups for vitamins and minerals. Within these groups the vitamins and minerals need not be listed in descending order of proportion.

9.2.2 The specific name shall be declared for ingredients of animal or plant origin and for food additives. In addition, appropriate functional classes for food additives shall be included on the label. The food additives INS number may also be optionally declared.

9.3 Declaration of Nutritive Value

The declaration of nutrition information for the product as defined in Section 2.1 shall contain the following information which should be in the following order:

a) the amount of energy, expressed in kilocalories (kcal) and/or kilojoules (kJ), and the number of grams of protein, carbohydrate and fat per 100 g or per 100 ml of the food as sold [as well as] per 100 ml of the food ready for use, when prepared according to the instructions on the label.

b) the total quantity of each vitamin, and mineral as listed in paragraph 3.1.3 of Section B and any other ingredient as listed in paragraph 3.2 of Section B per 100 g or per 100 ml of the food as sold [as well as] per 100 ml of the food ready for use, when prepared according to the instructions on the label.

c) In addition, the declaration of nutrients in a) and b) per 100 kilocalories (kcal) (or per 100 kilojoules) (kJ) and/or per serving size, provided that the serving size is quantified on the label, is permitted.

9.4 Date Marking and Storage Instructions

9.4.1 The date marking and storage instructions shall be in accordance with section 4.7 of the General Standard for the Labelling of Prepackaged Foods.

9.4.2 Where practicable, storage instructions shall be in close proximity to the date marking.

9.5 Information for use

9.5.1 Ready to use products in liquid form should be used directly. Concentrated liquid products and powdered products, must be prepared with potable water that is safe or has been rendered safe by previous boiling before feeding, according to directions for use. Adequate directions for the appropriate preparation and handling should be in accordance with Good Hygienic Practice.

9.5.2 Adequate directions for the appropriate preparation and use of the product, including its storage and disposal after preparation, i.e. that product remaining after feeding should be discarded, shall appear on the label.

9.5.3 The label shall carry clear graphic instructions illustrating the method of preparation of the product.

9.5.4 The directions should be accompanied by a warning about the health hazards of inappropriate preparation, storage and use.

9.5.5 Adequate directions regarding the storage of the product after the container has been opened, shall appear on the label.

9.5.6 The label of the product as defined in Section 2.1 shall include a statement that the product shall not be introduced to infants 12 months of age or less, and is not to be used as a sole source of nutrition.
9.6  Additional Labelling Requirements

9.6.1  The label of the product as defined in Section 2.1 shall have no image, text or representation, including pictures of feeding bottles, that could undermine or discourage breastfeeding or which idealises the use of the product as defined in Section 2.1. The terms 'humanized', 'maternalized' or other similar terms must not be used on the label.

9.6.2  Labels should not discourage breastfeeding. Each container label shall have a clear, conspicuous and easily readable message which includes the following points:

a) the statement “Breastfeeding is recommended up to two years and beyond.”

b) a statement that the mother/caregiver should seek advice of a health worker on proper feeding of the young child.

9.6.3  The label shall have no pictures of infants, older infants, young children and women or any other picture, text, or representation that:

9.6.3.1 undermines or discourages breastfeeding; or that makes a comparison to breast-milk, or suggests that the product is similar, equivalent to or superior to breast-milk;

9.6.3.2 might convey an endorsement or anything that may be construed as an endorsement by a professional or any other body, unless this has been specifically approved by relevant national or regional regulatory authorities.

9.6.4  The product as defined in Section 2.1 shall be distinctly labelled in such a way as to avoid any risk of confusion with infant formula, follow-up formula for older infants, and formula for special medical purposes intended for infants, in particular as to the text, images and colours used, to enable consumers to make a clear distinction between them.

9.6.5  The labelling of the product as defined in Section 2.1 shall not refer to infant formula, follow-up formula for older infants, or formula for special medical purposes intended for infants, including numbers, text, statements, or images of these products.
REVIEW OF THE STANDARD FOR FOLLOW-UP FORMULA:
Remaining sections for Sections A and B
(at Step 4)

[Section A: Follow up formula for older infants]

3.3 Purity requirements

3.3.1 General

All ingredients shall be clean, of good quality, safe and suitable for ingestion by [older] infants. from the 6th month on and young children. They shall conform with their normal quality requirements, such as colour, flavour and odour.

3.3.2 Vitamin Compounds and Mineral Salts (Recommendation 4a)

3.3.2.1 Vitamin compounds and mineral salts used in accordance with Sections 3.3.1 and 3.3.2 should be selected from the Advisory List for Mineral Salts and Vitamin Compounds for Use in Foods for Infants and Children approved by the Codex Alimentarius Commission (CXG 10-1979).

3.3.2.2 The amounts of sodium derived from vitamin and mineral ingredients shall be within the limit for sodium in Section 3.1.

3.4 Consistency and Particle Size

When prepared according to the directions of use, the product shall be free of lumps and of large, coarse particles.

3.5 Specific prohibitions

The product and its components shall not have been treated by ionizing radiation.

4. Food additives

The following additives are permitted:

<table>
<thead>
<tr>
<th>INS</th>
<th>Additive</th>
<th>Maximum level in 100 mL of the product ready for consumption</th>
</tr>
</thead>
<tbody>
<tr>
<td>412</td>
<td>Guar gum</td>
<td>0.1 g</td>
</tr>
<tr>
<td>410</td>
<td>Carob bean gum</td>
<td>0.1 g</td>
</tr>
<tr>
<td>1412</td>
<td>Distarch phosphate</td>
<td>0.5 g singly or in combination in soy-based products only; 2.5 g singly or in combination in hydrolyzed protein and/or amino acid-based products only</td>
</tr>
<tr>
<td>1414</td>
<td>Acetylated distarch phosphate</td>
<td></td>
</tr>
<tr>
<td>1413</td>
<td>Phosphated distarch phosphate</td>
<td></td>
</tr>
<tr>
<td>1422</td>
<td>Acetylated distarch adipate</td>
<td></td>
</tr>
<tr>
<td>407</td>
<td>Carrageenan</td>
<td>0.03 g singly or in combination in milk and soy-based products only; 0.1 g singly or in combination in hydrolyzed protein and/or amino acid-based liquid products only</td>
</tr>
<tr>
<td>440</td>
<td>Pectins</td>
<td>1 g</td>
</tr>
</tbody>
</table>

4.2 Emulsifier

<table>
<thead>
<tr>
<th>INS</th>
<th>Additive</th>
<th>Maximum level in 100 mL of the product ready for consumption</th>
</tr>
</thead>
<tbody>
<tr>
<td>322</td>
<td>Lecithin</td>
<td>0.5 g</td>
</tr>
<tr>
<td>471</td>
<td>Mono- and Di-glycerides</td>
<td>0.4 g</td>
</tr>
</tbody>
</table>

4.3 Acidity Regulator

<table>
<thead>
<tr>
<th>INS</th>
<th>Additive</th>
<th>Maximum level in 100 mL of the product ready for consumption</th>
</tr>
</thead>
<tbody>
<tr>
<td>500ii</td>
<td>Sodium hydrogen carbonate</td>
<td>Limited by GMP</td>
</tr>
<tr>
<td>500i</td>
<td>Sodium carbonate</td>
<td></td>
</tr>
<tr>
<td>331i</td>
<td>Sodium dihydrogen citrate</td>
<td>Within the limits for sodium in Section 3.1</td>
</tr>
<tr>
<td>331ii</td>
<td>Trisodium citrate</td>
<td></td>
</tr>
<tr>
<td>524</td>
<td>Sodium hydroxide</td>
<td></td>
</tr>
<tr>
<td>501ii</td>
<td>Potassium hydrogen carbonate</td>
<td></td>
</tr>
</tbody>
</table>
### 4.4 Antioxidant

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>307b</td>
<td>Mixed tocopherols concentrate</td>
<td>3 mg singly or in combination</td>
</tr>
<tr>
<td>307a, c</td>
<td>α-tocopherol</td>
<td></td>
</tr>
<tr>
<td>304</td>
<td>L-ascorbyl palmitate</td>
<td></td>
</tr>
<tr>
<td>300</td>
<td>Ascorbic acid, L-</td>
<td></td>
</tr>
<tr>
<td>301</td>
<td>Sodium ascorbate</td>
<td></td>
</tr>
<tr>
<td>302</td>
<td>Calcium ascorbate</td>
<td></td>
</tr>
</tbody>
</table>

### 4.5 Packaging Gases

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>290</td>
<td>Carbon dioxide</td>
<td>GMP</td>
</tr>
<tr>
<td>941</td>
<td>Nitrogen</td>
<td>GMP</td>
</tr>
</tbody>
</table>

### 4.6 Flavourings

Natural Fruit Extracts: GMP

Vanilla extract: GMP

Ethyl vanillin ([JECFA no. 893]): 5 mg/100 ml

Vanillin ([JECFA no. 889]): 5 mg/100 ml

*The flavourings used in products covered by this standard should comply with the Guidelines for the Use of Flavourings (CXG 66-2008)*

### 4.7 Carry-Over Principle

#### Option 1:

Section 4 of the General Standard for Food Additives (CXS 192-1995) shall apply.

#### Option 2:

Only the food additives listed in this Section or in the Advisory List of Mineral Salts and Vitamin Compounds for Use in Foods for Infants and Children (CXG 10-1979) may be present in the foods described in [section 2.1 of this Standard], as a result of carry-over from a raw material or other ingredient (including food additive) used to produce the food, subject to the following conditions:

- a) The amount of the food additive in the raw materials or other ingredients (including food additives) does not exceed the maximum level specified; and b) The food into which the food additive is carried over does not contain the food additive in greater quantity than would be introduced by the use of the raw materials or ingredients under good manufacturing practice, consistent with the provisions on carry-over in the Preamble of the General Standard for Food Additives (CXS 192-1995)

- b) The food into which the food additive is carried over does not contain the food additive in greater quantity than would be introduced by the use of the raw materials or ingredients under good manufacturing practice, consistent with the provisions on carry-over in the Preamble of the General Standard for Food Additives (CXS 192-1995).

### 5. Contaminants

The products covered by this Standard shall comply with the Maximum levels of the General Standard for Contaminants and Toxins in Food and Feed (CXS 193-1995).

The products covered by this Standard shall comply with the maximum residues limits for pesticides established by the Codex Alimentarius Commission.

### 6. Hygiene

6.1 It is recommended that the product covered by the provisions of this standard be prepared and handled in accordance with the appropriate sections of the General Principles of Food Hygiene (CXC 1-1969), and
other relevant Codex texts such as the *Code of Hygienic Practice for Powdered Formulæ for Infants and Young Children* (CXC 66-2008).

[the *Code of Hygienic Practice for Aseptically Processed and Packaged Low-acid Foods* (CXC 40-1993) and the *Code of Hygienic Practice for Low and Acidified Low-acid Canned Foods* (CXC 23-1979)]

6.2 The products should comply with any microbiological criteria established in accordance with the *Principles and Guidelines for the Establishment and Application of Microbiological Criteria Related to Foods* (CXG 21-1997).

7. Packaging

7.1 The product shall be packed in containers which will safeguard the hygienic and other qualities of the food. When in liquid form, the product shall be packed in hermetically sealed containers; nitrogen and carbon dioxide may be used as a packing media.

7.2 The containers, including packaging materials, shall be made only of substances which are safe and suitable for their intended uses. Where the Codex Alimentarius Commission has established a standard for any such substance used as packaging materials, that standard shall apply.

8. Fill of containers

In the case of products in ready-to-eat form, the fill of container shall be:

(i) not less than 80% v/v for products weighing less than 150 g (5 ½ oz.);
(ii) not less than 85% v/v for products in the weight range 150-250 g (5 ¼ - 9 oz.); and
(iii) not less than 90% v/v for products weighing more than 250 g (9 oz.) of the water capacity of the container. The water capacity of the container is the volume of distilled water at 20°C which the sealed container will hold when completely filled.

10. Methods of Analysis and sampling

For checking the compliance with this Standard, the methods of analysis contained in the *Recommended Methods of Analysis and Sampling* (CXS 234-1999) relevant to the provisions in this standard, shall be used.

Section B: Drink/product for young children with added nutrients or drink for young children

3.3 Purity requirements

3.3.1 General

All ingredients shall be clean, of good quality, safe and suitable for ingestion by *infants from the 6th month on and young children*. They shall conform with their normal quality requirements, such as colour, flavour and odour.

3.3.2 Vitamin Compounds and Mineral Salts

Vitamin compounds and mineral salts used in accordance with Sections 3.3.1 and 3.3.2 should be selected from the *Advisory List for Mineral Salts and Vitamin Compounds for Use in Foods for Infants and Children* approved by the Codex Alimentarius Commission (CXG 10-1979).

The amounts of sodium derived from vitamin and mineral ingredients shall be within the limit for sodium in Section 3.2.6.

3.4 Consistency and particle size

When prepared according to the directions of use, the product shall be free of lumps and of large, coarse particles.

3.5 Specific prohibitions

The product and its components shall not have been treated by ionizing radiation.

4. Food additives

The following additives are permitted:

<table>
<thead>
<tr>
<th>INS</th>
<th>Additive</th>
<th>Maximum level in 100 mL of the product ready for consumption</th>
</tr>
</thead>
<tbody>
<tr>
<td>412</td>
<td>Guar gum</td>
<td>0.1 g</td>
</tr>
</tbody>
</table>
### 4.1 Carbohydrates

<table>
<thead>
<tr>
<th>410</th>
<th>Carob bean gum</th>
<th>0.1 g</th>
</tr>
</thead>
<tbody>
<tr>
<td>1412</td>
<td>Distarch phosphate</td>
<td>0.5 g singly or in combination in soy-based products only; 2.5 g singly or in combination in hydrolyzed protein and/or amino acid-based products only</td>
</tr>
<tr>
<td>1414</td>
<td>Acetylated distarch phosphate</td>
<td></td>
</tr>
<tr>
<td>1413</td>
<td>Phosphated distarch phosphate</td>
<td></td>
</tr>
<tr>
<td>1422</td>
<td>Acetylated distarch adipate</td>
<td></td>
</tr>
<tr>
<td>407</td>
<td>Carrageenan</td>
<td>0.03 g singly or in combination in milk and soy-based products only; 0.1 g singly or in combination in hydrolyzed protein and/or amino acid-based liquid products only</td>
</tr>
<tr>
<td>440</td>
<td>Pectins</td>
<td>1 g</td>
</tr>
</tbody>
</table>

### 4.2 Emulsifier

| 322 | Lecithin | 0.5 g |
| 471 | Mono- and Di-glycerides | 0.4 g |

### 4.3 Acidity Regulator

| 500i | Sodium hydrogen carbonate | Limited by GMP |
| 500i | Sodium carbonate |  |
| 331i | Sodium dihydrogen citrate |  |
| 331ii | Trisodium citrate |  |
| 524 | Sodium hydroxide |  |
| 501i | Potassium hydrogen carbonate | Limited by GMP |
| 501i | Potassium carbonate |  |
| 332i | Potassium dihydrogen citrate |  |
| 332ii | Tripotassium citrate |  |
| 525 | Potassium hydroxide |  |
| 526 | Calcium hydroxide | Limited by GMP |
| 270 | L (+) Lactic acid | Limited by GMP |
| 330 | Citric acid | Limited by GMP |

### 4.4 Antioxidant

| 307b | Mixed tocopherols concentrate | 3 mg singly or in combination |
| 307a, c | α-tocopherol |  |
| 304 | L-ascorbyl palmitate |  |
| 300 | Ascorbic acid, L- | 5 mg singly or in combination, expressed as ascorbic acid (INS 300, 301,302,304) |
| 301 | Sodium ascorbate |  |
| 302 | Calcium ascorbate |  |

### 4.5 Packaging Gases

| 290 | Carbon dioxide | GMP |
| 941 | Nitrogen | GMP |

### 4.6 Flavourings (Recommendation 10b)

Natural Fruit Extracts: GMP

Vanilla extract: GMP

Ethyl vanillin [(JECFA no. 893)]: 5 mg/100 ml

Vanillin [(JECFA no. 889)]: 5 mg/100 ml

[The flavourings used in products covered by this standard should comply with the Guidelines for the Use of Flavourings (CXG 66-2008)]

### 4.7 Carry-Over Principle

Option 1:

Section 4 of the General Standard for Food Additives (CXS 192-1995) shall apply.
Option 2:

Only the food additives listed in this Section or in the Advisory List of Mineral Salts and Vitamin Compounds for Use in Foods for Infants and Children (CXG 10-1979) may be present in the foods described in [section 2.1 of this Standard], as a result of carry-over from a raw material or other ingredient (including food additive) used to produce the food, subject to the following conditions:

a) The amount of the food additive in the raw materials or other ingredients (including food additives) does not exceed the maximum level specified; and b) The food into which the food additive is carried over does not contain the food additive in greater quantity than would be introduced by the use of the raw materials or ingredients under good manufacturing practice, consistent with the provisions on carry-over in the Preamble of the General Standard for Food Additives (CXS 192-1995); and

The food into which the food additive is carried over does not contain the food additive in greater quantity than would be introduced by the use of the raw materials or ingredients under good manufacturing practice, consistent with the provisions on carry-over in the Preamble of the General Standard for Food Additives (CXS 192-1995)

5. Contaminants

The products covered by this Standard shall comply with the Maximum levels of the General Standard for Contaminants and Toxins in Food and Feed (CXS 193-1995).

The products covered by this Standard shall comply with the maximum residues limits for pesticides established by the Codex Alimentarius Commission.

6. Hygiene

6.1 It is recommended that the product covered by the provisions of this standard be prepared and handled in accordance with the appropriate sections of the General Principles of Food Hygiene (CXC 1-1969), and other relevant Codex texts such as the Code of Hygienic Practice for Powdered Formulae for Infants and Young Children (CXC 66-2008)

[the Code of Hygienic Practice for Aseptically Processed and Packaged Low-acid Foods (CXC 40-1993) and the Code of Hygienic Practice for Low and Acidified Low-acid Canned Foods (CXC 23-1979)]

6.2 The products should comply with any microbiological criteria established in accordance with the Principles and Guidelines for the Establishment and Application of Microbiological Criteria Related to Foods (CXG 21-1997).

7. Packaging

7.1 The product shall be packed in containers which will safeguard the hygienic and other qualities of the food. When in liquid form, the product shall be packed in hermetically sealed containers; nitrogen and carbon dioxide may be used as a packing media.

7.2 The containers, including packaging materials, shall be made only of substances which are safe and suitable for their intended uses. Where the Codex Alimentarius Commission has established a standard for any such substance used as packaging materials, that standard shall apply.

8. Fill of containers

In the case of products in ready-to-eat form, the fill of container shall be:

(i) not less than 80% v/v for products weighing less than 150 g (5 ¼ oz.);
(ii) not less than 85% v/v for products in the weight range 150-250 g (5 ¼ - 9 oz.); and
(iii) not less than 90% v/v for products weighing more than 250 g (9 oz.) of the water capacity of the container. The water capacity of the container is the volume of distilled water at 20°C which the sealed container will hold when completely filled.

10. Methods of analysis

For checking the compliance with this Standard, the methods of analysis contained in the Recommended Methods of Analysis and Sampling (CXS 234-1999) relevant to the provisions in this standard, shall be used]
PROPOSED DRAFT GUIDELINES FOR READY TO USE THERAPEUTIC FOODS (RUTF)
(at Step 5)

[1. PREAMBLE]

Children affected by severe acute malnutrition (SAM) need safe, palatable foods with a high energy content and adequate amounts of vitamins, minerals and other nutrients. Children with SAM need efficacious and timely intervention and RUTF is one of the options for the dietary management of children with uncomplicated SAM from 6-59 months. These guidelines should be used in accordance with technical recommendations that are based on the relevant evidence and related Codex texts/documents by WHO, UNICEF and WFP.


2. PURPOSE OF THE GUIDELINES

To provide guidance on technical and nutritional aspects of the production of Ready to Use Therapeutic Foods for children from the age of 6 to 59 months with severe acute malnutrition, including

i. Nutritional Composition
ii. Raw Materials and Ingredients
iii. Good Manufacturing Practices
iv. Microbiological and Chemical Contaminant Criteria
v. Methods of Analysis and Sampling
vi. Provisions for Packaging and Labelling

3. SCOPE

The provisions of these guidelines apply to Ready to Use Therapeutic Foods for children from age 6 to 59 months with severe acute malnutrition. Ready-to-Use Supplementary Foods (RUSF), micronutrient supplements, processed cereal based foods, formulated complementary foods for older infants and young children, canned baby foods are not covered by these guidelines.

2Guidelines for Vitamin and Mineral Food Supplements (CXG 55-2005)
3Standard for Processed Cereal-Based Foods for Infants and Young Children (CXS 74-1981)
4Guidelines on Formulated Complementary Foods for Older Infants and Young Children (CXG 8-1991)

4. DESCRIPTION

4.1 Ready-to-Use Therapeutic Foods (RUTF) are foods for special medical purposes and are high-energy and contain adequate protein and other essential nutrients for the dietary management of children from 6 to 59 months with severe acute malnutrition without medical complications with appetite. These foods should be soft or crushable and should be easy for children to eat without any prior preparation.

4.2 Severe Acute Malnutrition is defined by weight for height (or length) less than –3 Z-score of the median WHO growth standards, or by mid upper arm circumference (MUAC) <11.5 cm, or by the presence of bilateral oedema.
5. SUITABLE RAW MATERIALS AND INGREDIENTS

RUTF are made of ingredients embedded in a lipid-rich matrix e.g. paste or biscuit, resulting in an energy and nutrient-dense food. The following raw materials, many of which can be sourced locally, are suitable ingredients for the production of RUTF under the specified conditions given below. Any formulation of RUTF shall comply with Section 3 of the *Standard for the Labelling of and Claims for Foods for Special Medical Purposes* (CXS 180-1991) including the specification that their use should have been demonstrated, by scientific evidence, to be safe and beneficial in meeting the nutritional requirements of the persons for whom they are intended.

5.1 Basic Raw Materials and Ingredients

5.1.1 Milk and other Dairy Products

Milk and other dairy products used in the manufacturing of RUTF must comply with the *Standard for Milk Powders and Cream Powder* (CXS 207-1999) and the *Standard for Whey Powders* (CXS 289-1995), and other Codex milk and milk product standards as well as other guidelines and Codes of Practice recommended by Codex Alimentarius Commission, which are relevant to these products. Relevant codes of practice include the *Code of Hygienic Practice for Milk and Milk Products* (CXC 57-2004) and the *Code of Hygienic Practices for Low-Moisture Foods* (CXC 75-2015).

5.1.2 Legumes and Seeds

Legumes and seeds such as soybeans, lentils, chickpeas, cowpeas, beans, peanut, sesame and other types of legumes and seeds must comply with the relevant Codex Alimentarius texts when used in the manufacturing of RUTF.

Legumes and seeds must be appropriately processed to reduce, as much as possible, the anti-nutritional factors normally present, such as phytate, lectins (haemagglutinins), trypsin, chymotrypsin inhibitors and phytoestrogens.

Field beans or Faba beans (*Vicia faba* L) should not be used in the formulation of RUTF because of the danger of favism.

5.1.3 Fats and Oils

Fats and oils used in the manufacturing of RUTF must comply with the relevant Codex Alimentarius texts. Fats and oils are incorporated as technologically feasible for the purpose of achieving the energy density and providing essential fatty acids. Care must be taken to avoid oxidized fat which will adversely affect nutrition, flavour and shelf life.

Partially Hydrogenated fats and oils should not be used in RUTF.

5.1.4 Cereals, Roots and Tubers and their derived Products

All milled cereals, roots and tubers and their derived products suitable for human consumption may be used provided that they are processed in such a way that the fibre content is reduced, when necessary, and that the effects of anti-nutritional factors such as phytates, tannins or other phenolic materials, lectins, trypsin, and chymotrypsin inhibitors which can lower the protein quality and digestibility, amino acid bioavailability and mineral absorption are removed or reduced, whilst retaining maximum nutrient value.

5.1.5 Vitamins and Minerals

Vitamin and mineral forms used must be soluble and easily absorbed by patients with SAM. Children with SAM have low or absent gastric acid which means that they should not be given inorganic salts of minerals that are insoluble or requiring an acid gastric environment for absorption, in order to avoid metabolic acidosis. It is important that RUTF should have a mineral composition that leads to a moderate excess of non-metabolizable buffer base. The non-metabolizable buffer base can be approximated by the formula: estimated absorbed millimoles (sodium + potassium + calcium + magnesium) - (phosphorus + chloride).

All added vitamins and minerals must be in accordance with the *Advisory Lists of Nutrient Compounds for use in Foods for Special Dietary Uses Intended for Infants and Young Children* (CXG 10-1979). Examples of mineral forms for RUTF formulation can be found in the *WHO Management of severe malnutrition: A manual for physicians and other senior health workers* (1999). The amount of vitamins and minerals added to achieve the target level must be adjusted based on the chemical form, interaction, and impaired absorption with other nutrients and non-nutrients and scientific evidence showing adequate stability and bioavailability in the finished product.
5.2 Other Ingredients

5.2.1 Carbohydrates

Carbohydrates are used to achieve energy requirements in balance with proteins and lipids. Plant starch, lactose, maltodextrin and sucrose are the preferred carbohydrates in RUTF. Free sugars should be limited and should not exceed 20% of total energy. Only precooked and/or gelatinized starches may be added. Glucose and fructose should not be used. Carbohydrates must adhere to the relevant Codex Alimentarius texts.

Honey should not be used in RUTF due to the risk of infant botulism from *Clostridium botulinum*.

5.2.2 Food Additives

Only the food additives listed in this Section (Table A: Food Additives in RUTF Formulation) or in the *Advisory Lists of Nutrient Compounds for Use in Foods for Special Dietary Uses Intended for Infants and Young Children* (CXG 10-1979) may be present in the foods described in section 4.1 of this Guideline. Other than by direct addition, an additive may be present in RUTF as a result of carry-over from a raw material or other ingredient (including food additive) used to produce the food, subject to the following conditions:

a) The additive is acceptable for use in the raw materials or other ingredients (including food additives) according to the *General Standard for Food Additives* (CXS 192-1995)

b) The amount of the additive in the raw materials or other ingredients (including food additives) does not exceed the maximum use level specified in the *General Standard for Food Additives* (CXS 192-1995); and

c) The food into which the additive is carried over does not contain the additive in greater quantity than would be introduced by the use of the raw materials or ingredients under proper technological conditions or good manufacturing practice, consistent with the provisions on carry-over in the Preamble of the *General Standard for Food Additives* (CXS 192-1995).

Table A: Food Additives in RUTF Formulation

<table>
<thead>
<tr>
<th>Functional Class</th>
<th>Food Additive</th>
<th>International Numbering System (INS)</th>
<th>Maximum Use Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emulsifier</td>
<td>Mono- and di-glycerides of fatty acids</td>
<td>471</td>
<td>4000 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Citric and fatty acid esters of glycerol</td>
<td>472c</td>
<td>9000 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Lecithin</td>
<td>322(i)</td>
<td>5000 mg/kg</td>
</tr>
<tr>
<td>Antioxidant</td>
<td>Ascorbyl palmitate</td>
<td>304</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Tocopherol concentrate, mixed</td>
<td>307b</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td></td>
<td>Ascorbic acid, L</td>
<td>300</td>
<td>GMP</td>
</tr>
<tr>
<td>Acidity regulator</td>
<td>Citric acid</td>
<td>330</td>
<td>GMP</td>
</tr>
<tr>
<td>Packaging gas</td>
<td>Nitrogen</td>
<td>941</td>
<td>GMP</td>
</tr>
<tr>
<td></td>
<td>Carbon dioxide</td>
<td>290</td>
<td>GMP</td>
</tr>
<tr>
<td>Carrier</td>
<td>Silicon dioxide, amorphous</td>
<td>551</td>
<td>10 mg/kg</td>
</tr>
</tbody>
</table>

6. NUTRITIONAL COMPOSITION AND QUALITY FACTORS

The nutritional composition of RUTF shall comply with the requirements set out in the table in the Annex. Furthermore, the following requirements shall be complied with.

6.1 Energy

The energy density of the formulated RUTF should be between 5.2 - 5.5 kcal per gram. The energy density of RUTF can be achieved during manufacturing by the addition of energy containing ingredients (i.e. fats and oils and/or digestible carbohydrates) and/or processing the basic raw materials and ingredients as indicated in Section 8.
6.2 Proteins

Protein should provide 10% to 12% of the total energy.

Protein quality should be determined using Protein Digestibility Corrected Amino Acid Score (PDCAAS), calculated according to the reference amino acid requirement and scoring patterns related to catch up growth of 10 g/kg/day in the target population for RUTF which is children with SAM aged 6 to 59 months.

For all RUTF formulations, the PDCAAS shall not be less than 90. The PDCAAS shall be calculated using, appropriate digestibility values and the reference amino acid pattern as stipulated in the Report of the FAO Expert Working Group: Protein quality assessment in follow-up formula for young children and ready to use therapeutic foods (2018).

High quality protein will be achieved with RUTF formulations containing a minimum of 50% of protein from milk products.

In formulations with lower PDCAAS scores, the quality and/or quantity of protein should be adjusted to achieve the desired value. The addition of limiting amino acids, solely in the L-form, shall be permitted only in amounts necessary to improve the protein quality of the RUTF.

6.3 Lipids

Lipids should provide 45% to 60% of the total energy.

[The level of linoleic acid should not be less than 333mg 346 mg per 100 kcal and shall not be more than 1110 mg per 100 kcal. The level of alpha-linolenic acid should not be less than 33 mg/100kcal.]

6.4 Vitamins and Minerals

RUTF should contain the vitamins and minerals presented in the annex: Nutritional Composition of RUTF. RUTF should comply with the minimum and maximum or guidance upper levels in the annex.

6.5 WATER ACTIVITY

RUTF is a low-moisture food with a water activity of 0.6 or below.

7. CONTAMINANTS

It is recommended that the products covered by the provisions of these guidelines and the ingredients used in such products comply with the General Standard for Contaminants and Toxins in Food and Feed (CXS 193-1995), Maximum Residue Limits (MRLs) and Risk Management Recommendations (RMRs) for Residues of Veterinary Drugs in Foods (CXM 2-2015) and Codex Maximum Residue Limits for Pesticides.

Further guidance is given by codex Codes of practice and should be adhered to.

The product should not contain contaminants or other undesirable substances (e.g. biologically active substances, metal fragments) in amounts which may represent a risk to the health of children.

8. PROCESSING TECHNOLOGIES

Processing technologies used for RUTF and their ingredients shall be validated to prove that they do not alter the nutritional value of RUTF and that they allow the reduction of anti-nutritive factors. Milling or grinding, roasting, toasting are examples of processing technologies that can be used on ingredients.

Any technologies used should take into consideration the target group and any impact on the integrity of the nutrient content of the products. In addition to the practices described above, Good Hygiene Practices should be implemented for manufacturing of RUTF, according to the General Principles of Food Hygiene (CXC 1-1969) and Code of Hygienic Practices for Low Moisture Foods (CXC 75-2015) to avoid cross contamination during the storage of raw materials and the manufacturing process.

RUTF and/or their raw materials should be treated with a validated microbial reduction treatment in order to inactivate pathogens such as *Salmonella*, noting that some pathogens have increased heat resistance characteristics at reduced water activities in food matrices. Commonly used microbial reduction treatments that could be applied to RUTF and/or their raw materials include both thermal and non-thermal control measures.

For additional information on validation of control measures, refer to the Guidelines for the Validation of Food Safety Control Measures (CXG 69-2008). Additionally, refer to the Principles and Guidelines for the Conduct of Microbiological Risk Management (MRM) (CXG 63-2007).
9. GOOD MANUFACTURING PRACTICES AND GOOD HYGIENE PRACTICES

It is recommended that the products covered by the provisions of these guidelines be prepared and handled in accordance with the appropriate sections of the General Principles of Food Hygiene (CXC 1-1969), and Code of Hygienic Practice for Low-Moisture Foods (CXC 75-2015), and other relevant Codex texts.

The product should comply with any microbiological criteria established in accordance with the Principles and Guidelines for the Establishment and Application of Microbiological Criteria Related to Foods (CXG 21-1997).

The ingredients and final product should be prepared, packed and held under sanitary conditions and should comply with relevant Codex texts.

10. METHODS OF ANALYSIS AND SAMPLING

It is recommended that methods of analysis and sampling of RUTF be in accordance with the Recommended Methods of Analysis and Sampling (CXS 234-1999).

11. PACKAGING

It is recommended that RUTF be packaged in such a way to safeguard the hygienic and other qualities including nutritional properties of the food for the duration of its defined shelf-life.

The packaging materials shall be made only of substances which are safe and suitable for their intended uses. Where the Codex Alimentarius Commission has established a standard for any such substance used as packaging materials, that standard shall apply.

12. LABELLING

It is recommended that the labelling of RUTF for children from 6 to 59 months with SAM be in accordance with the Standard for the Labelling of and Claims for Foods for Special Medical Purposes (CXS 180-1991), the General Standard for the Labelling of and Claims for Pre-packaged Foods for Special Dietary Uses (CXS 146-1985), and Guidelines on Nutrition Labelling (CXG 2-1985).

12.1 The Name of the Food

The name of the food to be declared on the label shall indicate that the food is a Ready-To-Use Therapeutic Food for Children from 6 to 59 months with SAM. The appropriate designation indicating the true nature of the food should be in accordance with national legislation. The age from which the product is recommended for use shall appear in close proximity to the name of the food.

12.2 List of Ingredients

The list of ingredients shall be declared in accordance with Section 4.2 of the General Standard for the Labelling of Prepackaged Foods (CXS 1-1985).

12.3 Additional Mandatory Labelling Requirements


12.4 The following additional statements shall appear on the label of RUTF:

- The product is not to be used for Nasogastric Tube (NG tube) administration.
- The product should be used in conjunction with breastfeeding.
- Exclusive breastfeeding is recommended for the first 6 months of life, and continued breastfeeding is recommended for up to two years or beyond.

12.5 Instructions for use

- The label should indicate clearly from which age the product is recommended for use. This age shall not be less than six months for any product.
- Feeding instructions shall be given; preferably accompanied by graphical presentations.
- The time within which the product should be consumed after opening should be clearly indicated.
Table: Nutritional Composition of RUTF

<table>
<thead>
<tr>
<th>Energy</th>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>kcal/100g</td>
<td>520</td>
<td>550</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Protein</th>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>g/100kcal</td>
<td>2.5</td>
<td>3.0</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lipids</th>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>g/100kcal</td>
<td>5</td>
<td>7</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>n-6 Fatty acids</th>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mg/100kcal</td>
<td>330</td>
<td>[1111] or [780]</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>n-3 Fatty acids</th>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mg/100kcal</td>
<td>[33] or [110]</td>
<td>280</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Vitamin A</th>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 µg RE/100kcal</td>
<td>145</td>
<td>308</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

2 1 µg RE = 3.33 IU Vitamin A = 1 µg trans retinol. Retinol contents shall be provided by preformed retinol, while any contents of carotenoids should not be included in the calculation and declaration of vitamin A activity.

<table>
<thead>
<tr>
<th>Vitamin D</th>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 µg100 kcal</td>
<td>2.7</td>
<td>4.2</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

3 1 µg calciferol = 40 IU vitamin D.

Two forms of Vitamin D allowed in RUTF formulation are cholecalciferol (D3) and ergocalciferol (D2).

<table>
<thead>
<tr>
<th>Vitamin E</th>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 mg α-TE/100 kcal</td>
<td>3.6</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

4 1 mg α-tocopherol = 1 mg RRR-α-tocopherol (d-α-tocopherol)

41 mg RRR-α-tocopherol = 2.00 mg all-rac-α-tocopherol (dl-α-tocopherol)

<table>
<thead>
<tr>
<th>Vitamin K</th>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>μg/100 kcal</td>
<td>2.7</td>
<td>6</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Vitamin B1</th>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td>mg/100 kcal</td>
<td>0.09</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Vitamin</td>
<td>Unit</td>
<td>Minimum</td>
<td>Maximum</td>
<td>GUL</td>
</tr>
<tr>
<td>-----------</td>
<td>------------</td>
<td>---------</td>
<td>---------</td>
<td>-----</td>
</tr>
<tr>
<td>Vitamin B2</td>
<td>mg/100 kcal</td>
<td>0.29</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vitamin C</td>
<td>mg/100 kcal</td>
<td>9</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vitamin B6</td>
<td>mg/100 kcal</td>
<td>0.11</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vitamin B12</td>
<td>µg/100 kcal</td>
<td>0.29</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Folic Acid</td>
<td>µg/100 kcal</td>
<td>36</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

$^5$ 1 µg of folic acid = 1.7 µg of Dietary Folate Equivalents (DFE)

<table>
<thead>
<tr>
<th>Niacin</th>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mg/100 kcal</td>
<td>0.91</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pantothenic Acid</th>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mg/100 kcal</td>
<td>0.55</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Biotin</th>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>µg/100 kcal</td>
<td>11</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Minerals</th>
<th>Sodium</th>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>mg/100 kcal</td>
<td>-</td>
<td>56</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Potassium</th>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mg/100 kcal</td>
<td>200</td>
<td>308</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Calcium</th>
<th>Unit</th>
<th>Minimum</th>
<th>Maximum</th>
<th>GUL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mg/100 kcal</td>
<td>55</td>
<td>151</td>
<td>-</td>
</tr>
<tr>
<td>Mineral</td>
<td>Unit</td>
<td>Minimum</td>
<td>Maximum</td>
<td>GUL</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------</td>
<td>---------</td>
<td>---------</td>
<td>-----</td>
</tr>
<tr>
<td>Phosphorus</td>
<td>mg/100 kcal</td>
<td>55</td>
<td>151</td>
<td>-</td>
</tr>
<tr>
<td>Magnesium</td>
<td>mg/100 kcal</td>
<td>[15] or [30]</td>
<td>[45] or [90]</td>
<td>-</td>
</tr>
<tr>
<td>Iron</td>
<td>mg/100 kcal</td>
<td>1.8</td>
<td>2.7</td>
<td>-</td>
</tr>
<tr>
<td>Zinc</td>
<td>mg/100 kcal</td>
<td>2</td>
<td>2.7</td>
<td>-</td>
</tr>
<tr>
<td>Copper</td>
<td>mg/100 kcal</td>
<td>0.25</td>
<td>0.35</td>
<td>-</td>
</tr>
<tr>
<td>Selenium</td>
<td>µg /100 kcal</td>
<td>3.6</td>
<td>8</td>
<td>-</td>
</tr>
<tr>
<td>Iodine</td>
<td>µg /100 kcal</td>
<td>13</td>
<td>27</td>
<td>-</td>
</tr>
</tbody>
</table>
APPENDIX VII

PROJECT DOCUMENT OF A PROPOSAL FOR NEW WORK TO REVISE NUTRIENT REFERENCE VALUES OF VITAMINS AND MINERALS (CXG 2-1985)

UPDATED TO INCLUDE TIMELINES FOR NRVS-R FOR PERSONS AGED 6-36 MONTHS OF AGE

(for information only)

1. PURPOSE AND THE SCOPE OF THE PROPOSED NEW WORK

Section 3.4.4 of the Codex Guidelines for Nutrition Labelling (CX/GL 2-1985) provides that numerical information on vitamins, minerals and protein should be expressed as a percentage of the reference labelling value referred to as “Nutrient Reference Value” (NRV). Since the first introduction of this guideline in 1985, Section 3.4.4 was amended once in 1993 following the Report of a Joint FAO/WHO Consultation on Recommended Allowances of Nutrients for Food Labelling Purposes (Helsinki, Finland, 12-16 September 1988). At that time, it was indicated that the definition and review of these values was on-going process, subject to revision according to new scientific data by the Committee of Food Labelling (CCFL). The CCFL also recognized a need for general principles to guide the choice and amendment of NRVs, and had requested the advice of the Committee on Nutrition and Foods for Special Dietary Uses in this respect (ALINORM 93/40).

Currently the list of NRVs in Codex Guidelines for Nutrition Labelling covers 9 vitamins (A, D, C, thiamin, riboflavin, niacin, B6, folic acid and B12), 5 minerals (Calcium, Magnesium, Iron, Zinc, Iodine) and protein, which were in general based on the Reference RDAs for adult men. These values are indicated as a basis for expressing nutrient content in nutrition labelling of food supplements in the Codex Guidelines for Vitamin and Mineral Food Supplements (CXG 55-2005). Also the Codex Guidelines for Use of Nutrition and Health Claims (CXG 23-1997) indicates NRVs as a basis for criteria for nutrition and health claims.

At the 25th Session of the Codex Committee on Nutrition and Foods for Special Dietary Uses (CCNFSDU) agreed that the current list of NRVs in the Codex Guidelines for Nutrition Labelling was incomplete and required additions and updates. It was also pointed out that a set of principles should be developed for the establishment of NRVs taking into account the experience of member countries in the establishment of reference values for the purpose of labelling.

The purpose of the proposed new work is to develop the science-based general principles for establishing NRVs and to revise the list of NRVs in the Codex Guidelines for Nutrition Labelling, taking full account of the prior work related to nutrient reference values.

2. ITS RELEVANCE AND TIMELINES

WHA Resolution 57.17 endorsing the Global Strategy requested the Codex Alimentarius Commission to continue to give full consideration within the framework of its operational mandate, to measures which it might take to contribute towards the improvement of health standards of foods consistent with the aims and objectives of the Global Strategy.

Accordingly, the 28th Session of the Commission agreed to ask WHO and FAO to prepare a document focused on actions that could be taken by Codex including specific proposals for new work for consideration by the CCNFSDU and the CCFL. At its 29th Session of the Commission, it was agreed to complete a document containing concrete proposals for possible actions by Codex and to circulate for comments and consideration by the CCNFSDU and CCFL.

The CCNFSDU and CCFL had discussed extensively the proposals for actions and both Committees agreed for CCNFSDU to revise the NRVs of vitamins and minerals in the Guidelines for Nutrition Labelling (ALINORM 07/30/26). Therefore the proposal of this new work is timely as well as relevant.

3. THE MAIN ASPECTS TO BE COVERED

This work would involve a process to develop the general principles for establishment of vitamin and mineral NRVs for the general population as a first step.

The next step would be a process to review all available reference values and their scientific basis by the principles agreed upon and, if appropriate, update and extend the current list of vitamin and mineral NRVs in the Guidelines for the Nutrition Labelling.

Once the above is completed, the Committee would establish vitamin and mineral NRVs for labelling for individuals 6 months to 36 months of age. The Committee could then begin to work to establish principles that would apply to NRVs for this age group, using as a basis the principles identified for NRVs for the general
population and modifying them as appropriate. Once those principles are developed, the NRVs for this age group would be established.

4. AN ASSESSMENT AGAINST THE CRITERIA FOR THE ESTABLISHMENT OF WORK PRIORITIES

**Consumer protection from the point of view of health, food safety, ensuring fair practices in the food trade and taking into account the identified needs of developing countries:** This proposed new work would provide Codex and national/regional authorities principles to be used in establishing NRVs, thus assisting in establishing appropriate level of protection for consumers. The project could particularly assist countries that have limited experience with NRVs, particularly for selecting NRVs for labelling purposes.

**Diversification of national legislations and apparent resultant or potential impediments to international trade:** This proposed new work would provide internationally-recognized scientific general principles that Codex and national/regional authorities may use to carry out establishing NRVs for labelling purposes. Such internationally-agreed principles can help ensure consistent approaches for establishing NRVs for labelling purposes.

**Scope of work and establishment of priorities between the various sections of the work:** The scope of the work relates to work previously undertaken by Codex on a high priority basis.

**Work already undertaken by other organizations in this field:** This proposed new work is consistent with, complements, and builds upon work already undertaken by CCFL.

5. RELEVANCE TO THE CODEX STRATEGIC OBJECTIVES

This proposal is consistent with the following strategic goals presented in the Codex Strategic Plan 2008-2013:

- Promoting Sound Regulatory Frameworks (Activity 1.3);
- Promoting Widest and Consistent Application of Scientific Principles and Risk Analysis (Activities 2.3).

And the Codex Strategic Plan 2020-2025:

- Identify needs and emerging issues (Goal 1, Objective 1.1)
- Use scientific advice consistently in line with Codex risk analysis principles (Goal 2, Objective 2.1)
- Promote the submission and use of globally representative data in developing and reviewing Codex standards (Goal 2, Objective 2.2)

6. INFORMATION ON THE RELATION BETWEEN THE PROPOSAL AND OTHER EXISTING CODEX DOCUMENTS

The Codex Guidelines on Nutrition Labelling (CXG 2-1985) and Codex Guidelines for Vitamin and Mineral Food Supplements (CXG 55-2005) indicate the NRVs as a basis for expressing nutrient content in nutrition labelling of all foods including conventional foods and food supplements. The Codex Guidelines for Use of Nutrition and Health Claims (CXG 23-1997) also indicates NRVs as a basis for criteria for nutrition and health claims.

7. IDENTIFICATION OF ANY REQUIREMENT FOR AND AVAILABILITY OF EXPERT SCIENTIFIC ADVICE.

Scientific advice from FAO/WHO could be identified at a later stage. There might be a need for scientific advice which would focus on the requirements for each of the 24 nutrients were derived by FAO/WHO and 6 RASBs and evaluate and rank these nutrient requirements based on quality of evidence to help inform the work of the Committee.

8. IDENTIFICATION OF ANY NEED FOR TECHNICAL INPUT TO THE STANDARD FROM EXTERNAL BODIES SO THAT THIS CAN BE PLANNED FOR

None foreseen
9. UPDATED TIMELINE FOR COMPLETION OF THE NRVs-R WORK INVOLVED FOR PERSONS 6-36 MONTHS OF AGE

<table>
<thead>
<tr>
<th>Activity</th>
<th>Year/Step</th>
</tr>
</thead>
<tbody>
<tr>
<td>Developing General Principles for the establishment of these NRVs-R</td>
<td>2021/Step 5</td>
</tr>
<tr>
<td>for persons aged 6 to 36 months and how they should be used including</td>
<td></td>
</tr>
<tr>
<td>which foods they should apply to</td>
<td></td>
</tr>
<tr>
<td>Establishing NRVs-R for each nutrient</td>
<td>2021-2023/Step 5</td>
</tr>
<tr>
<td>Amending text in relevant Codex texts</td>
<td>2024/Step 5</td>
</tr>
<tr>
<td>Adoption by the Commission</td>
<td>2025</td>
</tr>
</tbody>
</table>
APPENDIX VIII, Part A

CCNFSDU framework for appraising the technological need for food additives

(Information document)

SCOPE

The framework applies for the use of additives in foods within the mandate of CCNFSDU (i.e. standardized foods or non-standardized foods following a request by CCFA).

Q1 IDENTITY AND INTENDED USE

Q1.1: Provide name and INS No of the food additive as listed in CXG 36-1989 (for substances not yet included in CAC/GL 36-1989, chemical name of the substance).

Q1.2: Describe the food and its form (e.g. liquid, powder) for which the additive is intended to be used and indicate the relevant CCNFSDU standard and if known the GSFA food subcategory.

Q1.3: Indicate and justify the range of the proposed use level of the food additive needed to accomplish the desired technological effect at the lowest possible use level.

Q2 COMPLIANCE WITH SECTION 3.2 OF THE PREAMBLE TO THE GSFA

Q2.1: Describe the technological function of the food additive relative to the CXG 36-1989 (include the functional class) and the advantage conferred by its use.

Q2.2: Does the use of an additive serve one or more of the needs set out from (a) through (d) of Section 3.2 of the Preamble to the GSFA? Indicate which one(s).

a) To preserve the nutritional quality of the food; an intentional reduction in the nutritional quality of a food would be justified in the circumstances dealt with in sub-paragraph (b) and also in other circumstances where the food does not constitute a significant item in a normal diet;

b) To provide necessary ingredients or constituents for foods manufactured for groups of consumers having special dietary needs;

c) To enhance the keeping quality or stability of a food or to improve its organoleptic properties, provided that this does not change the nature, substance or quality of the food so as to deceive the consumer;

d) To provide aids in the manufacture, processing, preparation, treatment, packing, transport or storage of food, provided that the additive is not used to disguise the effects of the use of faulty raw materials or of undesirable (including unhygienic) practices or techniques during the course of any of these activities.

Q2.3: Cannot the objectives set out from (a) through (d) of Section 3.2 of the Preamble to the GSFA be achieved by other means that are economically and technologically practicable?

Q2.4: Would the use of this food additive in the intended food(s) modify any characteristic of the food that might mislead the consumer? For example the nature, substance, quality or nutritional quality of the food, the use of faulty raw materials or of undesirable (including unhygienic) practices or techniques by which the consumer might be misled.

Q3 COMPLIANCE WITH THE APPROACH ON THE USE OF ADDITIVES IN FOODS INTENDED FOR INFANTS AND YOUNG CHILDREN

Q3.1: Does the proposed food additive perform the same/similar technological purpose as other additives that have already been authorized for use in the same product category? If not, what is the justification for the need for an additive with a new functional class and/or technological purpose? If yes, what advantage(s) does the proposed additive provide over currently permitted options?
Annex I: Decision tree on the CCNFSDU framework for appraising the technological need for food additives

**Q1 IDENTITY AND INTENDED USE**

Is the INS number and/or (chemical) name of the substance provided? Is the use intended for foods within CCNFSDU responsibility? Is the use level(s) provided and justified? *(See Q1.1-1.3)*

- No → **Discard the proposal**
- Yes → **Q2 COMPLIANCE WITH SECTION 3.2 OF THE GSFA PREAMBLE**

Is the proposed use in compliance with all criteria of Section 3.2 of the Preamble to the GSFA? *(See Q2.1-2.4)*

- No → **Discard the proposal**
- Yes → The proposed use is for foods intended for infants and young children

**Q3 COMPLIANCE WITH THE APPROACH FOR INFANTS AND YOUNG CHILDREN**

Does the additive perform the same/similar purpose as other additives already authorized in the same product? If not, what is the justification for an additive with a new functional class and/or technological purpose? If yes, what advantage(s) does the proposed additive provide over currently permitted options? *(See Q3.1)*

- No → **Discard the proposal**
- Yes → The technological need is appraised by CCNFSDU for foods intended for infants and young children and when relevant* the sponsor could submit the request for inclusion of the additive into the JECFA priority list.

* The framework applies to three potential scenarios:
  - To appraise and justify the technological need prior to a possible inclusion of the additive in the JECFA priority list;
  - To appraise the technological need for the use of additives within the CCNFSDU standards that does not warrant the JECFA assessment (e.g. in case of a development of new standards for additives already assessed by JECFA);
  - To answer requests from CCFA concerning the technological justification for the use of additives in foods under the purview of the CCNFSDU.

** The outcome of assessing Q3 (i.e. YES/NO) is whether the proposed use complies with the approach for the use of additives in baby foods.
Annex II: Form for appraising the technological need for the use of additives in foods within the mandate of CCNFSDU (i.e. standardized or non-standardized foods following a request by CCFA)

**THE PROPOSAL IS SUBMITTED BY:**

### Q1 IDENTITY AND INTENDED USE

<table>
<thead>
<tr>
<th>Q1.1 Name and INS number of the food additive as listed in CXG 36-1989:</th>
</tr>
</thead>
<tbody>
<tr>
<td>For substances not yet included in CXG 36-1989, chemical name of the substance.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Q1.2 Describe the food and its form (e.g. liquid, powder) for which the additive is intended to be used and indicate the relevant CCNFSDU standard and if known the GSFA food subcategory</th>
</tr>
</thead>
</table>

**CCNFSDU standard**

<table>
<thead>
<tr>
<th>Reference</th>
<th>Name of the standard</th>
<th>Comments (e.g. limitation of use to specific products)</th>
</tr>
</thead>
</table>

**GSFA food category**

<table>
<thead>
<tr>
<th>Food category No</th>
<th>Name of the GSFA food category</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Q1.3 Indicate and justify the range of the proposed use level of the food additive needed to accomplish the desired technological effect at the lowest possible use level</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Proposed (range of) lowest possible use level to accomplish the desired effect (expressed on the final product as consumed)</th>
<th>Justification of the level(s) proposed</th>
</tr>
</thead>
</table>

**Q2 COMPLIANCE WITH SECTION 3.2 OF THE PREAMBLE TO THE GSFA**

<table>
<thead>
<tr>
<th>Q2.1 Describe the technological function of the food additive relative to the CXG 36-1989 (include the functional class) and the advantage conferred by its use</th>
</tr>
</thead>
</table>

*Technological function relative to the CXG 36-1989:*

*Advantage from the use of the additive:*

<table>
<thead>
<tr>
<th>Q2.2 Does the use of the food additive serve one or more of the needs set out from (a) through (d) of Section 3.2 of the Preamble to the GSFA? Indicate which one(s)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Q2.3 Cannot the objectives set out from (a) through (d) of Section 3.2 of the Preamble to the GSFA be achieved by other means that are economically and technologically practicable?</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Q2.4 Would the use of this food additive in the intended food(s) modify any characteristic of the food that might mislead the consumer?</th>
</tr>
</thead>
</table>

*For example the nature, substance, quality or nutritional quality of the food, the use of faulty raw materials or of undesirable (including unhygienic) practices or techniques by which the consumer might be misled.*
<table>
<thead>
<tr>
<th>Q3 COMPLIANCE WITH THE APPROACH ON THE USE OF ADDITIVES IN FOODS INTENDED FOR INFANTS AND YOUNG CHILDREN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3.1 Does the proposed food additive perform the same/similar technological purpose as other food additives that have already been authorized for use in the same product category?  <strong>If not, what is the justification for the need for a food additive with a new functional class and/or technological purpose?</strong>  If yes, what advantage(s) does the proposed food additive provide over currently permitted options?</td>
</tr>
</tbody>
</table>
**APPENDIX VIII, Part B**

**Amendment to the Standard for Infant Formula and Formulas for Special medical purposes Intended for Infants (CXS 72-1981)**

(New food additive provisions)

(for adoption by CAC43)

Section A: Standard for infant formula

4. FOOD ADDITIVES

<table>
<thead>
<tr>
<th>INS</th>
<th>Additive</th>
<th>Maximum level in 100ml of the product ready for consumption</th>
</tr>
</thead>
<tbody>
<tr>
<td>440</td>
<td>Pectins</td>
<td>0.2g in liquid hydrolysed protein infant formula only.</td>
</tr>
<tr>
<td>415</td>
<td>Xanthan gum</td>
<td>0.1g in powdered hydrolysed protein and/or amino acid based infant formula only</td>
</tr>
</tbody>
</table>
APPENDIX IX

DRAFT GUIDELINE FOR THE PRELIMINARY ASSESSMENT AND IDENTIFICATION OF WORK PRIORITIES FOR CCNFSDU

(For use by the PWG for CCNFSDU42)

1. The following guideline is intended to assist the Codex Committee on Nutrition and Foods for Special Dietary Uses (CCNFSDU) to identify and prioritize its work.

2. Proposals for new work should follow the process and criteria outlined in the Procedural Manual for Proposals to Undertake New Work or Revise a Standard, in addition to the following criteria specific to CCNFSDU.

Criteria for Prioritization of New Work Proposals

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Further information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revision of existing texts</td>
<td>Describe the rationale for the proposed revision of an existing CCNFSDU text. Is it necessary due to new scientific findings and/or other developments? Can these new findings or developments cause a safety concern to a special group of people?</td>
</tr>
<tr>
<td>Request from CAC</td>
<td>Has the CAC requested CCNFSDU to work on a CCNFSDU text or to start new work?</td>
</tr>
<tr>
<td>Request from other Codex committees</td>
<td>Has another Codex Committee asked to consider a revision of an existing CCNFSDU text or to consider new work?</td>
</tr>
<tr>
<td>Availability of scientific advice</td>
<td>Is scientific advice available or will be provided soon?</td>
</tr>
<tr>
<td>Target group</td>
<td>Describe the target group of the proposal. Does the proposal refer to a vulnerable target group (infants, the aged, patients, etc.) or is the target group large (e.g. whole population)?</td>
</tr>
<tr>
<td>Impact on public health</td>
<td>Describe the impact on public health (high/medium/low?).</td>
</tr>
<tr>
<td>Impact on food safety</td>
<td>Describe the impact on food safety (high/medium/low?).</td>
</tr>
<tr>
<td>Impact on fair trade practices</td>
<td>Describe the impact on fair trade practices (high/medium/low?).</td>
</tr>
</tbody>
</table>

Process for Considering and Prioritizing Proposals for New Work

3. Proposals for new work and/or revision of an existing text should be submitted following a Codex Circular Letter (CL) before each session. This ensures that all proposals will be submitted within a deadline and all members have adequate time to consider them.

4. New work proposals should be submitted as a discussion paper together with a project document according to the Procedural Manual and address also the additional criteria outlined above.

5. The criteria should be addressed in a self-assessment and should include a detailed rationale. Pertinent references should accompany the assessment.

6. The rationale of the criteria “impact on public health”, “impact on food safety” and “impact on fair trade practices” includes a rating, whether the appropriate impact is high, medium or low. The choice of the respective impact level has to be justified.

7. Proposals for new work received in response to the CL will be transmitted to the CCNFSDU host country Secretariat. The CCNFSDU host country Secretariat will prepare a summary document presenting the proposals for new work and the associated self-assignment against the above criteria. The document will be distributed by the Codex Secretariat to Codex members and observers for review.

8. Revisions of existing texts necessary due to new scientific findings and/or other developments and requests from CAC or other Codex Committees on CCNFSDU texts will be prioritized.
9. The ad hoc Working Group for the Establishment of CCNFSDU Work Priorities will meet as decided by the Committee, e.g. on the day prior to the plenary session of CCNFSDU or intra-session, to develop recommendations for consideration by the Committee during the CCNFSDU session. The ad hoc Working Group will be co-chaired by the host country and a voluntary delegation. The following Terms of Reference (ToR) of the ad hoc Working Group are proposed:

   a. To conduct a case-by-case review of every proposal on the basis of a decision tree and the detailed rationale including the rating (high/medium/low impact) as presented in the discussion paper and to propose a list of work proposals ranked according to their priority.

   b. To prepare a report to be presented to the plenary to enable CCNFSDU to evaluate and decide on the new work proposals.

10. It is proposed that, at the CCNFSDU session, the ad hoc Working Group Chair introduces the recommendations to the Committee. The Committee will then accept or reject a proposal for new work and/or revision of an existing text, or return it to the proposing party for additional information. Depending on the workload of CCNFSDU, the Committee may decide to not accept any new work proposal at a session.

11. If accepted by the Committee, a proposal will be submitted to CAC with a request for approval as new work.

**Decision Tree**

12. The following decision tree serves as a tool for the ad hoc Working Group to classify new work proposals:
DECISION TREE FOR THE PRELIMINARY ASSESSMENT AND PRIORITIZATION OF NEW WORK PROPOSALS FOR CCNFSDU

Is the information complete?

- yes
  - Proposal to Committee to reject the new work proposal and request further information.

- no
  - Revision of existing text necessary due to new scientific findings and/or developments?
    - yes
      - Proposal to Committee to prioritize ahead of other new work proposals.
    - no
      - Work request from CAC?
        - yes
          - Work request from other Committees?
            - yes
              - Regarding existing CCNFSDU texts?
                - yes
                  - Discussion of every proposal during ad-hoc Working Group.
                  - Prioritization on the basis of the answers and detailed rationale.
                - no
                  - Could lead to a deferral of the proposal until advice is provided (lower priority).
        - no
          - Availability of scientific advice?
            - yes
              - Proposal to Committee to reject the new work proposal and request further information.
            - no
              - Answer to the following questions:
                - Target group vulnerable* (infants, the aged, patients etc.)?
                  - yes
                    - High impact on public health**?
                      - yes
                        - High impact on food safety**?
                          - yes
                            - High impact on fair trade practices**?
                              - yes
                                - Discussion of every proposal during ad-hoc Working Group.
                                - Prioritization on the basis of the answers and detailed rationale.
                              - no
                                - High impact on fair trade practices**?
                                  - yes
                                    - High impact on public health**?
                                      - yes
                                        - High impact on food safety**?
                                          - yes
                                            - High impact on fair trade practices**?
                                              - no
                                                - Proposal to Committee to reject the new work proposal and request further information.
                                          - no
                                            - High impact on food safety**?
                                              - yes
                                                - High impact on public health**?
                                                  - yes
                                                    - High impact on fair trade practices**?
                                                      - yes
                                                        - Discussion of every proposal during ad-hoc Working Group.
                                                        - Prioritization on the basis of the answers and detailed rationale.